annual report active positive outlook life keeps going every dayoverview overview performance defined remarkable rd output delivery sustained financial performance shareholders please go gskcom performance highlights bn bn bn bn group turnover core operating profit total operating profit returned shareholders p p major medicines approved core earnings per share total earnings per share estimated return rd investment st st potential phase iii study starts potential medicines phase iii data access medicines index pharmaceutical company sign alltrials expected campaign research transparency front cover story betty aged pictured chronic health important obstructive pulmonary disease copd try take care lung capacity means finds even everyday tasks difficult health tools medicines inhaled oxygen allow best live normal life bettys mindset stay busy active every week goes rehab exercise classes copd disease lungs leads betty copd patient damaged airways causing become north carolina usa narrower making harder air get million people around world estimated copd patients like betty reason gsk investing respiratory research healthcare company past years research new medicines see cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report number adjusted measures used report performance business measures defined reconciliation core results total results set mission gsk mission contents strategic report improve quality chairmans statement ceos review human life enabling business overview global context business model people feel strategic priorities performed better live longer risk management grow deliver simplify financial architecture responsible business financial review governance remuneration board corporate executive team chairmans letter board report shareholders committee reports remuneration committee chairmans annual statement annual report remuneration remuneration policy report financial statements directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap investor information quarterly trend fiveyear record product development pipeline products competition intellectual property risk factors share capital share price dividends tax information shareholders annual general meeting us law regulation shareholder services contacts gsk annual report strategic report chairmans statement chairmans statement shareholders value significant changes made recent years evidenced performance year since sir andrew became clear following pages audit risk committee group made good progress oversee issues challenges faced ceo company strategy management encourage creation returned billion environment gsk achieve board believes business seeing strategic ambitions responsible shareholders benefits significant changes sustainable manner management team driven recent years deliver sustainable growth reduce doubt commercial success risk enhance returns shareholders directly linked operating responsible way meets changing expectations notably strong performance society respect company continues rd organisation six major adopt industryleading positions range new product approvals areas including issues respiratory disease hiv cancer critical longerterm prospects announcement plans group achieved evolve way business interacts time rd effectively managing healthcare professionals pays sales staff cost base deliver improved estimated rate developments particularly pleased return particularly encouraging see worth noting since sir andrew way board strongly supports became ceo gsks market capitalisation commitments company made grown approximately billion advance transparency around clinical trial around billion company data welcomes subsequent actions returned billion shareholders companies field time via billion dividends billion hoped steps advance share buybacks medical science improve patient care allegations fraudulent behaviour risk management commitment certain employees within business ethical behaviour china wholly contrary companys board aims assure integrity values addition chinese government gsks business operations rigorous investigation commissioned processes systems year independent review chinese operations risk management key part law firm ropes gray boards discussions implement appropriate actions necessary conclusion investigations gsk annual report board gender diversity governance remuneration regarding composition board mindful changes outlined priority diversity terms gender new uk narrative remuneration length tenure business experience reporting regulations annual report across developed emerging markets adheres new reporting standards year gsk female representation board level particular years remuneration exceeds original aspiration report comprises two parts start board firmly believes require shareholder approval groups diverse balance experience insight forthcoming agm details set tom de swanns letter shareholders perspectives background among board members best longterm report interests group shareholders board changes composition prospects female number changes board male closing board would like thank year would like thank sir crispin sir andrew executive team davis stood may valuable commitment year contributions nearly ten years service group demonstrated ability april pleased hans wijers deliver innovation constantly striving join board nonexecutive director substantial change confident extensive experience running global group continue identify grasp companies already proved great many opportunities strengthen gsks value board discussions performance reward shareholders also planned changes create sustainable longterm value society chairmanships several board committees tom de swaan succeeded sir crispin davis chairman remuneration committee judy lewent succeeded tom chairman audit risk committee tom remaining member committee addition would like thank sir deryck maughan agreeing remain board sir christopher gent additional two years chairman succeeded sir robert wilson senior independent director may sir derycks considerable experience knowledge gsks businesses provide continuity balance finally sir robert wilson stands agm ten years exceptional service would like thank longstanding commitment group gsk annual report strategic report ceos review ceos review year company performance defined remarkable output rd organisation led sector new past six years making overall gsk accounted fda new fundamental changes gsk deliver innovation drug approvals since medicine approvals access products patients achieved fda approvals returned billion customers improved sustainable financial new molecular entities nmes performance shareholders company shareholders saw strong delivery conversion advanced pipeline priorities approved products represents next step strategy deliver sustainable organic year led sector new growth value shareholders medicine approvals returned billion shareholders dividends share particular want note growing buybacks helping generate best annual strength respiratory portfolio total shareholder return tsr performance advair flovent ventolin breo anoro since formation gsk seven respiratory products latestage development confident ability grew sales earnings line maintain leadership position area guidance turnover billion well next decade core earnings per share p cer achieved trading result addition highlighted approvals despite unexpected challenges future pipeline opportunity remains extensive including significantly reduced sales around nmes phase iiiii chinese business clinical development expect phase iii readouts six nmes also continued take action planning ten nme phase iii starts key reform business model better meet areas respiratory oncology expectations society particular took immunoinflammation industryleading positions actions improve global public health increase transparency importantly also continue improve clinical data modernise commercial financial efficiency rd estimated practices interactions customers internal rate return rd investments good progress exceptional rd delivery continue target longerterm basis productive period rd improved rd productivity also output companys history underpinning strategy create six major new medicine files profiled flexibility around pricing new start five approved medicines meet needs payers breo anoro respiratory disease governments tafinlar mekinist melanoma skin cancer tivicay hiv expecting regulatory decisions albiglutide remaining asset group first half addition launched new injectable quadrivalent flu vaccine usa gsk annual report broadly based sales growth creating greater flexibility invest delighted achieved significant terms sales saw broadlybased growth markets new product milestone malaria vaccine candidate performance improved launches together continued demonstrated could potentially performance us business sales improvement financial efficiency halve number malaria cases young excluding divestment strengthens ability deliver earnings children vaccine potential save vesicare also saw stabilisation per share growth ahead sales lives hundreds thousands children european business reported flat business remains highly cash generative africa plan file approval sales benefits restructuring billion free cash flow committed making programme helping offset economic addition realised billion available notforprofit price pricing pressures region divestments leaving net debt billion higher priority remain committed investing end year continue focus valuesbased conduct employees continuing growth important emerging using cash protect credit profile past years focused markets business sales region fund organic investment restructuring bringing life values transparency year fourth quarter programmes well ongoing respect people integrity patient excluding china commitment growing dividend focus thoughtful share buybacks bolton acquisitions really mean human level year also took steps increase whichever offers attractive returns equity holdings fastgrowing indian strong belief pharmaceuticals consumer subsidiaries companys values allegations made changing business model announced plans build new china behaviour individuals manufacturing capacity country made considerable progress disappointing investigation agenda operate responsibly matter authorities china consumer healthcare sales grew excluding meet changing expectations society continues cooperating fully divested brands growth across regions made new commitments increase company committed learning transparency clinical research early lessons taking appropriate action optimising reshaping year announced support relation outcome investigation portfolio alltrials campaign became continue take steps optimise first pharmaceutical company commit outlook focus portfolio publishing detailed clinical study reports looking see continued momentum divested anticoagulant medicines may also business targeting core earnings products million also first industry launch online system per share eps growth cer created new established products portfolio enabling researchers request access turnover growth around cer made older largely nonpromoted anonymised patientlevel data clinical exdivestment basis eps base brands aim finding opportunities trials pleased companies p turnover billion range reduce complexity enhance profitability also adopting approach guidance takes account rollout new optimise value group products products along potential competition also announced plans evolve way generics older products lovaza also completed significant divestment sell market products healthcare consumer healthcare business professionals align activities closing would like thank sale drinks brands lucozade ribena interests patients remove employees partners suppliers suntory japan billion perception conflict interest specifically continued commitment support overall iconic brands particularly plan stop direct payments healthcare confident core focus innovative uk believe growth potential better professionals speaking engagements product development programme realised company existing category attendance medical conferences investment coupled changes presence substantial drinks distribution extend principle us patient first making business model positioning infrastructure emerging markets programme globally decouple sales team company competitively long term remuneration prescription generation financial efficiencies continue expand access medicines cash generation people living developing world operationally continue restructure signed groundbreaking simplify business reduce longterm fiveyear partnership save children cost base delivered incremental combine resources capabilities yearonyear savings around million two organisations help save lives ongoing structural initiatives one million children living poorest sir andrew witty countries africa chief executive officer gsk annual report strategic report business overview business overview scienceled global healthcare company researches develops broad range innovative products three primary areas pharmaceuticals vaccines consumer healthcare bn group turnover cer pharmaceuticals vaccines consumer healthcare bn bn bn turnover group turnover group turnover group pharmaceuticals business develops vaccines business one largest develop market range consumer makes medicines treat broad range world producing paediatric healthcare products based scientific acute chronic diseases portfolio adult vaccines range infectious innovation brands four main made patentprotected diseases distributed categories total wellness oral care offpatent medicines million doses countries nutrition skin health include supplied number wellknown brands developing countries sensodyne panadol horlicks sales therapy area sales category sales category respiratory paediatric vaccines total wellness antivirals includes vaccines polio oral care diphtheria tetanus pertussis measles central nervous system nutrition mumps rubella meningitis c chicken cardiovascular urogenital pox pneumococcal disease skin health rotavirus infection metabolic adolescent adult travel antibacterials includes vaccines flu oncology emesis pandemic seasonal human papilloma virus cervical cancer dermatology hepatitis b typhoid meningitis rare diseases acwy booster vaccines diphtheria tetanus pertussis polio immunoinflammation viiv healthcare hiv read read read gsk annual report global reach significant global commercial presence markets network manufacturing sites countries large rd centres uk usa spain belgium china employees reshaped business recent years better align strategic approach place since allowed us better access markets highgrowth potential including asia pacific latin america japan employees region employees region rd business sustained investment rd spent billion noncore items billion total usa usa search develop innovative medicines europe europe vaccines consumer products emap emap year saw significant delivery japan japan latestage pipeline six key medicines approved regulators usa alone dedicated research programmes turnover region turnover region diseases affect developing world one healthcare companies researching new vaccines new medicines three world health organizations priority diseases hivaids malaria tuberculosis bn core rd expenditure usa usa europe europe emap emap japan japan potential phase iii study starts structured turnover segment core rd expenditure three primary areas business bn allocation commercial business structured us pharmaceuticals vaccines combination regional units areas focus europe pharmaceuticals vaccines pharmaceuticals vaccines operate emap pharmaceuticals vaccines pharmaceuticals geographical segments combine two businesses consumer healthcare japan pharmaceuticals vaccines vaccines business functions global unit viiv healthcare consumer healthcare viiv healthcare specialist hiv company trading founded pfizer joined shionogi consumer healthcare read trading turnover includes canada calculation core results noncore items puerto rico australasia central vaccine set tender sales contract manufacturing sales gsk annual report strategic report global context global context opportunities challenges despite continuing macroeconomic market challenges around world remains significant need medicines healthcare treatments global economic overview based imf assessments outlook regional pharmaceutical global economic growth continued global economic growth market sales affected fallout international highest rates likely seen financial crisis began developing economies india asian performance slower regions subsaharan africa see figure originally predicted international factors political turbulence within monetary fund imf also european union instability growth preceding year middle east likely continue affect bn international business environment usa economy grew annual rate indicators suggest underlying global healthcare market recovery supported rebound total global pharmaceutical market sales sales world pharmaceutical market housing market continued fall rose slightly billion cer year source ims data unemployment rate peak september billion end despite previous year according industry earlier announcements federal reserve information company ims held tapering quantitative easing measures year emerging markets asia pacific saw largest sales growth pushing eurozone economy remained weak proportion total sales region unemployment high labour markets sales europe depressed growth year largely unchanged total stringent fiscal reforms introduced north american pharmaceutical sales number eurozone countries caused billion representing market social political tensions top therapeutic classes sales japan governments fiscal stimulus unchanged terms positioning oncology monetary easing support private immunomodulatory represented total consumption investment appears sales growth central nervous system effect economy grew decline areas year also declines see figure performance emerging markets ims institute healthcare informatics regions highly variable china growth predicts annual spend prescription remained stable much medicines grow slowly growth coming second half year north america europe japan whereas inward investment india grew spending emerging nations grow growth subdued economies overall result economic expansion middle east north africa latin america population changes markets russia compared many currencies put pressure us federal population growth reserves tapering announcements may evolving lifestyles figure current predicted growth rates population growth increasing prosperity emerging markets global changes lifestyle governments responses dynamics likely expand need medicines healthcare products future united nations forecasts global population reach billion usa us sales steady compared billion birth partly result rates decline europe japan likely patent expiries blockbuster offset sharp rise populations medicines however north elsewhere particularly middle east american region still remains southern asia top pharmaceutical market total sales bn world output advanced economies emerging market developing countries sales source weo update january imf gsk annual report figure total global sales medicines therapeutic classes people also living longer partly result medical advances like vaccination oncologyimmunomodulatory prevented treated diseases previously central nervous system caused significant number deaths alimentary tract metabolic people live longer likely cardiovascular system develop diseases ageing leading r ale l op thir ea rt tr hy e ray ps yt e c bined greater demand medical treatments countries rising populations many growth global sales cer economies experiencing improved economic outlooks prosperity increases seen trends towards sedentary lifestyles increased reference ims data consumption food alcohol tobacco data include vaccines sales corresponding rise chronic non communicable diseases ncds type diabetes heart disease diseases europe already disproportionately affect low overall performance better middleincome countries nearly europe sales deaths ncds occur approximately austerity measures projected global increase deaths fiscal issues many countries main drivers continued slow emap ncds greatest growth region emerging markets continue grow increase african eastern quickly sales mediterranean regions sales diverse areas predicted continue grow strongly governments around globe pressure improve healthcare provision strong healthcare infrastructure bn absent people often purchase medicines households developing countries spend greater proportion sales income healthcare counterparts developed markets recent pharma futures report estimates outofpocket costs high china india brazil economic growth emerging markets likely mirrored increased spending healthcare governments individuals demand medicines vaccines consumer healthcare products expected continue grow significantly faster regions mature markets bn next years number nongovernmental organisations world health organization leading sales efforts support regions countries prioritising introducing wider healthcare provision particular emphasis infant immunisations ultimately potential prevent millions deaths see figure price controls regulatory pressures prescription medicines vaccines industry highly regulated individual governments overall responsibility determining products marketed countries many cases stateregulated systems products priced wide variations regional countryspecific laws around regulations medicines present challenges availability new products different japan markets many governments mandatory price cuts seeking control costs reduce spending imposed national healthcare budgets particularly alternate years sales japan proportion spent medicines saw approximately growth squeezed market continues supportive new medicines bn sales gsk annual report strategic report global context global context continued usa industry regulators legislation us regulatory agency food created new resourcing needs figure best chance drug administration fda approved requirements around monitoring reporting childhood new molecular entities managing safety issues expanded according world health many approvals marked year saw debate eu proposals first approval medicine market improve regulations around conducting organization wide range number experimental medicines clinical trials aim boosting clinical vaccines available contribute development review expedited research eu member states proposals prevention control breakthrough therapy designation nearing finalisation could simplify vaccinepreventable infections programme result safety clincial trials processes europe birth rates rise developing countries innovation act act designed come effect tremendous opportunity speed approvals process offer children protection many medicines intended treat serious life austerity programmes restricted budgets infections common childhood threatening conditions enabling continued create challenges healthcare preventable vaccines medicines reach patients sooner see systems across europe countries global vaccine action plan figure expedited development pressure drug prices remained high predicts widening governments used range cost usa government price containment measures international access vaccines could prevent controls private sector purchases reference pricing squeeze efficiencies million deaths however pharmaceutical manufacturers drug budgets end decade required federal law provide rebates government certain medicines overall access patients treatments order qualify reimbursement remains variable increasing use managed various healthcare programmes entry schemes launching new products rebates shared states significant reforms pricing systems eg federal government offset overall france uk sweden industrywide cost prescription drugs provided stability agreements manage entire medicaid insurance programme low drugs budget helped extent figure expedited development income americans rebates increased furthermore countries policies expanded affordable care implemented reduce shortages yrs act aca although increase means medicines others patients additional costs pharmaceutical seen payments prescription manufacturers also allowing medicaid products increase provide greater access patients japan prescription medicines japanese regulator pharmaceutical expansion medicaid programme medical device agency pmda expedited review process together new health insurance approved medicines containing new introduced us food marketplaces financial penalty active ingredients six months certain americans choose purchase april september drug administration way speeding availability insurance launched january april pmda produced roadmap caused great deal uncertainty medicines intended treat outlining desire strengthen insurance market serious lifethreatening conditions partnerships foreign regulatory agencies recent review found reduced europe including fda ema agencies number years required asia heightened spirit cooperation european medicines agency ema clinical testing candidate medicines speed regulatory approvals improve regulates new medicines breakthrough therapy quality safety measures well european union approved medicines designation average improve quality quantity research containing new active substances speed information years clinical testing compared novel medicines shared globally approved compared approved europe also first years underwent two approvals biosimilar monoclonal government japan continues progress standard review antibodies mabs number additional initiatives likely affect prescriptions medicine industry pharmacovigilance risk assessment include goal committee prac introduced part prescriptions filled generic medicines revised eu pharmacovigilance legislation march introduction health completed first year operation technology assessments evaluating led increase amount pharmaceuticals medical devices information available public regulators scrutiny safety medicines gsk annual report emerging markets countries india brazil argentina across emerging markets prescription introduced considering practices medicines regulated variety ways may restrict grant patents certain different countries industry types inventions commonly available present significant challenges developed countries also requirement additional marketspecific indications countries considering documentation example markets widespread use compulsory licensing china india russia vietnam nigeria essentially individual company require local clinical data order seeking use anothers patents meet regulatory requirements without seeking rights holders consent pays patent owner set usually marketing authorisation application maa low fee license requirements continue evolve emerging markets align closely patents expire medicines europe usa japan terms medicines subject competition format content generic products effect particularly acute western markets many governments region including generic products rapidly capture indonesia china india looking large share market generic expand population covered manufacturers typically incur significant governmentfunded health schemes costs rd able offer could increase opportunities high products considerably lower prices volume tenders also impact pricing branded competitors although specific tools methods pressures generic competition country implements control health apply significantly vaccines spending varies governments everywhere biological products products continue seek ways manage healthcare patents exist active ingredients spending including spending medicines delivery device emerging markets many larger emerging markets known heritage brand existing medicines brazil russia china india whether patent also valued governments attempting manage costs patients pricing controls several markets authorities looking ways control consumer healthcare help manage outofpocket spending development timelines consumer patients example india healthcare products significantly shorter introducing price controls patented intellectual property protections nonpatented products international prescription medicines reference prices remains frequent approach however consumer healthcare products reducing pricing countries like turkey also subject national regulation comparable brazil australia china russia testing approval manufacturing also expected introduce soon labelling marketing products high trends emerging markets include standards technical appraisal frequently protectionist policies favour local involve lengthy review approval process cutting red tape domestic suppliers cause delay product launches new european proposals consumer healthcare products also intellectual property patent cut clinical trial regulation could protection greater reliance brand loyalty simplify rd requirements trademark protection create value across journey scientific breakthrough eu member states markets developing approved new medicine vaccine countries market becoming takes many years incur significant challenging retailers consolidated costs ensure reasonable reward globalised strengthening expertise investment research negotiating powers based pharmaceutical companies rely protection intellectual property competition via patents trademarks regulatory data protection registered designs copyrights main consumer healthcare competitors domain name registrations include colgatepalmolive johnson johnson procter gamble reckitt benckiser unilever patents generally year term pfizer novartis filing long development time medicines patent life significantly competition prescription products eroded launch countries comes companies researching lost time restored making patentprotected medicines sometimes patents may challenged indications treat similar diseases expire courts may determine medicines principal researchbased patent invalid noninfringed pharmaceutical vaccines competitors unenforceable leading loss include abbvie amgen astrazeneca bayer protection innovation legal bristolmyers squibb eli lilly johnson jurisdiction significant litigation gsk johnson merck co novartis novonordisk summarised note financial pfizer roche holdings sanofi takeda references statements legal proceedings addition many locallyoperating fig gvap plan httpwwwwhointimmunizationglobal operate markets intellectual companies compete gsk certain vaccineactionplandovgvapenindexhtml property rights particularly patents markets fig fda review processapprovals httpwww data protection less enforceable reuterscomarticleususafdajama idusbrer governments seek control prices increase access medicines population limiting rights gsk annual report strategic report business model business model create value continute adapt business model deliver sustainable performance innovation expanding access mission people insights people critical ability achieve continuously investigate needs challenging inspiring mission mission rely knowledge patients consumers understanding improve quality human life enabling expertise ability innovate every helps us ensure medicines products people feel better live longer employee asked perform ethical meet requirements intended mission gives us purpose develop integrity strive create workplace also addressing specific needs innovative medicines products make culture employees feel valued markets make available available many people need able take ownership professional possible development maximise potential business model mission underpinned number see responsible business key factors broadly based balanced strategic priorities business across pharmaceuticals vaccines values consumer healthcare core three strategic priorities grow put values patient focus business model concepts innovation diversified global business deliver transparency integrity respect access create value researching products value simplify operating people heart every decision manufacturing innovative products model place since make focused integrating making accessible many people designed help us produce values culture decisionmaking need possible sustainable growth improved operational work well meeting quality financial performance reshaped improving healthcare making affordable policy controls required us continue business better align strategic accessible people huge challenge review challenge practices approach substantially one requires combined effort ensure actions meet exceed different company terms geography expectations society products capabilities see responsible business five years ago see strategic priorities mission business model outputs improve quality rd benefits patients human life enabling discovering customers people developing innovative medicines feel better live longer cash profit generation underpinned manufacturing values making shipping shareholder value high standard products people around world returns strategic priorities wider benefits commercialisation distribution society insights increasing access products reinvestment gsk annual report meet challenge everyone involved also increased work taken strategic decision industry healthcare professionals universities alongside external partners capturing introduce flexible approaches pricing healthcare funders including governments scientific diversity exists across academia reflect countrys wealth ability charities regulators need work research charities within companies pay poorest countries together mind partnership sharing inherent risks rd included capping prices developed collaboration key principle market levels forming alliances non process research grow business approach governmental organisations reduce prices knowledge expertise create intellectual highvolume contracts continue reform business model property business model ultimately relies example taken industryleading environment appropriately protects developed markets pioneered novel positions improve global public health intellectual property provides us reimbursement approaches widen access pricing access strategies opportunity earn reasonable return newer medicines priced increase transparency clinical trial rd investment current treatments data modernise commercial see deliver section see grow section practices interactions customers rd manufacturing outputs ability consistently produce high quality discovering developing new medicines products distribute delivering innovation maximising access long expensive uncertain process global network key part business products generates value patients requires us highly selective model extensive manufacturing shareholders society widely invest resources primary goal organisation supply chain makes rd develop innovative new medicines primary contribution make products distributes products countries offer significant improvements provide benefits patients consumers around world existing treatments focus efforts successful delivery generates profitable areas science presents new see simplify section sustainable performance turn opportunities likely lead significant allows us generate value returns medical advances commercialisation distribution shareholders enables us reinvest large researchbased company commercial success depends market business significant scale resource expertise presence customer understanding also create value making direct bring search new focus expanding access indirect economic social contributions medicines recent years challenged seek make products widely countries operate traditional hierarchical rd business accessible possible countries wider benefits society include contributions model creating smaller agile levels income development tax employment enhancing accountable earlystage rd groups gsk presence market frequently wellbeing local communities groups tasked seeking requirement medicine global community initiatives biological targets involved disease made available wide geographical creating molecules biopharmaceuticals spread helps addition allows ultimately become new medicines us understand unique characteristics marketplace adapt business model address specific healthcare needs requirements gsk annual report strategic report strategic priorities strategic priorities deliver strategy designed deliver sustainable growth reduce risk improve longterm financial performance returns shareholders aim progress grow creating balanced total sales grew billion business product portfolio capable excluding divestments diversified delivering sustainable sales growth performance generated multiple centred three business businesses geographies reflecting business areas pharmaceuticals vaccines successful implementation strategy consumer healthcare deliver changed rd organisation received approvals better able sustain six major new products several products pipeline products offer valuable new indications existing medicines improvements treatment patients vaccines value healthcare providers also generated high volume phase iii underpinned focus data key assets pipeline improving productivity rates estimated return rd investment return rd increased simplify business continues change several restructuring programmes shape transforming operate track deliver total annual operating reduce complexity savings billion compared become efficient delivered incremental model savings million frees resources reinvest elsewhere business also making good progress transforming manufacturing network supply chain enterprise wide processes responsible responsible business central made considerable strategy deliver success progress agenda operate responsibly business important achieve specifically took action increase ensuring values embedded transparency clinical research data culture decisionmaking helps us better modernise commercial operations meet expectations society interactions customers also made progress driving access medicines poorest countries passed key milestone development potential vaccine malaria gsk annual report highlights priorities financial architecture bn successful launch commercialisation new financial architecture products pipeline designed support delivery group turnover continue invest key strategy enhance growth businesses including returns shareholders emerging markets vaccines focused four key priorities consumer healthcare delivering sustainable sales growth improving operating look opportunities leverage improving financial increase focus optimise group turnover outside usa europe efficiency converting value product portfolio read earnings cash applying architecture consistently driving better consistent decision delivery phase iii data making across company six potential new medicines improving delivery key vaccines around financial objectives earnings significant new product approvals nme phase iii starts per share growth free cash across flow generation continued focus increasing returned shareholders rd rate return reinvested bolton acquisitions wherever attractive returns available potential medicines phase iiiii development implementing financial read architecture helped us return billion shareholders dividends buybacks cost savings delivery restructuring outlook programmes targeting incremental savings rollout standardised core earnings per share growth enterprise platforms delivery cer base integrated supply chain p adjusted divestments completed sales growth around cer base days reduction working capital million adjusted divestments read completed range guidance reflects transition expect see file rtss malaria vaccine portfolio year candidate approval rollout new products also face approved offer potential competition generics increase volume medicines forprofit price older products lovaza supplied least developed countries implement changes since incentivise sales teams st work healthcare professionals pharmaceutical company sign alltrials campaign research transparency read gsk annual report strategic report performed performed key indicators measure performance number key indicators remuneration executives based many group turnover cash returned shareholders bn bn reported growth performed gsk returned billion shareholders via dividends share buybacks important continue focus delivering dividend growth returning free cash flow shareholders share buy backs offers attractive return alternative investments core operating profit margina total operating profit margin bn bn reported growth cer reported growth cer reported growth reported growth performed performed core operating profit billion total operating profit billion r oc e fo fl sr e ape c l e eto r snp c ge pe r n aea rxt tpi g aeg e llc p e ooa fi fr n sg n e c r bd e ye c hsl e ii gn ed n r c roo ys l ty p e po x ae pt rra c te il ae c ln lp e yta de og r fia e n fst ci p en ro teg ba nm yst ea h sr ig g ii n h n e cd ro e r oc yl f le r yed afl le e c c ot mng e income lower rd expenditure lower rd expenditure important objective remains improve operating leverage margin indicates costs managed sales grow core earnings per sharea total earnings per share p p reported growth cer reported growth cer reported growth reported growth performed performed effective cost control delivery noncore items included gains financial efficiencies enabled disposal groups lucozade group deliver core eps p ribena business anticoagulant increase cer products million impact important noncore items year largely earnings per share show portion offset profit allocated share key indicator performance returns generating shareholders dnedivid yub skcab dnedivid yub skcab dnedivid reported growth cer reported growth performed turnover adjusting disposals prior year driven growth usa japan emap important key objective strategy deliver sustainable broadlysourced sales growth yub skcab gsk annual report new product approvals usa new pharmaceuticals vaccines product performanceb approvals bn new product approvals reported growth cer performed performed exceptional year rd led sales new products billion approvals six significant products grew represented usa helping drive continued pharmaceuticals vaccines turnover improvement estimated rd internal important rate return measure shows delivery important sales year products launched measure shows rd prior five years rolling basis organisation delivering new products creates incentives improved drive growth group rd performance turnover major growth areasb free cash flowbc bn bn share total turnover reported growth performed growth excluding legal settlements saw continued pharmaceuticals growth emerging markets japan performed together consumer healthcare free cash flow billion vaccines consumer healthcare growth increase billion primarily impacted divestments reflecting lower tax legal payments made important measure focuses major growth important areas vaccines consumer healthcare measure shows cash generate emap japan dermatology available return shareholders highlights progress delivering reinvest business well strategy create broadbased sales effectiveness converting earnings growth resilient volatility cash effective working capital control investment discipline excluding divestments relative total shareholder returnbd w e use number adjusted measures c calculation free cash flow report performance described business include core results reconciliation provided used management calculation cer described planning reporting purposes simay lan ro lyt b de e sd cir ibc etl dy mco em asp ua rr ea sb l ue w edit h b constituents pharma peers companies core results exclude return index listed number items total results full definition core results found reconciliation core results total results provided b remuneration executives linked marked key indicators information executive pay policy found remuneration report glaxosmithkline total return glaxosmithkline pharma peers return index ftse total return index gsk annual report strategic report risk management risk management approach risk rigorous processes systems place help assure integrity business operations include identify manage risks could impact business management risk important factor longterm success business figure governance structure risk management key focus board senior management sound risk management helps us address inherent risks business board responsible system corporate creating value shareholders directors governance strategy risk management financial performance protecting company assets maintaining focus fundamentals product quality safety sustainability audit risk responsible reviewing approving aim identify assess manage risk committee adequacy effectiveness risk levels organisation employees management internal controls expected take accountability identifying escalating encountered risks appropriately managed risk corporate supports ceo managing management hierarchy focused making executive team business activities escalation simple rapid transparent approach allows us balance level type risk exposure ability pursue strategic priorities risk oversight authorised board assist compliance audit risk committee overseeing hierarchy risk management risk management internal control governance shown figure diagram council activities group summarises linked roles responsibilities relationships different oversight management groups figure provides business units responsible identifying assessing representation process framework managing risks within business around risk management committed conducting business accordance applicable laws regulations established company risk management ensure appropriate internal controls policies standards internal controls compliance effective risk management implemented together company values underpin boards approach risk management global risk management board responsible ensuring risks could adversely impact company appropriately managed oversight managed audit risk committee arc arc take holistic view looking financial results controls operations businesses management risk well considering new emerging risks information boards responsibilities included corporate governance section see board arc set direction risk management policies corporate executive team cet responsibility identifying approving monitoring enforcing key policies concerning risks controls determine group conducts business gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser figure governance structure risk management figure control framework e nterprise oversight frau mr ein wte rn ka l nc cn ot nro jul nction independent assurance values helps inde p endent bu rs isi kness monitoring e uas rn u bar uge se nh r eia st sk sw ae c se f iw vfe ie tc ecti sov e nl dy u ct disci epl ni fon c ea mn ed nt management cs ot na tn rodw lsar ri dt sten w cn ose np da e ur ce ct tos eu n db b je ync edt x ao teu rd ni ats l business parties including regulatory ot p ro blem ser sp nding activities training c ag cd te e n ivn q tr ec u li yle c f ry mt f ea w ss u ss r fikns nt e dw r nnh e gae sl na itg oe rm ine gnt communication f tr ao km e ath pe ps roe pa rc iati tv ei cie os r ra en cd ti actions improve internal controls across group gsk values key individual accountability gsk annual report line management accountability compliance business management accountability compliance audit assuranceeach year cet reviews risks facing responsibility rocc ensure business unit global support group agrees list significant area business robust processes function maintains risk management risks referred principal risks require place identify risks assign clear accountability compliance board rmcb purpose particular attention group perspective monitor effectiveness internal controls rmcbs identify specific operational including could cause actual results mitigation plans processes place legal compliance risks may affect differ materially expected historical ensure business units global support achievement business objectives results summary principal risks set functions escalate significant operational help ensure appropriate internal controls full description risk compliance issues internal external audit implemented relevant cet members presented risk factors pages results investigations rocc accountable different parts business onward arc timely manner present annual report rocc addition cet considers arc principal risks could interact across expect third parties uphold company compound impact high standards set global risk officer global ethics specific accountability assigned establish appropriate governance help compliance team responsible supporting designated individuals responsible ensure expectations met effective integration risk management developing overall group approach business units global support principal risks identified risk management within business functions audit assurance responsible particular exposure regard operational daytoday management risk independently assessing adequacy work cet arc supported rests within business committed effectiveness management risk areas risk oversight compliance council rocc responsible valuesbased business reporting outcomes rocc arc whose membership comprises senior executives management responsible embedding groups maintain independent reporting representing various business units global culture decision making lines outside business management support functions making gsk work principal risks principal risks listed believe could cause actual results differ materially expected historical results listed order significance full description risk definition context potential impact mitigating activities set pages risk factors patient safety antibribery corruption failure appropriately collect review followup report adverse failure foster culture within company bribery events potential sources could compromise corruption unacceptable adopt measures embed groups ability conduct robust safety signal detection procedures prevent bribery corruption employees interpretation ensure appropriate decisions taken complementary workers third party interactions respect riskbenefit profile groups products investigate allegations bribery corruption remediate including completeness accuracy product labels issues identified comply applicable abac legislation pursuit additional studiesanalyses appropriate research practices commercial practices scientific engagement failure protect inform patients involved human clinical failure engage commercial andor scientific activities trial research conduct objective ethical preclinical clinical trials consistent letter spirit legal industry company using sound scientific principles guarantee integrity discovery requirements relating marketing communications preclinical clinical development data manage human biological medicines associated therapeutic areas appropriate interactions samples according established ethical standards regulatory healthcare professionals hcps patients legitimate expectations treat animals ethically practice good animal transparent transfer value welfare appropriately disclose human subject research medicinal products ensure integrity regulatory filings data publish product quality environment health safety sustainability failure ensure product quality throughout manufacturing failure ethically manage environment health safety distribution processes resulting noncompliance sustainability consistent company objectives policies good manufacturing practice gmp regulations relevant laws regulations supply chain continuity intellectual property failure deliver continuous supply compliant finished product failure appropriately secure protect intellectual property rights financial reporting disclosure information protection noncompliance financial reporting disclosure requirements risk groups business activity critical sensitive computer changes recognition income expenses systems information available needed accessed authorised deliberately changed corrupted tax treasury crisis continuity management failure comply tax law significant losses due inability recover sustain critical operations following treasury activities disruption respond crisis incident timely manner regardless cause gsk annual report strategic report grow grow continue pursue strategy generating sustained broadly based sales growth past six years created regionally continue make significant balanced business product portfolio investments highergrowth markets capable delivering sustainable sales growth example asiapacific latin america japan reshaped us business believe positions vaccines consumer reflect changing market dynamics healthcare key pharmaceutical therapeutic enable successful launch multiple areas including respiratory hiv provides new product approvals received us significant competitive advantage last year europe restructuring opportunity synergies improve efficiencies focus resources growth opportunities continues challenging environment progress summary group turnover years bn reported turnover grew billion excluding divestments reported growth cer performance line guidance despite unexpected challenges generated multiple businesses geographies reflecting successful implementation strategy reported growth saw encouraging return growth cer excluding us pharmaceuticals vaccines business divestments stabilisation european business reported pharmaceutical vaccine sales grew emerging markets region excluding china consumer healthcare business also made sales emerging markets years bn progress sales excluding divestments year completed divestment drinks brands lucozade ribena two reported growth anticoagulant drugs arixtra fraxiparine cer also formed established products portfolio largely nonpromoted brands reported separately group sales gsk annual report building business emerging markets part focus emerging markets invested heavily brazil recent years economy expanding quickly terms healthcare sixth largest pharmaceutical market world pharmaceutical vaccines sales business brazil increased contributing overall growth across emerging markets region year excluding china well expanding sales medicines vaccines brazil committed scientific research latin america trust science programme collaborate outstanding scientific groups explore new ways treat priority diseases also formed collaboration paulo research foundation create new sustainable chemistry centre photo doctor hospital rio de janeiro brazil doctors also largest population million south america public healthcare system offers full coverage every citizen references ims world review analyst httpwwwabpiorguk industryinfoknowledgehubglobalindustrypagesindustry marketaspx httpdataworldbankorgindicatorshmedphyszs httpwwwkantarhealthcomdocsebooksbrazilthegem oflatinamericapdf priorities successful launch commercialisation new products pipeline key priority time continue invest target growth businesses emerging markets vaccines consumer healthcare continue look opportunities drive synergies across pharmaceuticals vaccines consumer healthcare review product portfolio increase focus reduce complexity optimise value gsk annual report strategic report grow pharmaceuticals vaccines usa us business performed well dynamic challenging environment made good progress new product approvals turnover bn marketplace cardiovascular urogenital sales fell usa undergoing perhaps greatest largely due ending transformation healthcare system vesicare copromotion agreement group turnover c w ia l lr e aa er acs nt cam hcp anl ae gm e sn u ft oca rht p f iwo ef nh tih c se h p htf yfo srt ir cd ia anb n l se w thh ei l le lc mre g icn e tt l ar ya l dl f rn u aee n r ctv ho igu se es n ey rs ict e cm msa pl ee ts ioe nc tli e payers pharmaceutical industry vaccines sales increase significant opportunity primarily result increases infanrix healthcare stakeholders including government pediarix sales million reported growth cer entities healthcare providers private boostrix sales million industry work together address benefited competitor supply challenges rising costs ageing shortages fluarixflulaval sales also population epidemic chronic strong million following disease factors along economic launch quadrivalent flu formulation uncertainty placing greater emphasis demand higher quality care lower operating profit bn costs better health outcomes portfolio progress course six approvals bn performance received fda breo ellipta anoro us pharmaceuticals vaccines turnover ellipta respiratory disease tafinlar operating profit r tho es e c n c l ub su iot ng r oe fw th e v ew sh ice r eth ce pp roa mct tiof n que ak din rii vs lefo nr flue l va co cm ina e sd w e n lle aw vn ij ie vc table agreement q excluded healthcares tivicay hiv overall gsk pharmaceuticals turnover accounted fda new drug approvals excluding vesicare vaccines since achieved reported growth cer turnover grew core operating profit approvals fda new molecular entities nme company therapy area particularly approvals breo ellipta anoro ellipta breakdown turnover strong performances respiratory oncology add strength respiratory portfolio growth vaccines supplemented existing products cer seven latestage respiratory sales grew advair development confident ability respiratory billion estimated underlying growth maintain leadership position area antivirals advair volume decline well next decade offset positive impact price mix central nervous system flovent sales million number products awaiting review cardiovascular line estimated underlying growth decisions fda submitted urogenital year ventolin sales grew million arzerra firstline treatment chronic metabolic launch breo ellipta began q lymphocytic leukaemia cll also million sales recorded quarter submitted fda application albiglutide antibacterials adult patients type diabetes filed oncology sales grew reflecting oncology emesis new drug applications ndas fluticasone continued strong growth contributions furoate asthma umeclidinium bromide vaccines votrient million promacta umec patients copd including dermatology million benefited chronic bronchitis emphysema new indication thrombocytopenia rare diseases associated hepatitis c received immunoinflammation q arzerra sales grew million oncology performance also reflected contributions totalling million tafinlar mekinist launched q monotherapy treatments achieved strong initial uptake braf v melanoma market gsk annual report developments september fda published draft guidance establish bioequivalence inhaled medicines like advair contain fluticasone propionate salmeterol administered diskus proposed generic versions submitted comments draft guidance fda identified date release final guidelines generic applicant seek market entry lapse diskus patent protection august would need send gsk paragraph iv certification november fda eased restrictions patient access avandia rosiglitazone following fda advisory committee review results rosiglitazone evaluated cardiovascular outcomes regulation glycemia diabetes record clinical trial continue see significant improvements customer interactions following changes made decouple working government pay number prescriptions provide bioterrorism protection issued sales representatives following announcement december change way interact healthcare anthrax one likely agents raxibacumab contract latest professionals start process used bioterrorist attack long line examples work implement changes usa us centers disease control closely us government expect place across prevention cdc classified working us government business start category biothreat texas university system establish part initiatives support health million biodefence pandemic following many years collaboration wellbeing communities markets influenzavaccines manufacturing facility biomedical advanced research operate invested million texas development authority patient assistance programmes awarded new contract provide novel approach drug development usa programmes inhalation anthrax treatment raxibacumab funding awarded designed help underprivileged families department health human million develop new antibiotics usa access essential healthcare services hhs via publicprivate agreement marks first time hhs taken portfolio provide doses four approach funding drug development years value approximately private sector company million million realised proud helping protect us citizens bioterrorism forms part broader fiveyear base contract yrarbil otohp ecneicspisb semaj inillavac gsk annual report strategic report grow pharmaceuticals vaccines europe europe restructuring improve business performance support new product approvals turnover bn marketplace sales central nervous system products europe remains challenging environment fell due generic competition governments continue implement growth vaccines sales austerity measures driven primarily successful tenders group turnover france germany uk introduced rotavirus vaccine rotarix boostrix announced either cuts freezes reductions diphtheria tetanus pertussis flat medicines budgets course supplemented launch nimenrix vaccine various strains meningitis southern europe austerity measures reported growth cer also continued drive price reductions portfolio progress however october spanish number new products received government announced plans repay approval europe included relvar billion debt ellipta asthma copd tafinlar pharmaceutical industry advanced metastatic melanoma introduction health technology fourstrain influenza vaccine assessment hta systems also impacting additionally twodose schedule operating profit bn european marketplace governments approved cancer vaccine cervarix using htas guide decisions bn allocation healthcare resources including year old girls synflorix also approved immunisation pneumonia expenditure medicines assessment infants children approval granted criteria becoming challenging operating profit around viewed acceptable new indications two existing products c clo inm icp aa lr mat eo ars u rn ec sr e ne dn pta al ib ee nn e pfi ot ps ua lg ata ioin ns st cn sc ol co ig aty e dr te hv ro ol mad cfo yr oc ph ero nn iaic h ne dp ta yt vit eis r b used conjunction trastuzumab certain types breast cancer reported growth cer performance european pharmaceuticals vaccines developments turnover billion flat compared restructuring european breakdown turnover benefits recent business course restructuring refocusing business growth reduce inefficiencies ensure focus offset continued pricing pressures cer investment areas growth generic competition number respiratory products potential reorganisation largely complete end antivirals pharmaceutical sales pharmaceuticals last year divested central nervous system billion vaccines grew anticoagulant products arixtra billion largely due improved cardiovascular fraxiparine aspen group tender performance operating profit urogenital million part transaction europe rose metabolic agreed transfer manufacturing site therapy area respiratory sales france aspen antibacterials reflecting increased competition december announced changes oncology emesis many markets seretide sales way compensate global sales billion volume decrease vaccines employees work directly prescribing net impact price mix serevent dermatology flovent sales healthcare professionals hcps removing individual sales targets changes rare diseases respectively roll global sales force immunoinflammation oncology sales grew million also announced changes work led sales votrient increased healthcare professionals million continued build start process end direct market share many markets revolade payments healthcare professionals received approval use thrombocytopenia speaking engagements attendance associated hepatitis c end q medical conferences start sales year increased million tafinlar launched q certain markets achieved strong uptake early launch markets gsk annual report openness offer early access innovative medicines committed ensuring patients across europe continue see could benefit innovative increasing number patients benefiting medicines access votrient achieved developing novel approaches ensure reimbursement status two cancer types sustainable manner across region advanced kidney cancer softtissue sarcoma engaging governments healthcare professionals regulators engaging oncologists committed ensuring patients also ensuring eligible patients across appropriate medicines benefit europe able access tafinlar ahead soon available reimbursement cost launched kidney cancer initiatives contributed product votrient uk agreed growth oncology business last provide headtohead data five years bringing innovative medicines standard care within two years market helping patients cancer results positive would retain access medicines quickly price negative would pay seeking key partner oncology rebate reduce price results became available positive agreed could retain original price european business supported number initiatives support health wellbeing science education local communities uk major supporter wellchild national charity sick children also implemented science education programme works secondary school teachers help inspire young people continue studies science technology engineering maths stem subjects help make connection science learn classroom potential future careers also continued provide financial support barretstown camp ireland provides therapeutic recreation programmes children serious illnesses families gsk annual report strategic report grow pharmaceuticals vaccines emap emerging markets asia pacific business delivered strong performance despite political unrest economic uncertainty markets turnover bn marketplace pharmaceuticals sales emap rose remain optimistic longterm billion excluding china prospects emerging markets respiratory therapy area sales grew emap region continues major engine led seretide million group turnover growth industry characterised veramyst grew million growing populations increased gdp ventolin sales million demanding middle classes oncology sales grew million greater spending healthcare led strong growth votrient business fundamentals region million promacta reported growth cer strong expected remain million however sales tykerb coming years hycamtin declined million economic currency volatility continued million respectively cause shortterm uncertainty sales antibacterials grew countries subdued growth part million primarily due attributed price pressures created increase sales augmentin governments tightly managing healthcare million operating profit bn budgets particularly brazil korea india sales antivirals fell due declines bn performance zeffix hepsera emap pharmaceuticals vaccines turnover vaccines sales grew billion operating profit grew billion adversely excluding china reflecting strong affected ongoing investigation china tender performances cervarix vaccine supply issues excluding infanrixpediarix partially offset tough c weh rin ea u pp ha rm ina c ee mu atic pa l os pa en rd v tina gc c pin roe fis ina les c exo im stp ina gri vo c cw init eh e n e r sin b nr da z si il g nw ee aa nin et wai ned reported growth cer emap technology transfer agreement boostrix india finalised joint venture focus regionally pharmaceuticals vaccines early stage research development growth strong middle east breakdown turnover sixinone combination paediatric vaccine africa latin america help protect children polio growth southeast asia partially offset infectious diseases cer declines korea india respiratory performance india affected portfolio progress government price controls introduced antivirals addition filing new pipeline products middle year however continue central nervous system optimistic business prospects emap countries also implementing catchup programme aims bring cardiovascular country demonstrated open offer established products developing urogenital increase holding publiclylisted countries part programme indian pharmaceuticals subsidiary aim metabolic complete transaction received approvals products treating noncommunicable diseases antibacterials china sales business respiratory antibiotics oncology oncology emesis china subject investigation vaccines government authorities allegations developments fraudulent behaviour concerned dermatology following announcement december disappointed allegations markets within emap business rare diseases cooperating fully chinese authorities started implement changes way immunoinflammation compensate sales employees work directly prescribing healthcare professionals hcps removing individual sales targets changes roll entire global sales force gsk annual report across emap region continuing expand leastdeveloped markets new formulation help low incomes estimate million people underserved healthcare provision developing countries emerging markets packaged actual medicine market access dcma unit manages looking innovative ways expand individual dose capsules allowing commercial business worlds poorest access products purchased quantities small four countries focuses volume rather capsules time cuts overall cost instance asthma patients emerging profit growth created medicine enabling patients markets low incomes pay new operating unit embrace countries buy medicine quantities fit medicines directly however many across subsaharan africa least cash flow people often paid weekly developed countries first step even daily basis purchase new inhaler available four markets broader growth strategy africa medicines normally sold large philippines indonesia kenya nigeria remain fully committed supporting packs reach many submitted regulatory healthcare across emerging markets approvals markets ultimately response developed smaller despite challenges exist hope open access many pack sizes inhaler device less countries regions believe patients currently unable afford costly produce ventolin rotacaps uses improving patient access medicines inhaled respiratory medicines reengineered version established vaccines patient benefit gsk inhaler technology one five also key longerterm success times less expensive produce business may added commitment gavi alliance new agreement supply cervarix four new gavi demonstration projects significantly discounted price also extended synflorix vaccine supply agreement order protect additional million children worlds poorest countries partnership barclays seeks increase pneumococcal diseases meningitis access affordable healthcare helping pneumonia latest commitments create improved economic conditions add existing agreements supply growth combining skills gavi million doses synflorix expertise barclays help remove next decade million doses financial barriers healthcare access also rotarix next five years supporting small business development job creation starting zambia part drive improve access vaccines healthcare developing may announced financial support countries entered two new one million community health workers partnerships one save children campaign aims train health workers another barclays bank alliance provide essential services poorest save children longterm communities subsaharan africa strategic global partnership aims help save lives one million children combining expertise resources influence two groups touch many areas business particular using rd knowledge partnership see gsk annual report strategic report grow pharmaceuticals vaccines japan strong performance pharmaceutical products offsets challenging environment vaccines business japan turnover bn marketplace portfolio progress japan remains worlds second largest japanese business received prescription medicine market usa three regulatory approvals arzerra vast majority residents covered chronic lymphocytic leukemia cll relvar group turnover social health insurance remainder ellipta asthma paxil posttraumatic receiving public assistance demand stress disorder ptsd bringing total highquality medical treatments remains high number approvals since approval also received xyzal april government announced plans january allergic rhinitis promotion use generic reported growth cer medicines explicit goal increase focusing reducing gap generic drugs share market approvals pipeline products already accelerated generic launches japan usa europe categories japan became first country receive regulatory approval relvar ellipta asthma performance launch taking place early december pharmaceuticals vaccines sales japan september trametinib dabrafenib operating profit bn grew billion growth dolutegravir mepolizumab churg pharmaceuticals sales partially offset strauss syndrome granted orphan bn decline vaccines sales operating profit drug status subject priority review japan grew gsk orphan drug designations operating profit therapy area respiratory sales grew japan million adoair sales increased million also strong developments growth veramyst million japanese government reviews prices reported growth cer xyzal million relvar prescription medicines funded health ellipta launched december insurance every two years resulting average recorded sales million price cuts next revision due april discussions breakdown turnover antiviral sales grew due authorities industry around pricing governments decision stockpile flu growth began end year antiviral relenza cer september published details rare diseases sales pulmonary respiratory payments healthcare professionals arterial hypertension pah medicine volibris antivirals increased million however keeping new guidelines transparency japan pharmaceutical central nervous system sales flolan fell due impact manufacturers association price reduction well cardiovascular launch generic epoprostenol various continue support invest health urogenital manufacturers wellbeing communities markets metabolic operate provided several pharmaceutical products antibacterials performed strongly benign prostatic financial support area affected great east japan earthquake oncology emesis hyperplasia treatment avolve dutasteride addition supported save children increased sales million vaccines partnership employee fundraising became market leader january dermatology central nervous system cns medicines rare diseases remain important therapy area antiepileptic lamictal performed strongly sales growing million however generic competition led decline sales antidepressant paxil vaccines sales primarily reflecting impact cervarix suspension recommendation use hpv vaccines japan second half adverse comparison benefited final stages catchup hpv vaccination programme gsk annual report viiv healthcare viiv healthcare saw important milestone approval launch dolutegravir new treatment hiv turnover bn marketplace key element international strategy currently million people living create local partnerships generics hivaids across world around million manufacturers middle income countries people died aidsrelated causes end confirmed new group turnover since deaths estimated relationship emcure launch generic close per day maraviroc axentri india flat usa hiv market continues grow portfolio progress modest rate european marketplace strong viiv healthcare filed investigational single despite austerity measures changing healthcare reported growth cer tablet regimen combining dolutegravir abacavir systems associated pricing pressures lamivudine known dolutegravirtrii business outside regions remains usa eu october important priority continued focus work experimental integrase inhibitor resulted establishment new middle gsk continues progress study east africa hub leastdeveloped longacting injectable form drug lowincome subsaharan africa countries set begin second quarter major market issue one access operating profit bn developments performance bn access medicines major focus viiv healthcare turnover flat viiv healthcare billion growth generated operating profit maintained commitment supporting epzicomkivexa selzentrycelsentri people hiv countries maraviroc together introduction newly approved tivicay dolutegravir company offers royaltyfree voluntary licences notforprofit pricing lowincome offset impact continued competition reported growth cer older products operating profit grew leastdeveloped countries subsaharan africa people hiv live strong growth epzicom middleincome countries take kivexa million selzentry casebycase approach assesses local breakdown turnover celsentri million epzicom needs hiv medicines including kivexa performing particularly well across pipeline new breakthroughs growth regions business reflecting increased tivicay covered access policy cer confidence marketplace enhanced combivir position local guidelines north announced voluntary licence medicines patent pool foundation improve epivir america europe access abacavir children living hiv epzicomkivexa highlight approval addition number community tivicay usa august physician selzentry initiatives currently support response tivicay extremely trizivir positive product launch trajectory projects around world positive action positive action children fund pace best recent launches paediatric innovation seed fund hiv space tivicay recorded sales million viiv healthcare also committed million towards funding grassroots regionally sales north america grew driven projects usa addressing gaps care good performance epzicom selzentry services people living risk together launch tivicay europe hivaids sales declined arrival generic competition combivir offsetting strong growth continue support paediatric kivexa international region sales also innovation seed fund focused declined increase generic competition five projects including mature portfolio balanced strong collaboration clinton health access growth kivexa latin america japan initiative mylan pharmaceuticals russia partnership aims produce tastemasked dispersible medicine paediatric use november mylan filed regulatory dossier prequalification regulatory approval procedure gsk annual report strategic report grow consumer healthcare consumer healthcare performance strong particularly oral care nutrition areas boosted renewed focus core brands turnover bn marketplace skin health sales grew million global consumer healthcare marketplace led abreva usa wide diverse individual regional level excluding noncore marketplace region presenting otc products divested us sales group turnover challenges opportunities grew million led strong developed economies europe asia contributions oral care brands alli north america competition intense abreva partially offset main market players strive gain market declines gastrointestinal products due share via innovation aggressive marketing increased competitor activity reported growth cer increasingly premiumbranded competitors smoking control products must drive market value offering consumers europe sales grew billion superior clearly differentiated products helped strong growth products compete ownlabel offerings respiratory health pain oral care sales growth slowed slightly emerging markets europe flat strong growth long term prospects remain strong driven sensodyne denture care brands emerging middle class greater disposable offset decline aquafresh operating profit bn income increased gdp impacted supply issues q bn rest world markets include india performance china latin america africa grew overall consumer healthcare turnover grew billion reflecting growth across operating profit billion excluding categories markets performance noncore otc brands divested india particularly strong sales first half turnover grew india remains important market operating profit consumer healthcare business reinforced reported growth cer grew investment publiclylisted consumer healthcare subsidiary brought consumer healthcare business holding share year structured around four categories total breakdown turnover wellness oral care nutrition skin health developments growth total wellness sales excluding noncore extended approach innovation cer otc brands divested first launch shopper science lab half grew billion severe total wellness see case study human performance cold flu season early helped drive lab oral care growth several respiratory brands nutrition offset reduction total wellness two worldclass facilities enrich sales china driven regulatory changes ability better serve consumers skin health deepening understanding influences increase oral care sales decision shelf improving rd billion driven growth sensodyne capability working elite performers toothpaste sensitivity acid erosion understand human performance applying denture care brands new products mass consumers also continued strategy nutrition category grew emerging increase focus core portfolio markets recording increase family consumer healthcare brands particular nutrition horlicks due emphasis emerging markets element increased consumer access india sale lucozade ribena geographic expansion bangladesh drinks brands suntory beverage food ltd pakistan addition functional beverages japanese consumer goods company grew emerging markets billion completed sale europe end gsk annual report shopping habits shoppers gsk innovation isnt limited use shopper science lab rd organisation also see explore habits behaviours understand technological innovation could allow us influences consumer choices deepen understanding flexibility facility allows us analyse influences consumer decisions different store layouts shelf enhancements enable us improve experience packaging displays improve consumers ultimately increase shopper experience point purchase sales opening high tech shopper collaborate research facility shopper science lab retail partners identify best joint value significant step towards creation opportunities largest advanced investing facilities ssl shopper insight collaboration facility allows gsk stay forefront europe fitted cuttingedge science shopping giving us competitive technology including virtual insight advantage fastpaced world engagement touch screen wall eyetracking consumer healthcare completely skin sensors monitor consumers keeping aim becoming first emotional reactions mock retail best fastmoving consumer healthcare pharmacy store company driven science values gsk annual report strategic report deliver deliver strategy increase productivity rd improve rates return underpinned changes made recent years organisation ways working broken traditional hierarchical underpinned focus rd business structure create smaller agile improving rates return rd autonomous teams scientists believe changes rd organisation also increased level externalisation ways working allowing us sustain research allowing us explore new areas pipeline products offer valuable science sharing risk groups improvements treatment patients rigorous allocate investment healthcare providers across pharmaceutical vaccine consumer healthcare rd changing processes able make decisions earlier around pipeline progressions meant medicines significantly differentiated existing therapies progressed progress summary new product approvals usa received approvals six significant new products including treatments new product approvals respiratory diseases asthma copd malignant melanoma skin cancer hiv well new vaccine four strains flu also received approval new indications several existing vaccines cancer medicines well gaining significant approvals also generated high volume phase iii data key assets pipeline unprecedented level latestage pipeline delivery company overall return pharmaceuticals estimated internal rate return vaccines rd investment increasing due combination greater innovation effective asset progression successful approvals coupled reductions rd estimated irr spend continue target internal rate return longer term basis target gsk annual report treating hiv hivaids claimed million lives past years usa million people hiv due improvements treatments year old hiv treatment usa expected live life expectancy approaching general population established viiv healthcare pfizer focus hiv treatment research longterm collaboration joint development several novel medicines joined shionogi viiv healthcare received approval tivicay dolutegravir integrase inhibitor treatment hiv providing patients new treatment option parker pictured learned hivpositive healthy means everything possibly keep body best shape may spend time people care parker aged texas usa references world health organization hivaids fact sheet accessed httpwwwwhointmediacentrefactsheetsfsen accessed december centers disease control prevention hiv united states glance accessed httpwwwcdcgovhiv statisticsbasicsataglancehtml accessed december samji h cescon hogg rs modur sp althoff kn et al closing gap increases life expectancy among treated hivpositive individuals united states canada plos one e doijournalpone priorities remain confident ability sustain pipeline delivery key focus delivery phase iii data six potential new medicines vaccines also planning phase iii stage progressions around ten new products key areas respiratory oncology vaccines driving improvements ways working across rd organisation continue priority increasing levels output maintained without increased expenditure gsk annual report strategic report deliver pipeline progress new treatment options rd organisation performed exceptionally well record number approvals encouraging evidence ability sustain output six major new medicine files profiled hivaids initial phase iii data also received start five approved breo viiv healthcare company established darapladib chronic coronary heart disease anoro respiratory disease tafinlar pfizer focus hiv treatment therapeutic vaccine magea mekinist melanoma skin cancer research gained approval tivicay melanoma primary endpoint tivicay hiv expecting regulatory usa europe tivicay first oncedaily darapladib study first coprimary decisions albiglutide remaining asset integrase inhibitor need endpoint magea study group first half addition used conjunction booster drug met process analysing launched new injectable quadrivalent approved use treatment data determine whether flu vaccine usa naive treatmentexperienced patients patient subgroups would benefit treatments phase iii studies productive period companys history overall gsk accounted vaccines mage lung cancer darapladib acute coronary syndrome read fda new drug approvals year gained approvals two since achieved new quadrivalent flu vaccines flulaval handed back rights partner companies approvals new molecular entities usa fluarix europe fourstrain four assets ipx parkinsons usa company vaccines provide added protection versus disease returned impax pharmaceuticals traditional trivalent vaccines due delays anticipated regulatory respiratory approval launch dates disappointing europe hpv vaccine cervarix received within respiratory breo ellipta oncedaily approval twodose schedule addition phase iii data prompted us return rights combined steroid longacting beta existing three doses european migalastat fabry disease amicus agonist approved usa medicines agency also approved additional therapeutics vercirnon crohns disease treatment copd product indication pnuemonia synflorix chemocentryx drisapersen name relvar ellipta approved infants children pneumonia continues duchenne muscular dystrophy prosensa treatment asthma japan relvar one leading causes death also decided pursue development ellipta also received marketing authorisation children five tykerb either head neck gastric europe copd asthma cancer studies medicine indications failed meet primary endpoints another new product copd anoro ellipta strong pipeline also approved usa anoro ellipta promising progress made remain confident capable first oncedaily product reach number phase iii assets progressing delivering strong sustainable pipeline market usa combines two long regulatory filing years end potential new medicines acting bronchodilators single inhaler around new molecular entities nmes relvarbreo anoro administered files submitted usa europe phase iiiii clinical development using novel inhaler device ellipta albiglutide treatment type diabetes expect phase iii readouts single tablet combination tivicay nmes including magea darapladib oncology viivs kivexa treatment hiv arzerra mepolizumab severe asthma first line treatment chronic lymphocytic phase iii studies also start around oncology business strengthened leukemia cll umeclidinium long ten new assets number regulatory approvals acting muscuranic antagonist component two new products tafinlar mekinist anoro copd approved usa use singly usa filed fluticasone fuorate metastatic melanoma fdas steroid component relvarbreo accelerated approval process use monotherapy asthma europe first combination oral targeted therapies submitted votrient ovarian cancer accelerated approval contingent results phase iii trial expect regulatory decisions europe designed evaluate clinical benefit anoro ellipta incruse mekinist combination patient population mekinisttafinlar combination use tafinlar also gained european approval important year malaria expect decision europe vaccine candidate phase iii data showing mekinist combination use months followup vaccine new indications two existing products almost halved number malaria cases portfolio tyverb revolade young children reduced around also approved regulators quarter number malaria cases infants using data intend submit regulatory file europe asset gsk annual report six significant new product approvals relvarbreo ellipta anoro ellipta tivicay fluticasone furoatevilanterol umeclidinium vilanterol dolutegravir combination oncedaily inhaled first oncedaily dual bronchodilator integrase inhibitor approved corticosteroid longacting beta treat chronic obstructive pulmonary usa europe treatment agonist bronchodilator disease copd usa hiv combination antiretroviral therapy approved usa treat copd combines two longacting europe treat asthma copd bronchodilators one device first integrase inhibitor japan treat asthma need used conjunction new dry powder inhaler ellipta enables booster drug offers hour efficacy simultaneous delivery medicines daily dose approved patients new treatment million people usa already received new dry powder inhaler ellipta enables estimated affected copd hiv medicines simultaneous delivery medicines national heart lung blood institute globally million people living despite medical advances half hiv end asthma patients continue experience poor control significant symptoms million people died aidsrelated european respiratory review illnesses worldwide th people currently asthma leading cause death worldwide people living hiv copd international copd coalition tafinlar mekinist fluarixflulaval dabrafenib trametinib quadrivalent influenza vaccine pill metastatic melanoma approved firstinclass targeted treatment seasonal influenza vaccine usa europe melanoma approved usa protects four different strains virus medicine targets patients median age newly diagnosed genetic mutation braf metastatic melanoma patient almost offers additional protection compared decade younger patients traditional threestrain vaccines approximately half people cancers cancer network metastatic melanoma braf influenza serious public health mutation fdaapproved mek inhibitor problem cause severe illness patients braf even death melanoma causes skin vk mutations cancerrelated deaths epidemics occur yearly autumn american cancer society number people worldwide winter diagnosed melanoma usa estimated vaccination effective way deaths melanoma prevent infection national cancer institute one two patients worldwide metastatic melanoma expected survive year diagnosis st k malignant melanoma cases class mek inhibitor seasonal influenza may cause braf mutation lancet oncology deaths per year worldwide gsk annual report strategic report deliver investment rd focus productivity remain committed improving productivity research development develop innovative new products greater efficiency core rd expenditure primary goal rd discover rate return determined assessing develop new medicines provide advances rd costs involved discovering current treatments valued developing late stage pipeline projects patients payers profits newly approved medicines vaccines achieve people work rd regulatory approval become available organisation core rd spend patients careful allocation rd billion rd year spending critical rd spend spread across three calculated estimated businesses pharmaceuticals vaccines rd internal rate return irr consumer healthcare stated longterm aim increasing rd process pharmaceuticals combination innovation vaccines long expensive uncertain effective asset progression successful difficult predict products approvals reductions rd spend succeed fail therefore important led improvement current estimated pharmaceuticals drive efficiencies wherever possible irr continue target vaccines offset risks key priority longerterm basis consumer healthcare continued implementing improvements improvement estimated irr across rd organisation increasing important measure financial discipline levels output could maintained without strategic progress improve increased expenditure economics research development level regulation approvals also underpins strategy create processes consumer healthcare products flexibility around pricing differ pharmaceuticals new medicines vaccines research development times calculation irr incorporates actual shorter costs significantly less predicted sales figures based probabilities innovation consumer products based success medicines pipeline developing new products formulations also take account estimate meet customers needs attributable rd costs estimated profit across three areas make decisions margins capital investment working rd investment based capital requirements see best opportunities calculation includes products market science believe launched january december effective determining investment compounds phases iib iii requirements basis fixed proportion development process calculation sales based actual sales forecast sales adjusted calculating rate return rd reflect expected failure rates broadly declining rd productivity issue line standard industry failure rates pharmaceutical industry whole cost base used calculation faced past decade result comprises estimate attributable rd become important companies costs actual projected milestone provide greater level transparency payments appropriate returns rd organisations make determine capital investment allocation gsk annual report pharmaceuticals rd search new medicines pharmaceuticals rd organisation restructured create research groups agile autonomous outwardfacing believe structure key building strong pipeline innovative new medicines core pharmaceutical investment people employed earlystage research pharmaceuticals rd business earlystage research drug discovery pharmaceuticals core rd expenditure aim identify biological targets involved billion decline compared development diseases previous year viewed create small molecules biopharmaceuticals context record number approvals interact disease targets gained strong pipeline outputs ultimately leading new medicines year believe evidence recent years transformed strategy increasing rd productivity pharmaceutical rd organisation aim working enhancing efficiency productivity length time costs involved drug new approach three key elements first discovery development make essential broken traditional hierarchical highly selective invest rd business model created smaller resources distribute expenditure agile earlystage rd groups called across early stage research latestage discovery performance units dpus second discovery development focus areas changed processes development scientific advances opened progressing experimental medicines facilities central support new opportunities consider significantly differentiated existing likely lead significant medical advances therapies third increasing amount also ensure evaluate experimental research external partners products key points development enabling us access new areas science pathway confident share risk development putting resources projects believe dpu structure helps us maintain highest probability succeeding flexibility discovery research investment key rd centres uk usa focusing promising scientific spain china announced opportunities plans significantly expand rejuvenate dpus dpu facilities significantly scientists work pennsylvania usa ensure particular disease pathway area well placed maintain position science dpu responsible discovery leader rd attract new talent development potential new medicines early stage clinical trials completion phase lla timeline development stages pharmaceutical research drug discovery compounds compounds compounds number patientssubjects yrevocsiderp regulatory approval postmarketing preclinical clinical trials review launch surveillance phase phase ii phase iii approved new medicine years years years ind submitted nda submitted gsk annual report strategic report deliver pharmaceuticals rd continued dpus given budget also known commit medicine governance progress dpu business plans development decision typically rd governance structure aims regularly reviewed discovery investment made phase iia trials ensure clear accountabilities product board dib membership dib includes compound tested small number reviews oversight strategic issues senior rd commercial management human volunteers point devise overall budget management across rd external individuals expertise including instigate largerscale studies humans owned rd executive team life science investment experience using investigational medicine three governance boards determine understanding payer perspectives investigate efficacy safety investment lifecycle rd early chaired president rd time work optimise commercialisation beginning dib continued active deal compounds physical properties described earlier making collaborating external formulation produced portfolio investment board pib assesses companies individuals academics efficiently sufficient quantities technical commercial investment case particular active venture manufacturing process cases project progress development funding instrumental start research may include developing new pib cochaired chairman four venture funds year focusing devices deliver medicines see rd president north america different areas science regions see case study patientcentric design pharmaceuticals includes heads nurturing biotech ecosystem stages successful pharmaceutical region along also ran two competitions one goal use results studies head global manufacturing increasing understanding nascent field submit regulatory file approval pib accountable investment bioelectronics view regulatory agencies decisions funding allocation across forming partnerships academia responsibility guiding investigational latestage pharma rd investments core discovery expenditure medicine later stages medicines discovery development million approximately development filing rests medicines biopharm rd oncology stiefel rare development teams mdts small units diseases emerging markets rd six ten people allows investment decisions made latestage development holistic way ensuring balance around new molecular compound demonstrated diversity assets differing risk profiles entities phase iiiii clinical development potential proof concept novelty opportunity development cost works make decision whether potential reimbursed payers advance latestage development nurturing biotech ecosystem discovery research exciting innovative alone instrumental also time consuming high risk startup four venture funds focusing factors along global different areas science rare diseases economic downturn resulted fewer bioelectronics regions west coast investments earlystage life sciences usa companies past several years one funds san diegobased number venture capital firms avalon ventures groundbreaking stopped investing altogether sector efforts fund launch ten fewer investments average earlystage life science companies amount invested fallen first company formed fill gaps ensure innovative collaboration announced december ideas dont get lost lack less nine months fund financing taken creative formally launched approach early research investment participation venture creation participation funding activities gain access broad number venture capital funds range early research programmes including one fund pharmaceutical cases option buy companies industry competitor demonstrate scientific promise gsk annual report projects reviewed pib certain key decision points commit medicine development commit phase iii commit file funding generally allocated next key decision point typically two four years ahead pib also carries annual latestage funding review investment projects reviewed adjusted necessary prioritised individual late stage project incurred annual expenditure total annual rd expenditure commercial accountability board cab responsible commercial alignment investment decisions innovative marketed products portfolio governing transition rd portfolio commercial operations cab reviews individual assets commit launch milestone beyond including endorsement commercial strategy global targets assets cab also approves investments phase iiibiv evidence generation conducts postlaunch reviews annual reviews reimbursement decisions predicted performance important governance boards rd include scientific review board srb governing body accountable scientific patientcentric design assessment rd portfolio support investment decision making portfolio investment board pib srb key challenge designing inhalers ellipta inhaler unusual debate review endorsement asthma copd treatments make two compounds make unified rd view scientific aspects delivery mechanism simple relvarbreo fluticasone furoate assets srb establishes view reliable possible patients vilanterol anoro umeclidiminum overall scientific promise asset ensuring effectively delivers dose vilanterol stored separately within development plan deliver asset cost medicine inhaler rather combined effectiveness clinical plan opportunities stored together compounds risks likely product profile gsk forefront respiratory come contact dose gaps evidence missing remains science since launch ventolin administered actuated patient uncertain srb view formal rd years ago year unveiled means two medicines position communicated pib new ellipta multidose dry powder inhaler need blend together marking next generation gsk two important governance boards rd would require new formulation innovation inhalation devices technology investment board tib developed new dual combination makes investment decisions new ellipta inhaler result separate storage especially platform technologies licensing options ten years design development important combinations based collaborations point entry planning involved testing medicines blended due physical clinical trials new product supply tailoring designs based patient chemical interactions medicines nps board governing body experience designed easy blended ellipta accountable technical feasibility patients use minimum number potential allow three compounds infrastructure assessments covering aspects steps open inhale close stored delivered potentially physical product supply chain used across new inhaled respiratory could enable new treatment combinations medicines ellipta inhaler recently regulatory governance board launched single inhaler approved deliver relvarbreo led chief regulatory anoro inhalation products officer operated throughout focus enhancing compliance company wide standards increasing efficiency regulatory services aligning capabilities business needs globally locally gsk annual report strategic report deliver vaccines rd prevention efforts vaccines rd centred discovering developing prophylactic therapeutic vaccines protect people infectious diseases cancers chronic disorders rd effort within vaccines focused research vaccines divided highlights development new prophylactic earlystage research laterstage therapeutic vaccines stringently development aim identify managing prioritising investment develop vaccines help body raise decisions core rd investment immune response infective million organism newerstage research scientists working diseased cells scientists working new development new vaccines pharmaceuticals rd resources vaccines currently around vaccines required length time takes discover development range diseases develop new vaccines means essential received number approvals new highly selective indications year see pages concentrate efforts focus key part approach vaccines rd areas advances opened new expanding access new vaccine scientific opportunities consider vaccines development technologies acquisition year likely lead significant medical advances swissbased company okairos example purchase provided us access discovery development novel vaccine platform technology discovery development new could play important role development vaccine complex process typically new prophylactic vaccines well takes years new classes therapeutic vaccines acquisition also brought earlystage assets vaccine discovery begins identifying new diseases respiratory syncytial virus antigens specific structures hepatitis c virus malaria tuberculosis ebola pathogens viruses bacteria parasites hiv cancer cells recognised immune system produce highlight results pathogens yeast bacteria mammalian largescale phase iii trial malaria vaccine cells genetically manipulate candidate rtss demonstrated purified formulated vaccine continued protect young children vaccine antigen creates infants clinical malaria months bodys immune response vaccination vaccines research development cycle registration identify produce preclinical proof phase phase ii phase iii file post marketing antigens antigens testing concept surveillance research including immunology preclinical development clinical development including post marketing surveillance transfer process manufacturing years years years year gsk annual report cases formulation vaccine clinical lots involves mixing antigens proprietary adjuvant systems use adjuvants improve immune systems response antigens contained vaccines innovating area adjuvant systems years candidate vaccines usually combination several antigens final composition vaccine antigens adjuvant may change time traditionally vaccines used prevent illness however pioneering different approach designed programme bodys immune system fight existing diseases represents new treatment model therapeutic vaccine evaluating immunotherapeutic concept variety tumour types first read phase iii data investigational magea antigenspecific cancer immunotherapeutic melanoma science supply chain patients came trial meet first coprimary endpoint continuing trial second many vaccines need kept constant initiative part vaccine discovery coprimary endpoint assessed results temperature c c partnership unveiled october expected asset also manufacture administration brazil would also fund development lung cancer phase iii coldchain known considered research biomedical technologies data indication read many biggest challenge getting potential overcome partnerships collaborations vaccines people around world significant longstanding barrier scientific partners funding bodies play particularly hot remote resource vaccine access developing countries increasingly important role vaccines limited regions overall partnership aims integrate research example collaborative key players vaccine development effort overcome challenge approach new research agreement biotechnology institutions pharmaceutical signed early stage research partnership bill melinda gates foundation bmgf companies nongovernment organisations bill melinda gates foundation aims accelerate advances vaccine ngos academia drive advances bmgf year million agreement rd potential transform vaccine rd potential support research seeing global health transform global health make vaccines rd efforts also include lifecycle heat stable thus reducing need management vaccines already market continuous refrigeration anticipate emerge pipeline increase value products bring extending reach adapting ensure meet needs patients several key decision points board overall view early vaccine development process commit advanced projects chaired senior governance research decide initiate full research vice presidents discovery development programme commit candidate development vdcb recommendations progress consolidated organisation decide invest resources move clinical projects submitted vib vaccine discovery development teams development commit early clinical simplify infrastructure focus timely vib chaired president vaccines development commit phase iii registration decision making enhance clarity board makes final decision whether launch accountability since continued invest project evaluating vdcbs improve efficiency investment oversight key decisions rests recommendation alongside public health operational transformation programmes two bodies vaccine development benefit business opportunity development commercial board vdcb vaccine costs risks project timing overall continued emphasise investment board vib evolution portfolio vaccines importance project teams vaccine leadership teams responsible vdcb reviews research project daytoday progress research strategy advises scientific technical development including identifying commercial feasibility developing new products skoorb nairdaivag gsk annual report strategic report deliver consumer healthcare rd product innovation ongoing commitment innovation creating new scientifically differentiated products demonstrated contribution global sales products innovation portfolio critical sensodyne repair protect highlights continue grow consumer healthcare oral care innovation continued lead business focus creating continual sensitive teeth category introduction pipeline new scientifically differentiated sensodyne repair protect usa products define four consumer developing novel nonaqueous stannous healthcare categories fluoride formulation oral care rd team new technologies formulations able help consumers deal rd investment provide products meet needs dentin hypersensitivity active ingredient consumers valued experts sensodyne repair protect stannous reinforce leadership positions particularly fluoride builds repairing layer areas sensitive teeth family nutrition vulnerable areas teeth help protect smoking cessation pain due instability water used oral health products many commitment innovation reflected years addressing stability issues investment million core global sales innovative products incorporating product formulation consumer healthcare rd sensodyne repair protect provides proven increased overall effective lasting relief twinge sales came innovative products launched sensitivity offers everyday cavity protection recent years key contributions came fluoride niquitin strips womens horlicks launched niquitin strips first continuing success range oral stopsmoking aid strip format horlicks across indian subcontinent designed light smokers patented launched womens horlicks formula suspends nicotine polymer scientific formulation specifically meets systemwater soluble matrix combined unique nutritional needs women thin format enables dissolve region designed include mouth approximately minutes clinical daily requirements iron calcium studies shown effectiveness folate vital nutrients product relieving urge smoke seconds become first health drink women allowing consumers benefit fast india complete list macronutrients effective craving relief discrete format recommended world health already launched product organization three markets study human performance gsk human performance lab scientific data performance leading science facility focused applied results scientists apply research discovery research combines developing new products science expertise external advisors meet anticipate health needs cuttingedge technology deepen wider population understanding human performance working partnership individuals organisations committed elite human performance professional athletes sports governing bodies sports teams extreme explorers able improve understanding body brain function done drive improvements human performance gsk annual report pipeline progress late stage summary pipeline remains extensive total around new molecular entities nmes phase iiiii clinical development summary pharmaceuticals vaccines phase iii development set comprehensive list medicines vaccines phases iii development available pages therapeutic area compound indication phase iii filed approved respiratory mepolizumab severe asthma also eosinophilic granulomatosis polyangiitis relvarbreo ellipta copd mortality outcomes vilanterol fluticasone furoate vilanterol copd fluticasone furoate asthma incruse ellipta umeclidinium copd also hyperhidrosis anoro ellipta umeclidinium vilanterol copd relvarbreo ellipta asthma vilanterol fluticasone furoate relvarbreo ellipta copd vilanterol fluticasone furoate paediatric vaccines mmr measles mumps rubella prophylaxis us mosquirix malaria rtss malaria prophylaxis plasmodium falciparum nimenrix menacwytt neisseria meningitis groups c w disease prophylaxis vaccines zoster herpes zoster prophylaxis flu pre pandemic prepandemic pandemic influenza prophylaxis flu vaccine seasonal influenza prophylaxis antigenspecific cancer magea immunotherapeutic treatment melanoma immunotherapeutic magea immunotherapeutic treatment nonsmall cell lung cancer hiv dolutegravir abacavir hiv infections fixed dose combination sulphate lamivudine tivicay dolutegravir hiv infections oncology arzerra ofatumumab chronic lymphocytic leukaemia use relapsed patients arzerra ofatumumab diffuse large b cell lymphoma relapsed patients arzerra ofatumumab follicular lymphoma refractory relapsed patients mekinist trametinib metastatic melanoma adjuvant therapy tafinlar dabrafenib tyverbtykerb lapatinib breast cancer neoadjuvant adjuvant therapy votrient pazopanib renal cell cancer adjuvant therapy arzerra ofatumumab chronic lymphocytic leukaemia first line therapy votrient pazopanib ovarian cancer maintenance therapy mekinist trametinib metastatic melanoma mekinist trametinib metastatic melanoma tafinlar dabrafenib revoladepromacta hepatitis c induced thrombocytopaenia eltrombopag tafinlar dabrafenib metastatic melanoma tyverbtykerb lapatinib metastatic breast cancer combination trastuzumab cardiovascular darapladib atherosclerosis also diabetic macular oedema metabolic eperzan albiglutide type diabetes immunoinflammation benlysta sc belimumab systemic lupus erythematosus benlysta belimumab vasculitis sirukumab rheumatoid arthritis rare diseases adenosine deaminase severe combined immune deficiency adascid mepolizumab eosinophilic granulomatosis polyangiitis also severe asthma volibris ambrisentan chronic thromboembolic pulmonary hypertension infectious diseases relenza iv zanamivir influenza dermatology toctino alitretinoin chronic hand eczema duac low dose acne vulgaris inlicence alliance relationship third party use brand name approved regulatory authorities gsk annual report strategic report simplify simplify reducing complexity business remains central element strategy stop waste inefficiencies reinvest savings elsewhere business last six years implementing also investing new technology significant restructuring programmes streamline different parts business including manufacturing supply chain transforming global manufacturing finance hr network supply chain make efficient better able respond needs customers patients progress summary restructuring annual savings bn bn undertaking broad range restructuring change programmes began onwards restructuring savings simplifying many areas business supply chains finance hr rd total ongoing restructuring programmes delivered annual savings billion expected deliver billion annual savings year year incremental savings ongoing structural programmes million safety quality remain priority target manufacturing supply organisation transforming operations improve service end customers ensure safety sustainability working capital days operations created six regional business centres across globe bring together support functions order streamline standardise functional support working capital businesses days improvement adjusted global erp system deployment made significant divestments progress european intangible asset pharmaceutical revenue european impairments consumer healthcare revenue system creation established products portfolio allows us better allocate resources new portfolio medicines also achieving reduction inefficiencies realising opportunities reinvestment gsk annual report proximity production sales oral care products polident poligrip increased projected grow significantly coming years part ongoing efforts create streamlined flexible supply chain moved manufacturing active ingredient poligrip polident factory usa cork ireland ingredient travels miles road products manufactured dungarvan expected produce reduction poligrip cost goods also reduce carbon emissions pictured one employees dungarvan site ireland production active ingredient cork dramatically increase speed response changes customer demand well reducing cost production delivery joe power vp site director cork priorities continue restructure simplify business reduce longterm cost base manufacturing continue focus delivering products value optimal cost reduce pack presentations manufacturing defects waste fast track implementation integrated supply chain supported enterprise resource planning erp order improve supply service levels reduce stock outs reduce cost supply chain core business services continue migrate services focus improving service efficiency effectiveness also manage established products portfolio reduce complexity enhance profitability optimise value group products gsk annual report strategic report simplify simplify operating model continued transform operating model reduce costs complexity improve efficiency transformation operating model sites countries manufacturing simplification supply chain processes remains key business strategy pharmaceuticals consumer healthcare driving greater efficiency areas including enabling us standardise streamline products vaccines gms division logistics warehousing procurement important aspects business including responsible sites employing portfolio simplification manufacturing supply chain people make programmes early stage supply pharmaceutical consumer already reduced volatility improved restructuring programmes continuing healthcare products remaining sites responsiveness allowing better inventory contribute support delivery employing staff run management already delivered significant savings savings vaccines business million benefits pharmaceutical available reinvested priority supply chain growth businesses new product launches continue review network returns shareholders seek opportunities optimise operations also reducing complexity closed three smaller portfolio existing products restructuring progress manufacturing sites singapore usa discontinuing unprofitable packs began operational excellence mexico sold coleford site uk standardising pack presentation formats restructuring programme part divestment lucozade improving operational efficiency programme remains track deliver ribena brands announced one ensuring patient customer needs met billion annual savings site would leave network also see case study opposite year completed integration former human reached target discontinuations programme coming genome science manufacturing site year end remain target achieve close announced new major change usa acquired demiclen consumer reduction packs portfolio programme focus improving supply healthcare manufacturing facility slovakia fouryear period chain processes building capabilities support growth manufacturing rd restructuring core business services european business programme invested manufacturing network early stages remains track throughout year commitments totalling core business services cbs group deliver billion annual savings million announced set bring together support together two restructuring programmes across key centres uk india functions including facilities management hr produced annual savings billion implement improvements technological finance procurement centralised advances manufacturing processes team streamline standardise addition programmes began operations aim increase productivity separate structural initiative supply chain progress free time businesses reshape longterm operating expenses focus execution business strategy gms aligned organisationally liabilities produced reduction local markets reduce number new model responsibility entire approximately million longterm global support staff pharmaceutical consumer healthcare employment costs restructuring supply chains supplier invested global enterprise postemployment medical benefits delivery customer creating fully resource planning erp system benefit million integrated supply chain playing important role reducing costs restructured pension obligations improving service levels reducing working since consumer healthcare taking ongoing structural initiatives capital manufacturing supply chain business reforming simplifying together delivered incremental commercial operations rollout erp supply chain model implement yearonyear savings around million time budget endtoend chain delivered similar amount expected helping million savings since began following positive start made offset mix pressure fund ongoing created greater operating flexibility allowing progress made investment requirements us deliver products customers enrolling european pharmaceutical also continued integration quickly efficiently vaccines markets commercial erp human genome sciences business system european pharmaceuticals transferred learnings restructuring benefits revenues consumer pharmaceuticals around million healthcare revenues system manufacturing operations creating supply chain structures aligned supplier completed advance deployment global manufacturing supply delivery customer forecasting planning element global manufacturing supply erp system markets latin america gms division focused delivering vaccines supply chain also gsk businesses region forecast transformational plan enable us implementing endtoend transformation plan system data manufacture supply new programme improve customer service standards enabled consolidation product portfolio existing products reduce inventories leadtime reduction reporting business analysis consistently high quality improve forecast accuracy increased efficiency key priorities implementation endtoend inventory management new sales operational planning process well underway finalised end gsk annual report cutting variation drive enhance productivity beginning conducted result able discontinue initiative particularly important audit identified manufacturing imigran pack formats established products portfolio epp group making migraine treatment expect cut epp comprises around products imigran different packs achieved cost reductions well branded generics business varying size quantity tablets change total supply medicine local products together make different pack format required unique discontinuing least popular pack annual sales around billion many manufacturing process meaning formats resource ensure products longer promoted pack formats make greater continue meet demand important operating costs cost complexity manufacturing popular imigran packs processes products simplified far possible allow us focus bid reduce costs looked reduction pack formats new product launches products ways simplify number pack formats product one part overall greatest growth potential involved review imigran global initiative started packs listening patients find reduce number packs around pack formats liked best discontinued pack formats aiming cut overall number pack formats end also accelerating deployment umbrella cbs also improved forecasting planning processes conducted number targeted programmes across group enabled erp simplify business take costs result reduction supply chain operating example introduction new costs reduced inventory levels improved global platforms run standard enterprise forecasting roll expected wide processes reduce number completed mid individual business applications seen organisation decommission applications key element cbs approach since beginning total creation six regional multifunctional business service centres focus developing global category strategies delivering robust effective services begun standardise material markets sites regions specifications removed complexity opened four centres one costa rica two supply base usa one uk complementing hr started implementing people kuala lumpur poland began management element system globally operation global network end gsk agency foundation standardising continuously employees canada latin america improving support services offered system business units centralised model improve process efficiency effectiveness free time businesses focus execution business strategy local markets gsk annual report strategic report financial architecture financial architecture financial architecture designed support execution strategy enhance returns shareholders gsks financial architecture focused million contribution structural earnings per share four key priorities delivering sustainable benefits related savings significant progress improving sales growth improving operating leverage longterm employment costs financial efficiency together improving financial efficiency converting restructuring postemployment medical continued share buyback programme enabled earnings cash benefits approximately million lower us deliver core eps p financial architecture designed restructured pension top end eps guidance range ensure maximising returns obligations sustainable sales growth remain focused managing cost expect deliver core eps continue simplify business allocate base effectively operational growth cer turnover growth resources efficiently flexibly excellence programme initiated around cer exdivestment basis build leverage across pl drive remains track deliver annual savings eps base p turnover base earnings per share faster sales billion addition new billion turn convert earnings cash major change programme announced reinvest business return track deliver pretax savings cash conversion shareholders wherever returns look least billion business remains highly cashgenerative attractive continue balance cost savings continue focus improving applying architecture consistently continued investment business conversion earnings cash driving better consistent support new launches rd pipeline greater focus cash generation capital decision making across company key driver future sales allocation particular focus working capital allocation decisions growth increasing contributions capital continued make rigorously benchmarked using cash flow pipeline sales onwards remain progress excluding distorting impact return investment cfroi framework confident drive improvement disposals intangible writeoffs core operating margin medium term reduced working capital conversion cycle sales growth ten days reported sales grew billion financial efficiency cash basis delivered additional excluding impact product disposals despite pressure operating margin million savings despite renewed growth made sales grew five businesses financial efficiencies delivered many businesses need start respiratory oncology vaccines viiv significant value year building inventory behind new launches healthcare consumer healthcare contributed positive leverage reported developing endtoend supply chain accounted around sales core earnings per share eps joins manufacturing commercial grew cer move made financial efficiency gains businesses increase visibility accountability expect deliver sales growth around taking advantage era low flexibility hence reducing inventory cer excluding products divested interest rates secure attractive required releasing cash longterm funding rates without losing operating leverage flexibility overall reduced net funding returns shareholders core operating profit flat cer costs percentage points since free cash flow available invest reported basis core operating margin maintaining targeted credit rating business return shareholders declined percentage point ap preserve access shortterm consistent protecting credit profile related negative impact currency capital markets priority cover dividend free operating margin benefited reduced cash flow beyond requirement also continue align tax strategy rd costs higher royalty receipts offset available share buybacks bolton future business profile expected upward pressure cost sales acquisitions wherever attractive implemented number measures unwinding costs manufacturing returns available centralise pharmaceutical intellectual volume shortfalls adverse mix impact property product inventory ownership decision allocate preparing launches new pipeline uk allowed us reduce cash flow rigorously benchmarked using products groups continuing restructuring core tax rate returnsbased framework based cfroi programmes contributed incremental yearon ahead expectations comparisons year savings around million beginning year continue expect ongoing structural initiatives returned billion cash improvements tax rate especially shareholders paid billion dividends new products come ordinary dividend p per benefit newly introduced patent share addition bought back billion box arrangements uk core tax shares part longterm programme rate expected around started expect deliver continued dividend growth currently targeting share repurchases billion gsk annual report financial architecture drive improved returns focus returns sales growth eps returns shareholders operating free cash leverage flow financial efficiency cash flow growth measurement reporting january group report established products portfolio tail brands sales totalling billion billion excluding divestments separate segment set segment bring greater focus optimise value particular profits cash group products realise attractive value efforts also consider divestments gsk annual report strategic report responsible business responsible business responsible business central strategy mission deliver success important achieve operating responsibly ensuring values transparency clinical research embedded culture decisionmaking modernise commercial practices way helps us better meet expectations society interact customers passed significant milestone development continued take bold steps modify potential vaccine malaria business model specifically made progress driving access medicines continue invest people poorest countries took action increase working hard reduce environmental footprint progress summary made good progress towards announced plans evolve way sell forwardlooking commitments announced market products healthcare professionals commitments reported across align companys activities four areas aim address unmet global interests patients health needs aligned strategic priorities values people began rollout preventative healthcare health benefits partnership prevention increased volume medicines supplied least programme available employees developed countries since families worldwide achieved major milestone development launched new performance management system malaria vaccine candidate rtss lead us better link employee reward values submit regulatory file make vaccine available notforprofit price subsaharan africa planet formed innovative new partnership save scope carbon emissions children help save lives one million children operations grew slightly although five years declined since became first company awarded global behaviour certification carbon trusts water standard became first pharmaceutical company enable recognition yearonyear reductions external researchers access detailed anonymised operational water use globally patientlevel data clinical trials new online system gsk annual report malaria milestone last year malaria killed estimated people three quarters deaths occurred children five malaria parasite endemic subsaharan africa plasmodium falciparum also serious type malaria acute infections rapidly become lifethreatening working partnerships others carrying research vaccine fight malaria years achieved major milestone development worlds first vaccine p falciparum phase iii data showed vaccine almost halved number cases young children aged months first vaccination months vaccination based data previous studies plan submit regulatory application european medicines agency vaccine could available early nahya pictured paediatrician involved rtss malaria vaccine trial ifakara health institute tanzania hope malaria vaccine could help many many children could help reduce burden malaria disease n ahya salim paediatrician research scientist tanzania africa references world health organization fact sheet world malaria report december httpwwwwhointmalariamediaworldmalaria reportenindexhtml wellcome trust plasmodium falciparum httpmalariawellcomeacukdocwtdhtml priorities continue challenge business model every level ensure responding needs patients meeting wider expectations society next year begin twoyear process end practice paying health care professionals speak behalf move help put patient interests first gsk annual report ssttrraatteeggiicc rreeppoorrtt rreessppoonnssiibbllee bbuussiinneessss responsible business approach conduct business important us financial results achieve strive put values heart every decision make meet exceed expectations society commercial success directly linked improve access employ innovative significant contribution operating responsible way report funding mechanisms use flexible pricing elimination lymphatic filariasis lf approach progress making approach based countrys wealth control soiltransmitted helminths intestinal across four areas ability pay developing countries worms donation albendazole market access dcma operating unit tablets shipped million health seeks increase patient access tablets bringing total donated behaviour medicines vaccines around million billion tablets since people least developed countries people also researching new treatments ldcs defined united nations planet diseases sleeping sickness since dcma unit established chagas disease visceral leishmaniasis developed longerterm volume medicines supply ldcs commitments across four areas increased million units approximately malariarelated reflect global health needs million deaths reported last year gsk aligned strategic priorities committed tackling disease values transparency respect people price patented medicines invested million development integrity patient focus ldcs capped quarter malaria vaccine candidate rtss including developed world prices since collaborations path malaria vaccine year reporting progress also reinvested profits initiative support bill melinda commitments ldcs local healthcare capacity gates foundation year clinical trial corporate responsibility report available building projects countries reported data vaccine see gskcomresponsibility amounted million since intend submit regulatory following pages provide overview reinvested million application also developing approach aim make established offpatent tafenoquine treatment relapse prevention p vivax malaria products available developing countries health catch programme remain committed supporting world programme seeking approvals health organization objective eradicating mission improve quality human medicines markets polio completely providing vaccines life enabling people feel better received approvals products unicef provided million live longer main way doses oral polio vaccine global polio vaccines used tiered pricing model developing new medicines vaccines eradication initiative years updated consumer products increasing access approach better align countrys ability products need innovative science create pay least welloff countries work regardless ability pay value closely gavi unicef improve time need generate returns access vaccines organisations approach rd includes strategy sustainable business invests purchase large volumes vaccines open innovation diseases research new treatments tomorrow worlds poorest children always benefit developing world seeks stimulate achieve evolving lowest prices innovation enhance productivity business model implementing novel research process research aim take responsible approach approaches flexible pricing structures transformed approach intellectual pricing markets important prices also accelerating innovation property external partnerships reflect value medicines bring patients processes opening research findings also mindful burden current open innovation models resources others working new healthcare costs example priced focus diseases developing world ways partners newly launched products also exploring ways extend prices currently available despite models solve significant health access healthcare positively differentiated profiles example challenges traditional business committed improving access usa launched tafinlar braf model inadequate including antimicrobial patients need products irrespective inhibitor last year price around resistance noncommunicable diseases ability pay focusing product lower existing braf inhibitor alzheimers disease affordability availability investing early joined accelerated stronger healthcare systems developing diseases developing world medicines partnership amp new countries neglected tropical diseases ntds like leprosy partnership national institutes intestinal worms affect billions people health nih ten pharmaceutical companies worlds vulnerable communities three nonprofit organisations goal leading member london declaration amp transform current model gsk working bill melinda gates developing new diagnostics treatments foundation pharmaceutical challenging disease areas make data companies control eliminate ten generated available broad biomedical ntds affect billion people community participating providing funding alzheimers pilot gsk annual report programmes supported also believe sharing research context concerned financial giving findings positive negative disappointed allegations fraudulent stimulate innovation help others build behaviour china business existing research aim taking matter extremely seriously accelerate drugdevelopment process cooperating fully chinese authorities produce new medicines patients taken number actions including commissioning independent report health wellbeing international legal firm ropes gray communities extensive experience anticorruption committed improving health international risk wellbeing communities supporting programmes improve healthcare committed learning lessons infrastructure enhance science health required result chinese education assist humanitarian relief investigation take appropriate steps necessary outcome gsk donated medicines valued remain fully committed china supporting million cost million cash governments healthcare reforms health wellbeing product donations worth million supplying products patients education provided partners americares direct relief ima world health map international simplified policies underpinning project hope humanitarian aid code conduct completed annual partners distributed donated medicines business certification programme ethical countries included providing leadership certification requires managers giving supplies antibiotics basic medicines designated employees certify affected conflicts natural awareness understanding compliance disasters including earthquake pakistan gsks values policies typhoon philippines designated employees completed tornadoes usa certification process gsks annual impact awards continue support guiding principles channelled million business human rights endorsed outstanding healthcare charities united nations human rights council uk usa past years recognition principles undertook systemic assessment identify human rights impacts behaviour prioritised seven areas examine gsks policies processes also aim put interests patients updated gsk human rights statement consumers first decisions based findings assessment guided four values transparency ccaasshh million respect people integrity patient focus research practices pprroodduucct ta andn din inkinkdi nd million policies guidance codes time million conduct place people partners seek ensure research practices tmimaneagement million suppliers meet high ethical standards patient safety management remains first priority living values principles clinical trials conducted accordance ethical conduct priority gsk need good clinical practice gcp guidelines operate integrity around world employees complete training gcp interactions patients prescribers payers undertaking roles related gsk governments must live values sponsored clinical research failure uphold high ethical standards could gcprelated training activities impact companys success also conducted clinicalquality assurance assessments zero tolerance approach bribery corruption applies everyone gsk addition conducted investigations well third parties act behalf suspected irregularities took corrective company action appropriate independent regulatory authorities also performed inspections gsk sites investigators used conduct clinical trials gsk annual report strategic report responsible business responsible business continued built longstanding began programme strengthen dedicated medical commitment clinical trial transparency modify nearly packaging lines across scientific capability appropriately lead facilitate research help manufacturing sites internationally allowing engagement hcps improve advance medical science improve patient us provide unique serial numbers nearly multichannel capability including use digital care launched online system enable stock keeping units technologies ensure appropriate product researchers request access detailed disease area information provided greatly value relationships anonymised patientlevel data clinical hcps conveniently finally support many suppliers understand trials also began publishing clinical study fair balanced objective medical education pressures cash flow financing faced reports csrs medicines hcps provision independent smaller companies following change approved terminated development educational grants standard payment terms suppliers uk extend back formation gsk usa offered review continue offer appropriate fees starting commonly payment terms smaller suppliers identified hcps provide services gsk prescribed medicines also support micro small medium size enterprises sponsored clinical research advisory activities alltrials campaign calls full reporting europe diverse suppliers usa market research activities methods results trials also offer range supply chain finance essential provide us insights specific earlystage research use number options uk us suppliers diseases identification symptoms methods drug discovery work including diagnosis application clinical trial data several companies taken cases research involving animals medication dosage administration opportunities already planning use alternatives animals whenever effectively appropriately increased communications make however studies animal research communicate benefits risks smaller suppliers aware method used demonstrate medicines help meet patient needs support available effects potential new medicine living body tested humans sales marketing integrity people animals used research committed acting ethically practising good animal gsk important role play supporting people essential success welfare minimising number animals education healthcare professionals hcps focus building individual capabilities used number animals used providing accurate information aim support empower declined lower medicines help make best best animals research including treatment decision patients research carried contractors mice announced plans evolve way talent leadership development less animals use non interact hcps align activities human primates interests patients aim attract retain talented people investing training implement new compensation development tailored individuals manufacturing supply system apply gsk sales needs recognises potential efficient responsible manufacturing employees detail prescription products employees supply key gsk expect suppliers prescribing healthcare professionals uphold high standards set mean sales professionals evaluated leaders completed based code rewarded technical knowledge leading delivery programme helps conduct quality service deliver middlelevel managers translate strategic support improved patient care overall ambition business meaningful conduct audits governance risk performance business replacing action also enrolled leaders management environmental health individual sales targets onto leading business designed safety sustainability issues subset develop capabilities managing suppliers identified critical follows success actions business function people supply chain usa decoupled reward sales new management positions launched representatives number prescriptions gsk also member pharmaceutical management essentials teaches basic issued focusing instead demonstration supply chain initiative psci audits management skills values patient suppliers labour practices year continued support environment health safety performance addition intend phase practice entrylevel students internships paying hcps speak behalf moving endtoend supply chain operating industrial placements apprenticeships products disease areas audiences model pharmaceutical consumer graduate schemes increased prescribe influence prescribing healthcare products standardise graduate intake improve controls across entire supply chain work implement changes part aim recruit graduates effectively line local laws year continued address regulations across global business problem counterfeiting one effective coaching global focus start measure initially adopted china reached leaders countries use serial numbers product packages coaching programmes enable electronic monitoring purpose strengthen leadership capabilities patient safety gsk annual report pulse volunteer partnership programme gives employees opportunity work fulltime three six months non profit organisation charity help address global healthcare challenges developing leadership skills employees volunteered organisations including save children part new global partnership charity inclusion diversity focus enable gender diversity management senior roles introduced targeted individual group coaching sponsorship emerging diverse talent invite employees join dialogue sessions discuss address hidden barriers could hinder gender diversity end global workforce male female percentage women management continued rise women management positions partnership save children help save million lives svp vp director aim help save lives million one first lifesaving projects manager children partnership reformulation chlorhexidine antiseptic total save children combining found corsodyl mouthwash rd capabilities ontheground gel umbilical cord cleansing prevent women represent corporate expertise bring muchneeded infection newborns executive team exceeded medicines vaccines goal achieve least female board also registering childfriendly worlds poorest children train thousands representation female nonexecutive powderbased antibiotic drc help healthcare workers seek alleviate directors make board fight pneumonia one biggest killers child malnutrition ranked joint third female ftse children five interventions board report study womens new partnership builds two recommended representation boards uks collaboration save children report un commission lifesaving top companies past eight years including part commodities reinvestment programme employees gender number least developed countries also teamed save children award us million recognition africa malaria partnership male female total healthcare innovations originating board investing least million developing world designed reduce infant initiative encouraging employees mortality award split management contribute million year fund five organisations largest total employees raising establishing two signature portion awarded friends sick programmes demonstrate interventions children malawi development management senior managers defined democratic republic congo drc lowcost device help newborn companies act strategic report kenya joint paediatric board infants breathe directors report regulations includes persons responsible planning directing look new repurposed products controlling activities company tackle causes newborn strategically significant part company infant death board including directors undertakings included consolidated accounts nerdlihc eht evassogob assile gsk annual report strategic report responsible business responsible business continued making sure people disabilities access career opportunities capturing setting standard talent global focus us employee healthcare establish global disability council within gsk agree priority areas improving opportunities disabled people develop objectives drive disability agenda forward putting values practice monitor report progress offering competitive benefits packages rich cultural diversity employees including preventive healthcare key strength helping us meet diverse employees families needs patients healthcare providers partnership prevention pp countries operate staff programme offers eligible employees based emerging markets asia pacific family members access japan regions represented preventive health services little cost total workforce six nationalities pp available employees across represented corporate executive team gsk date pp benefits board place employees family monitor benchmark proportion members countries ethnic minorities workforce part pp pilot ran industry averages national population focused encouraging employees countries uk usa exercise improve diet engage groups representing diverse since developed global physical fitness communities programme launched engaging people ceo members corporate executive team deliver live broadcasts health safety wellbeing energy performance programme helps messages keep employees updated companys progress towards strategy progressive healthcare company employees remain focused energised commitments believe helping employees healthy productive end resilient productive priority brings employees countries participated frequent global employee survey helps us mission life people energy resilience training since understand performance employer taken steps address achieve goal zero harm employees employee assistance programme offers issues identified last survey completed focus preventing incidents advice information counselling focus training leaders occur training activities confidential helpline website better coaches supporting employees focused key risks driver safety available employees change better recognising individuals machineryrelated incidents two contributions serious incidents injury illness performance reward recognition rate per hours incentivising behaviour consistent introduced interim surveys worked values priority way evaluate individual business units functions underreported working recognise reward performance covered employees results include data number commercial announced new performance system showed businesses made operations business units come effect system significant improvements team leader designed ensure employees understand effectiveness priority area improvement also worked increase reporting near expected help based survey results miss incidents better understand connect contribution delivery events occur share gsk employees enthusiastic knowledge across business help strategy reward participants orange day volunteer prevent serious incidents result senior people disincentivise programme gives staff one paid day reported events unethical working practices using clawback year purpose also increase since mechanism allows us recover challenged employees around world performancerelated pay work together raise million also expanded network health year five years save children safety coordinators make sure safety committed supporting health programmes track expanded wellbeing employees driver safety programme five continents families year began phase global preventive healthcare continued implement risk reduction initiative partnership prevention initiatives improved process safety programme see setting standard manufacturing rd prevent serious employee healthcare events fires explosions releases hazardous substances gsk annual report planet carbon emissions tonne coe ensure continue deliver high quality products patients consumers scope emissions future must protect natural scope emissions resources need make today total scope emissions carbon set ambitious targets achieve carbonneutral value chain intensity ratios operational emissions remain lower sales revenue baseline engaging employees suppliers customers scope tonnes coe sales address carbon emissions value revenue millions chain sourcing raw materials fte transport use disposal products scope tonnes coefte using carbon footprint analyses top products target effective reductions scope scope carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition see table certified scope carbon emissions carbon trust carbon standard certifies making yearonyear overall reductions operations grew slightly emissions associated operations transport applying recertification although declined since emissions materially important carbon reduction strategy investments made start deliver carbon emission reductions see carbon emissions named cdp performance uk installed equipment site table scope emissions refer direct leadership indices global leader ware dismantle spent respiratory inhalers greenhouse gas emissions including burning tackling carbon emissions recycle components fuels energy emissions sales force transparent reporting repeated survey suppliers cars emissions manufacture metered packaging leaflet paper used dose inhalers process emissions water information help us purchasing manufacturing operations waste achieved reduction decisions treatment scope emissions include indirect water use previous year keeping greenhouse gas emissions consumption us track meet target cut impacts purchased electricity heat steam operational water use manage range important scope emissions excluding raw baseline issues reduce environmental impact materials increased across mapped water usage across value example use green chemistry value chain due strong sales hfa chain identified production aims reduce use hazardous chemicals propellantbased inhalers increased raw materials use accounts processes drug development since scope emissions estimated total water footprint replacing lower indirect emissions included operations represent environmental impact scope embedded carbon dioxide purchased raw materials propellant became first company green chemistry performance unit released patients use dispose awarded global certification carbon established researches ways metered dose inhalers well business trusts water standard part replace hazardous unsustainable chemicals travel air logistics assessment carbon trust audited sites better alternatives uk usa india materially important emissions support research sustainable chemistry emissions use metered dose investing new centre excellence waste inhalers detailed value chain green chemistry university carbon footprint performance data published generated waste nottingham uk pledged corporate responsibility report result business growth annual funding second centre reduced waste compared excellence sustainable chemistry important achievements include baseline total waste paulo brazil singapore best continuing carbon reduction sent landfill sites funding research green sustainable award carbon trust year achieved zero waste landfill manufacturing part partnership onyear overall reductions emissions aim halve singapore economic development board operational waste compared collaborating launch tool help zero waste landfill companies calculate carbon footprint tablet medicines distributed blister packs gsk annual report strategic report financial review financial review financial review summarises performance group year comparison results previous year financial review also sets balance sheet position group december group performance major restructuring costs charged working capital conversion cycle arriving operating profit include costs working capital conversion cycle financial review discusses operating arising operational excellence calculated number days sales financial performance group restructuring programme initiated outstanding plus days inventory outstanding financial outlook financial resources expanded less days purchases outstanding compare results year major change restructuring programme primarily results preceding year initiated restructuring costs cer growth cer basis review following acquisitions human order illustrate underlying performance discuss results core basis genome sciences inc august practice discuss results total basis stiefel laboratories inc july terms constant exchange rate cer growth rates included report reconciliations core results total growth represents growth calculated constant exchange rates cer results presented exchange rates used determine unless otherwise stated cer growth results overseas companies core results reporting aligns business discussed sterling remained unchanged performance reporting around used previous year cer use number adjusted measures underlying trading performance represents growth constant exchange report performance business group primary growth drivers rates represents growth actual measures used management removing volatility inherent many exchange rates planning reporting purposes noncore items discussions presentations core results reporting utilised restatement comparative investment analysts rating agencies basis internal performance reporting information defined measures core results presented set note financial defined ifrs may comparable discussed financial review statements presentation financial similarly described measures used believe approach provides investors statements amendment ias companies clearer view underlying trading employee benefits implemented core results reporting performance group also believe year effect reduce approach make groups total operating profit core results exclude following items results comparable majority million million total results amortisation peers many use similar million comparative information impairment intangible assets excluding forms underlying performance reporting restated accordingly computer software goodwill major discuss results although precise restructuring costs including costs calculations may differ financial review following material acquisitions legal charges also presents discusses total results net insurance recoveries expenses group settlement litigation government investigations operating free cash flow income royalty income disposals free cash flow net cash inflow associates products businesses operating activities less capital expenditure acquisition accounting adjustments interest dividends paid non material acquisitions together controlling interests plus proceeds tax effects items sale property plant equipment dividends received joint ventures associated undertakings free cash flow growth calculated sterling basis reconciliation presented gsk annual report financial review group turnover segment group turnover business restated growth growth cer restated growth growth pharmaceuticals vaccines cer us pharmaceuticals europe vaccines emap pharmaceuticals japan vaccines viiv healthcare consumer healthcare trading unallocated c er represents growth constant exchange rates represents pharmaceuticals growth actual exchange rates vaccines total group turnover million consumer healthcare excluding impact disposals primarily conclusion vesicare copromotion agreement us q us pharmaceuticals vaccines turnover noncore otc brands divested h turnover grew grew excluding impact conclusion vesicare pharmaceuticals vaccines turnover grew excluding copromotion agreement q pharmaceuticals turnover disposals grew pharmaceuticals turnover grew excluding vesicare grew sales respiratory excluding disposals grew growth us japan products grew million led growth advair emap partially offset continued pricing pressures although performance included benefit favourable stocking generic competition europe viiv healthcare turnover patterns fourth quarter oncology products also performed flat vaccines turnover grew despite adverse well growing million led strong performances comparison strong cervarix sales japan excluding votrient promacta initial impact launches cervarix japan vaccines sales grew reflecting strong tafinlar mekinist monotherapies year gains growth us infanrixpediarix boostrix partially offset impact generic competition lamictal benefited competitor supply issues fluarixflulaval number dermatology products increase benefited launch new quadrivalent formulation vaccines sales primarily resulted increases infanrix well better performance business europe consumer pediarix boostrix sales benefited competitor healthcare turnover increased million excluding supply shortages fluarixflulaval sales also strong following noncore otc brands divested h turnover grew launch quadrivalent flu formulation group turnover geographic region europe pharmaceuticals vaccines turnover million flat compared benefits recent restructuring refocusing business offset continued pricing restated growth growth pressures generic competition number products cer pharmaceutical sales million seretide us sales declined volume decline flat pricing oncology europe products particularly votrient promacta performed well emap avodart growth products offset japan lower sales number older products particularly impacted continued pricing measures generic competition vaccines sales grew largely due improved tender performance group sales outside usa europe accounted total turnover reported growth adversely impacted sales declines china gsk annual report strategic report financial review emap pharmaceuticals vaccines turnover respiratory million adversely affected ongoing respiratory sales grew million investigation china pharmaceuticals million us europe emap japan vaccines million china pharmaceuticals seretideadvair sales million largely driven vaccines sales driven primarily declines strong us performance flixotideflovent sales increased respiratory hepatitis products excluding china emap million ventolin sales grew million xyzal pharmaceuticals vaccines sales grew driven sales almost exclusively made japan grew million pharmaceuticals growth middle eastafrica latin america reflecting strong allergy season south east asia partially offset declines india korea us respiratory sales grew advair vaccines sales million excluding million compared estimated underlying growth china reflecting strong tender performances cervarix year volume decline offset positive infanrixpediarix partially offset tough comparison impact price mix flovent sales million estimated underlying growth year volume japan pharmaceuticals vaccines turnover grew decrease offset positive impact price mix ventolin million growth pharmaceuticals sales partially offset grew million estimated underlying growth decline vaccines sales strong growth respiratory driven mostly improved price realisation first half year products well relenza avodart lamictal partly launch breo ellipta began q million sales offset generic competition paxil sales vaccines sales primarily recorded quarter reflected impact cervarix suspension european respiratory sales reflecting increased recommendation use hpv vaccines japan competition many markets seretide sales second half adverse comparison million volume decrease net impact benefited final stages catchup hpv vaccination price mix serevent flovent sales programme respectively viiv healthcare turnover flat million growth respiratory sales emap grew excluding china led generated epzicom selzentry together introduction seretide grew million excluding china tivicay offset impact continued competition older seretide continued deliver strong growth across many emap products markets veramyst grew million ventolin increased consumer healthcare turnover excluding noncore otc brands million divested h grew growth four categories japan respiratory sales grew million strong growth us europe primarily arose growth xyzal veramyst adoair sales grew specialist oral health including sensodyne denture care million relvar ellipta launched december restocking alli stock much rest recording sales million world turnover grew strong growth india middle east latin america partly offset decline sales china driven antivirals impact shelving restrictions contac mandatory decrease sales antivirals reflected declines zeffix price reductions fenbid reported consumer healthcare turnover hepsera china partially offset tender shipments relenza grew million japan pharmaceuticals turnover central nervous system cns seroxatpaxil sales fell million primarily due generic restated growth growth competition japan europe requip sales fell cer million reflecting generic competition us europe respiratory lamictal sales fell million primarily result generic antivirals competition lamictal xr us started q central nervous system sales lamictal franchise us fell million cardiovascular urogenital cardiovascular urogenital metabolic sales category fell primarily result impact antibacterials conclusion vesicare copromotion agreement q oncology emesis excluding vesicare sales declined dermatology rare diseases avodart franchise grew million growth sales duodartjalyn avodart sales grew million immunoinflammation pharmaceuticals lovaza fell million result increased competition viiv healthcare hiv decline nonstatin dyslipidemia prescription market arixtra sales fell million gsk annual report metabolic rare diseases increase metabolic product sales primarily reflected higher volibris million mepron million sales prolia europe emap main drivers growth category flolan sales fell million primarily result biennial price antibacterials reduction japan q continued generic competition augmentin sales grew million strong growth us europe emap reflecting part comparison supply interruptions zinnat sales flat million immunoinflammation zinacef sales fell million benlysta turnover year million million us total inmarket sales benlysta us oncology emesis million oncology emesis sales grew million marking second consecutive year double digit percentage growth viiv healthcare hiv business us sales strong performances viiv healthcare sales million flat sales us votrient promacta arzerra also contributions europe emap epzicom launches two new metastatic melanoma products tafinlar kivexa sales increased million selzentry mekinist sales europe grew emap grew votrient million tivicay recorded sales million sales grew million promacta sales grew early stages launch us started august million arzerra sales grew million tykerb tivicay approved europe january launches tyverb sales fell million due increased competition planned several markets throughout growth contributions hycamtin europe emap argatroban us within business offset declines mature portion continued adversely affected generic competition portfolio mainly combivir million us continued strong growth contributions vaccines turnover votrient million promacta million benefited new indication growth growth thrombocytopenia associated hepatitis c received q cer arzerra grew million us performance also vaccines sales reflects contributions totalling million tafinlar mekinist launched q monotherapy treatments performance vaccines business improved towards end achieved strong uptake braf v melanoma market year significant increase tender sales last quarter first months market january tafinlar increase vaccines sales principally attributable mekinist approved fda combination use growth infanrixpediarix fluarixflulaval boostrix largely offset decline cervarix japan reflecting europe sales grew million led sales votrient suspension recommendations use hpv vaccines increased million continued build japan together adverse comparison strong cervarix market share many markets revolade received approval europe sales benefited final stages hpv use thrombocytopenia associated hepatitis c end vaccination catchup programme japan cervarix sales declined q sales year increased million million excluding cervarix japan vaccines sales tafinlar launched q certain markets increased achieved strong uptake early launch markets infanrixpediarix sales increased million growth emap sales grew million led strong growth primarily reflecting stronger tender shipments europe emap votrient million promacta well benefit us competitor supply shortage million region tykerb million boostrix sales also benefited competitor supply issue hycamtin million us grew million dermatology sales hepatitis vaccines fell million primarily reflecting sales declined million primarily result decline lower sales us result return competing vaccines us million continued suffer market second half together declines impact generic competition particularly bactroban duac europe china soriatane together effect disposal number synflorix sales increased million helped strong tail brands q emap sales grew million tender sales middle eastafrica latin america reflecting strong growth bactroban dermovate duac particularly middle eastafrica latin america european rotarix sales grew million strong growth middle sales grew million eastafrica europe partially offset impact increased competition japan fluarixflulaval sales increased million following launch quadrivalent formulation us gsk annual report strategic report financial review sales new pharmaceutical vaccine launches consumer healthcare turnover growth growth cer restated growth growth cer pharmaceuticals total wellness arzerra oral care benlysta nutrition duodartjalyn skin health lamictal xr mekinist potigatrobalt prolia restated growth growth relvarbreo ellipta cer tafinlar usa tivicay europe votrient row xgeva dermatology consumer healthcare turnover grew year excluding noncore otc brands divested h turnover grew vaccines reflecting overall growth three regions synflorix nimenrix total wellness total wellness sales excluding noncore otc brands divested h grew us europe alli new products launched last five years reported strong growth large part due stock inclusive sales new products million much severe cold flu season early helped grew year represented pharmaceuticals drive growth several respiratory brands including coldrex vaccines turnover q sales new products beechams panadol cold flu growth partly offset million grew represented pharmaceuticals reduction sales china contac due new shelving vaccines turnover requirements fenbid advance mandatory price tafinlar mekinist metastatic melanoma approved reductions launched us q q tivicay treatment hiv patients approved launched us oral care tafinlar granted approval launched europe strong growth oral care sales led growth specialist q breo ellipta launched us copd relvar oral health sensodyne sensitivity acid erosion ellipta granted approval europe copd asthma denture care brands aquafresh launched q addition launch activities currently underway anoro ellipta approved us nutrition treatment copd december nutrition sales grew strong growth rest world markets led horlicks boost india key expansion markets subcontinent lucozade grew ribena grew skin health skin health sales grew led abreva us regional performance excluding noncore otc products divested us sales grew led strong contributions oral care brands alli abreva partially offset declines gastrointestinal products reflecting increased competitor activity smoking control products impacted supply disruptions europe sales grew helped sales alli strong growth products respiratory health pain oral care sales europe flat strong growth sensodyne denture care brands offset decline aquafresh due part supply issues q rest world markets grew reflecting growth across categories markets particularly india partially offset reduction sales china mainly due reduction sales contac fenbid gsk annual report core results table analyses core rd expenditure categories use core reporting basis manage performance group definition core results set restated review groups total results set pages reconciliation total results core results presented discovery development facilities central support functions cost sales pharmaceuticals rd vaccines rd restated growth consumer healthcare rd turnover turnover cer core rd cost sales proportion pharmaceuticals rd investment made core cost sales turnover compared latestage portfolio decreased pharmaceuticals rd net currency effects percentage points costs impact percentage point reduction cost sales percentage due settlement early royalty agreement royalty income conclusion vesicare agreement cost sales royalty income million million included percentage increased percentage points reflected prior year royalty catchup adjustment recorded early expected impact unwinding costs manufacturing volume core operating profit shortfalls adverse mix impact preparing launches new pipeline products partially offset ongoing cost management better price realisation restructuring benefits restated growth selling general administration turnover turnover cer core operating profit restated growth core operating profit million flat cer terms turnover increase core operating margin turnover turnover cer percentage points lower excluding currency selling general effects margin declined percentage points reflected administration negative impact expected increase cost sales partially core sga costs percentage sales flat offset higher royalty income lower rd expenditure net favourable yearonyear benefits groups groups continuing restructuring programmes contributed restructuring programmes ongoing cost management efforts incremental yearonyear savings around million funded investments growth businesses preparations new ongoing structural initiatives product launches contribution structural benefits approximately advertising promotion expenses decreased selling million lower total savings realised changes distribution decreased general administration increased postretirement medical obligations approximately million group realised million savings research development capping future pensionable salary increases change basis future discretionary pension increases rpi cpi restated growth certain legacy plans turnover turnover cer research development core rd expenditure declined million turnover compared million turnover reflected completion number large trials phasing ongoing project spending well continuing cost management remain focused delivering improved return investment rd sales contribution reduced attrition cost reduction important drivers improving internal rate return rd expenditure determined percentage sales instead capital allocated using strict returns based criteria operations pharmaceuticals rd broadly split discovery activities completion phase iia trials development work phase iib onwards gsk annual report strategic report financial review core operating profit business net finance costs restated growth finance income margin margin interest income cer fair value movements pharmaceuticals vaccines pharmaceuticals finance expense vaccines interest expense consumer healthcare unwinding discounts liabilities remeasurements fair value movements corporate finance expense unallocated costs core operating profit core net finance expense million compared core operating profit segment million despite higher average net debt levels year largely driven continuing share repurchases restated growth dividends shareholders reflected strategy improve funding profile group net debt december turnover turnover cer billion lower december reflecting receipts pharmaceuticals billion disposals businesses intangible assets vaccines aspen shares investments realised largely end usa year europe emap share tax profits associates joint ventures japan share tax profits associates million viiv healthcare million principally arose groups holding pharmaceutical rd aspen pharmacare trading core profit taxation unallocated pharmaceuticals restated growth pharmaceuticals vaccines turnover turnover cer core profit tax consumer healthcare taxation corporate tax core profit amounted million included unallocated costs recognition us rd credits reflected effective core tax core operating profit rate continue believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation core earnings per share core eps p p increased cer terms actual exchange rates dividend board declared four interim dividends resulting dividend year pence pence increase dividend see note financial statements dividends gsk annual report core results reconciliation december acquisition core intangible intangible major legal accounting total results amortisation impairment restructuring charges results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions core results reconciliation december restated acquisition core intangible intangible major legal accounting total results amortisation impairment restructuring charges results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report financial review total results operating income operating income million million restated growth included profit disposal lucozade ribena business anticoagulant products million turnover turnover cer income included gains profit disposal noncore turnover otc brands million gain million arising cost sales revaluation preexisting collaborations part hgs selling general viiv healthcareshionogi joint venture acquisitions administration operating profit research development total operating profit million compared royalty income million noncore items resulted total net operating charges million million income intangible asset amortisation million million operating profit included million related amortisation benlysta net finance costs intangible asset acquired part hgs acquisition late profit disposal intangible asset impairments million million interest associates included writeoffs several rd assets together partial impairment lovaza reflecting reassessment groups share tax expectations likelihood potential generic competition profits associates joint ventures major restructuring charges million million profit taxation comprised million operational excellence programme million major change programme taxation million related acquisition hgs total profit taxation year operational excellence programme initiated total profit attributable several expansions expected cost approximately shareholders billion expected deliver annual pretax savings approximately billion end earnings per share p earnings per ads major change programme focuses opportunities simplify us supply chain processes build groups capabilities manufacturing rd restructure european pharmaceuticals business cost sales programme expected cost billion noncash total cost sales turnover compared charge million expected deliver annual pretax increase primarily reflected expected impact savings least billion unwinding costs manufacturing volume shortfalls adverse mix legal charges million million principally effects impact preparing launches new pipeline related provisions existing product liability matters products higher amortisation impairments intangible assets partially offset ongoing cost management better price acquisition accounting credits net million realisation restructuring benefits million credit included items related major acquisitions business equity investment asset disposals oneoff required selling general administration regulatory charges rd certain adjusting items total sga costs decreased turnover compared net credit included gains disposals lucozade ribena reflecting lower legal restructuring charges business anticoagulant products million net favourable yearonyear benefits groups restructuring net credit included gains profit disposal noncore otc programmes ongoing cost management efforts funded brands million gain million arising investments growth businesses preparations new revaluation preexisting collaborations part hgs viiv product launches healthcareshionogi joint venture acquisitions advertising promotion expenses decreased selling net finance costs distribution fell general administration decreased primarily reflecting lower legal charges finance income research development interest finance income fair value movements total rd expenditure declined million turnover compared million turnover reflected completion number large trials phasing ongoing project spending well continuing cost management finance expense partially offset higher restructuring required regulatory interest expense charges unwinding discounts liabilities remeasurements fair value movements finance expense total net finance expense million compared million despite higher average net debt levels year reflecting strategy improve funding profile group gsk annual report profit disposal interest associates critical accounting policies information pretax profit disposal interest associates judgements estimates made given note financial million nil reflected disposal million statements key accounting judgements estimates ordinary shares aspen pharmacare million relevant detailed notes financial statements indicated relate following areas share tax profits associates joint ventures turnover share tax profits associates million million principally arose groups holdings taxation note aspen pharmacare legal disputes notes profit taxation impairments goodwill intangible assets taking account net finance costs profit disposal interest notes associates share profits associates profit pensions postemployment benefits note taxation million compared million information judgements estimates made areas cer increase increase sterling terms given note financial statements key accounting taxation judgements estimates turnover restated respect turnover accounting policy largest business uk corporation tax uk statutory rate us pharmaceuticals vaccines us market less double taxation relief complex arrangements rebates discounts allowances following briefly describes nature arrangements existence us pharmaceuticals vaccines business overseas taxation current taxation arrangements certain indirect customers whereby deferred taxation customer able buy products wholesalers reduced prices chargeback represents difference taxation total profits invoice price wholesaler indirect customers charge taxation total profits amounted million contractual discounted price accruals estimating chargebacks represented effective tax rate calculated based terms agreement historical reflecting differing tax effects various noncore items experience product growth rates included net deferred tax charge million related customer rebates offered key managed care group unwinding deferred profit inventory existing inventory purchasing organisations gpo direct indirect produced prior restructuring supply chain sold customers arrangements require customer achieve charge taxation total profits also included deferred certain performance targets relating value product tax credits million primarily reflecting continuing purchased formulary status predetermined market shares restructuring supply chain compared predominantly non relative competitors accrual customer rebates cash deferred tax charge million groups estimated based specific terms agreement balance sheet december included tax payable liability historical experience product growth rates million tax recoverable asset million us medicaid programme stateadministered programme continue believe made adequate provision providing assistance certain poor vulnerable patients liabilities likely arise periods open medicaid drug rebate program established yet agreed tax authorities ultimate liability matters reduce state federal expenditure prescription drugs may vary amounts provided dependent upon patient protection affordable care act became outcome agreements relevant tax authorities litigation law participate providing rebates states accruals earnings per share medicaid rebates calculated based specific terms relevant regulations patient protection affordable total earnings per share p year compared care act p noncore net credits totalled p p charges cash discounts offered customers encourage prompt payment accrued time invoicing critical accounting policies adjusted subsequently reflect actual experience consolidated financial statements prepared accordance record accrual estimated sales returns applying ifrs adopted use european union also historical experience customer returns amounts invoiced ifrs issued iasb following accounting policies together market related information stock levels approved board described note financial wholesalers anticipated price increases competitor activity statements accounting principles policies required make estimates assumptions affect amounts assets liabilities revenue expenses reported financial statements actual amounts results could differ estimates gsk annual report strategic report financial review reconciliation gross turnover net turnover us legal disputes pharmaceuticals vaccines business follows respect accounting policy legal disputes following briefly describes process determine restated restated level provision necessary margin margin accordance requirements ias provisions contingent liabilities contingent assets provide gross turnover anticipated settlement costs outflow resources considered probable reliable estimate may made market driven likely outcome dispute legal expenses arising segments claims group may become involved government significant legal proceedings respect possible mandated state make reliable estimate expected financial effect programs could result ultimate resolution proceedings cash discounts cases appropriate disclosure cases would included customer annual report provision would made returns position could change time therefore prior year assurance losses result outcome legal adjustments proceedings exceed material amount amount items provisions reported groups financial statements total deductions like many pharmaceutical companies faced various net turnover complex product liability antitrust patent litigation well investigations operations conducted various governmental market driven segments consist primarily managed care regulatory agencies throughout year general counsel medicare plans gsk negotiates contract pricing group head groups legal function senior honoured via rebates chargebacks mandated segments consist vice president head global litigation group primarily medicaid federal government programs responsible litigation government investigations routinely receive government mandated pricing via rebates chargebacks brief chief executive officer chief financial officer total balance sheet accruals rebates discounts allowances board directors significant litigation pending returns us pharmaceuticals vaccines business group governmental investigations group december december follows meetings appropriate detail status significant litigation government investigations review matters december december number claims notified us information potential claims yet notified assessment validity claims progress made settling claims recent settlement levels potential managed care medicare part reimbursement insurers gpo rebates meetings also include assessment whether us government state programs sufficient information available us able make reliable cash discounts estimate potential outcomes disputes often external customer returns counsel assisting us various litigation matters investigations also assist briefing board senior management total following discussions matters possible make reliable estimate amount provision may monthly process operated monitor inventory levels required level provision legal disputes wholesalers abnormal movements process uses gross reviewed adjusted appropriate sales volumes prescription volumes based third party data sources information received key wholesalers aim maintain inventories consistent level year year based pattern consumption basis us pharmaceuticals vaccines inventory levels wholesalers distribution channels december estimated amount approximately five weeks turnover calculation uses third party information accuracy totally verified believed sufficiently reliable purpose gsk annual report financial position resources property plant equipment business sciencebased technologyintensive highly regulated governmental authorities allocate significant restated financial resources renewal maintenance property assets plant equipment minimise risks interruption production noncurrent assets achieve compliance regulatory standards number property plant equipment processes use chemicals hazardous materials goodwill total cost property plant equipment december intangible assets million net book value million investments associates joint ventures land buildings represented million plant investments equipment million assets construction million deferred tax assets invested million new renewal property plant equipment mainly related large number derivative financial instruments projects renewal improvement expansion facilities noncurrent assets various worldwide sites property mainly held freehold new total noncurrent assets investment financed liquid resources december current assets contractual commitments future capital expenditure inventories million operating lease commitments million believe facilities adequate current needs current tax recoverable trade receivables observe stringent procedures use specialist skills manage derivative financial instruments environmental risks activities environmental issues liquid investments sometimes dating operations modified discontinued reported planet note cash cash equivalents financial statements legal proceedings assets held sale total current assets goodwill total assets goodwill decreased year million december million decrease primarily reflects liabilities weakening overseas currencies current liabilities shortterm borrowings intangible assets trade payables intangible assets include cost intangibles acquired derivative financial instruments third parties computer software net book value current tax payable intangible assets december million shortterm provisions million decrease reflected assets acquired total current liabilities acquisition okairos ag million capitalised development costs million million computer noncurrent liabilities software costs offset amortisation impairment longterm borrowings existing intangibles million million respectively deferred tax liabilities investments pensions postemployment benefits held investments including associates joint ventures provisions carrying value december million derivative financial instruments million market value december noncurrent liabilities million million largest total noncurrent liabilities investments associate aspen pharmacare holdings total liabilities limited book value december net assets million million investment theravance inc book value december million equity million year sold million shares share capital aspen pharmacare holdings limited representing share premium account interest million investments include equity stakes retained earnings companies group research collaborations reserves provide access biotechnology developments potential interest shareholders equity interests companies arise business divestments noncontrolling interests total equity gsk annual report strategic report financial review derivative financial instruments assets net debt decreased million reflected receipts noncurrent current derivative financial instruments billion disposals lucozaderibena held fair value million million majority anticoagulant products businesses intangible assets part amount relates interest rate swaps foreign exchange groups investment aspen pharmacare holdings limited contracts designated nondesignated intercompany loans investments impact partly offset deposits accounting hedges consideration paid increase shareholding groups indian consumer healthcare subsidiary inventories cost million acquire okarios ag million inventory million decreased million groups strong cash generation enabled financing share year decrease reflects impact disposal lucozade repurchases billion dividend payments billion ribena anticoagulant products businesses partly offset higher vaccine stocks stockbuilding new product launches movements net debt trade receivables trade receivables million increased net debt beginning year reflecting receivable due aspen respect inventory manufacturing site formed part disposal increasedecrease cash bank overdrafts anticoagulants products business partly offset weakening cash inflow liquid investments overseas currencies net increase longterm loans net repayment shortterm loans derivative financial instruments liabilities debt subsidiary undertakings acquired held noncurrent current derivative financial exchange movements instruments fair value million million movements primarily relates foreign exchange contracts designated net debt end year nondesignated intercompany loans deposits external debt legal provisions accounting hedges total equity december total equity increased million trade payables december million increase arose principally trade payables amounting million increased reduction pension deficit million reduction million reflecting current year accrual postretirement provision million retained profits respect acquisition shares groups indian year exceeding shares repurchased partly offset liability pharmaceutical subsidiary million partly offset effect million arising open offer purchase shares held increased shareholding indian consumer healthcare noncontrolling interest groups indian pharmaceutical subsidiary accrued together weakening overseas subsidiary glaxosmithkline pharmaceuticals limited currencies summary movements equity set provisions carried deferred tax provisions shortterm restated noncurrent provisions million december million respect estimated future liabilities total equity beginning year million million related legal prior year adjustment ias r disputes provision made legal disputes january restated indemnified disposal liabilities employee related liabilities total comprehensive income year costs restructuring programmes extent balance dividends shareholders sheet date legal constructive obligation existed could reliably estimated shares issued changes noncontrolling interests pensions postemployment benefits forward contract relating noncontrolling account pension postemployment arrangements interest accordance ias deficits net surpluses shares purchased cancelled held allowing deferred taxation million treasury shares million pension arrangements million consideration received shares transferred million unfunded postemployment liabilities esop trusts december uk scheme purchased insurance contract shares acquired esop trusts guarantee payment specified pensioner liabilities sharebased incentive plans contract valued million december tax sharebased incentive plans net debt distributions noncontrolling interests total equity end year changes noncontrolling interests year primarily arose cash cash equivalents liquid investments voluntary open offer acquire shares gsk borrowings repayable within one year pharmaceuticals ltd groups pharmaceutical subsidiary india borrowings repayable one year net debt gsk annual report share purchases commitments respect loans future interest payable loans employee share ownership plan esop trusts disclosed taking account effect derivatives acquired million shares glaxosmithkline plc entered number research collaborations develop million shares held trusts satisfy future exercises new compounds pharmaceutical companies terms options awards group share option award arrangements include upfront fees equity investments schemes proportion shares held trusts respect loans commitments fund specified levels research awards rules scheme require us satisfy addition often agree make payments future exercises market purchases rather issue new milestones achieved shares shares held trusts matched options agreements relate compounds early awards granted stages development potential obligation make milestone december esop trusts held million payments continue number years compounds move million gsk shares future exercise share options successfully development process generally closer share awards carrying value million product marketing approval greater possibility million deducted reserves market success amounts shown within intangible assets value shares million million represent maximum would paid milestones million shares repurchased cost achieved include billion relates externalised million see note share capital share premium projects discovery portfolio number new commitments account currently targeting repurchases made licensing agreements including billion exact amount timing future purchases arrangements adimab llc immunocore ltd morphosys ag whether shares held treasury shares reached agreement trustees uk cancelled determined company dependent pension schemes make additional contributions three year market conditions factors december held period including eliminate pension deficit identified million shares treasury shares million shares december actuarial funding valuation deficit cost million million persists contributions would payable following four deducted retained earnings years depending level deficit table includes shares purchased period january commitment excludes normal ongoing annual funding february requirement uk approximately million information pension obligations see note financial commitments contingent liabilities statements pensions postemployment benefits financial commitments summarised note financial contingent liabilities statements commitments contingent liabilities obligations respect short longterm debt set following table sets contingent liabilities comprising note financial statements contingent liabilities discounted bills performance guarantees letters credit note financial statements net debt items arising normal course business expected expire amounts provided pensions postretirement benefits set note financial statements pensions total yr yrs yrs yrs postemployment benefits amounts provided restructuring programmes legal environmental disputes set guarantees note financial statements provisions contingent liabilities total contractual obligations commitments following table sets contractual obligations normal course business provided various commitments december fall due payment indemnification guarantees respect business disposals legal disputes subsequently arisen provision total yr yrs yrs yrs made outflow resources considered probable reliable estimate made likely outcome dispute loans included note financial statements interest loans provisions finance lease obligations provide outcome tax legal disputes finance lease charges outflow resources considered probable reliable estimate operating lease outflow may made december commitments disputes provision made possible intangible assets make reliable estimate potential outflow funds might property plant equipment required settle disputes possibility investments outflow remote purchase commitments ultimate liability matters may vary significantly pensions amounts provided dependent upon outcome litigation commitments proceedings negotiations relevant tax authorities total discussed risk factors pages notes financial statements taxation legal proceedings gsk annual report strategic report financial review cash generation conversion investment appraisal summary consolidated cash flow set formal process assessing potential investment proposals order ensure decisions aligned overall strategy process includes assessment cash flow return investment cfroi well net present value npv net cash inflow operating activities internal rate return irr timeline project net cash inflowoutflow investing activities long term also consider impact earnings credit profile net cash outflow financing activities relevant increasedecrease cash bank overdrafts discount rate used perform financial analyses decided cash bank overdrafts beginning year internally allow determination extent investments increasedecrease cash bank overdrafts cover cost capital specific investments discount rate exchange adjustments may adjusted take account country risk weightings cash bank overdrafts end year capital expenditure financial investment cash bank overdrafts end year cash payments tangible intangible fixed assets amounted comprise million million disposals realised million million cash payments acquire cash cash equivalents equity investments million million made overdrafts year sales equity investments realised million million net cash inflow operating activities year future cash flow million million increase primarily reflected legal expect future operating cash flow sufficient fund settlements billion lower together operating debt service costs satisfy normal levels phasing restructuring expenditure lower tax payments capital expenditure meet obligations existing licensing pension contributions partially offset smaller reduction agreements meet expenditure arising major working capital compared given supply chain investments restructuring programmes precise timing uncertain inventory launch preparation outlined note financial statements major restructuring free cash flow costs meet routine outflows including tax dividends free cash flow amount cash generated business subject risk factors discussed pages may meeting obligations interest tax dividends paid time time additional demands finance noncontrolling interests capital expenditure property acquisitions share repurchases access plant equipment intangible assets sources liquidity short longterm capital markets banks financial institutions addition cash flow operations needs free cash flow working capital free cash flow growth free cash flow million year increase working capital percentage turnover primarily reflected impact lower tax payments special uk pension contributions partly offset smaller reduction working working capital conversion cycle days capital increased expenditure property plant equipment working capital programme continued make progress paid dividends shareholders million spent improvements collection receivables million repurchasing shares effective management payables balances year reconciliation net cash inflow operating activities number initiatives implemented across supply chains closest equivalent ifrs measure free cash flow shown supporting pharmaceutical vaccines consumer healthcare businesses provided stronger endtoend accountability reconciliation free cash flow case programmes early stage already reduced volatility improved responsiveness allowing better inventory management net impact inventory limited net cash inflow operating activities significant investments also made improving purchase property plant equipment service levels preparing new product launches purchase intangible assets reported working capital conversion cycle days distorted disposal property plant equipment divestments made year intangible asset interest paid impairments included denominator used conversion interest received cycle computation yearend conversion cycles dividends received joint ventures adjusted factors around days around associated undertakings days respectively reduction days distributions noncontrolling interests free cash flow gsk annual report maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper bank borrowings leases treasury policies liquidity gsk reports sterling pays dividends sterling profits december cash liquid investments held role corporate treasury monitor manage external follows internal funding requirements financial risks support strategic objectives gsk operates global basis primarily subsidiary companies manage capital ensure bank balances deposits subsidiaries able operate going concerns optimise us treasury treasury repo returns shareholders appropriate balance debt equity treasury activities governed policies approved money market funds board directors recently july treasury corporate debt instruments management group tmg meeting chaired chief financial government securities officer takes place monthly basis review treasury activities members receive management information relating treasury cash liquid investments billion including amounts held activities viiv healthcare held centrally december capital management net debt billion december table financial strategy supports groups strategic priorities summarises cash gross debt effects hedging regularly reviewed board manage capital structure group appropriate mix debt equity gsks financial architecture designed support delivery cash liquid investments groups strategy enhance returns shareholders gross debt fixed four key priorities delivering sustainable sales growth improving operating leverage improving financial efficiency converting floating earnings cash free cash flow generated noninterest bearing returned shareholders reinvested bolton acquisitions net debt wherever attractive returns available gsk continues gsks policy borrow centrally order meet anticipated apply strict financial returnsbased criteria cash funding requirements cash flow forecast funding flow return investment order allocate capital assess requirements monitored tmg monthly basis investment opportunities whilst protecting credit profile strategy diversify liquidity sources using range business remains highly cash generative gsk facilities maintain broad access funding markets generated billion free cash flow addition realised gsks longterm credit ratings remained unchanged since billion divestments returned total february current ratings stable outlook billion shareholders billion dividends standard poors negative outlook moodys investors billion share repurchases net debt end service moodys shortterm credit ratings p year stood billion reduction billion compared standard poors moodys respectively previous year expect deliver continued dividend growth part longterm share buyback programme targeting share repurchases billion depending market conditions details see note financial statements financial instruments related disclosures gsk annual report strategic report financial review treasury operations counterparty risk management objective treasury activity manage posttax net cost gsk sets global counterparty limits banking income financial operations benefit earnings use investment counterparties based longterm credit ratings variety financial instruments finance operations moodys standard poors corporate treasurys usage derivative financial instruments manage market risks limits monitored daily corporate compliance officer operations derivatives principally comprising forward foreign cco operates independently corporate treasury currency contracts interest rate swaps used swap breach limits would reported cfo immediately borrowings liquid assets currencies required group cco also monitors credit rating counterparties purposes manage exposure financial risks changes changes ratings occur notifies corporate treasury foreign exchange rates interest rates changes made investment levels authority limits appropriate addition relationship banks credit ratings hold issue derivatives speculative purposes reviewed regularly report presented annually tmg treasury policies specifically prohibit activity transactions approval financial instruments undertaken manage risks arising underlying business activities speculation group reporting interest rate risk management gsk intends report core results performance gsks objective minimise effective net interest cost measured core results excluding divestments balance mix debt fixed floating interest rates time completed divestments include disposals policy interest rate risk management limits amount lucozade ribena anticoagulant products several floating interest payments prescribed percentage operating minor products summary restated core results excluding profit divestments set use interest rate swaps redenominate one bonds core results floating interest rates duration swaps matches core divested excluding duration principal instrument interest rate derivative results businesses divestments instruments accounted fair value hedges relevant liability turnover cost sales foreign exchange risk management selling general administration foreign currency transaction exposures arising internal external trade flows generally hedged groups objective research development minimise exposure overseas operating subsidiaries royalty income transaction risk matching local currency income local operating profit currency costs possible internal trading transactions profit tax matched centrally manage intercompany payment terms profit tax reduce foreign currency risk foreign currency cash flows hedged selectively management corporate treasury profit attributable shareholders tmg possible manage cash surpluses earnings per share pence p p p borrowing requirements subsidiary companies centrally using reconciliation core results total results set forward contracts hedge future repayments back originating currency strategic report order reduce foreign currency translation exposure seek denominate borrowings currencies principal assets strategic report approved duly authorised cash flows primarily denominated us dollars euros committee board directors february sterling certain borrowings swapped currencies signed behalf required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts major simon dingemans currencies also used reduce exposure investment chief financial officer overseas group assets tmg reviews ratio borrowings february assets major currencies monthly gsk annual report governance remuneration section board corporate executive team chairmans letter board report shareholders committee reports remuneration committee chairmans annual statement annual report remuneration remuneration policy report gsk annual report governance remuneration board board diversity experience international experience number directors experience scientific global finance usa industry europe emap tenure composition nonexecutives executive years nonexecutive years years male board considers nonexecutive directors female independent accordance uk corporate governance code sir christopher gent skills experience sir christopher many years experience leading global chairman businesses track record delivering outstanding performance highly competitive industries appointed managing director nationality vodafone plc became chief executive officer british retirement appointment date external appointments june chairman sir christopher nonexecutive director ferrari spa senior january adviser bain co member british airways international committee membership business advisory board chairman nominations corporate responsibility committees member remuneration finance committees sir andrew witty skills experience sir andrew joined gsk worked uk south africa chief executive officer usa singapore various senior roles appointed president gsk europe joined gsks corporate executive team nationality british awarded public service medal government singapore august also awarded public service star appointment date new year honours list awarded knighthood january chief services economy uk pharmaceutical industry executive officer may served lead nonexecutive board member department committee membership business innovation skills december also member finance committee president european federation pharmaceutical industries associations july external appointments sir andrew member uk prime ministers business advisory group appointed uk business ambassador group january simon dingemans skills experience prior joining gsk simon years experience chief financial officer investment banking sg warburg goldman sachs time advised broad range large corporates across number nationality industry sectors including pharmaceuticals consumer healthcare british simon advised gsk decade appointment appointment date closely involved number gsks key strategic projects including january chief establishment viiv healthcare financial officer april external appointments committee membership simon member corporate development council member finance committee national theatre deputy chairman group gsk annual report dr moncef slaoui skills experience moncef joined gsk vaccines engineered chairman global rd development robust vaccines pipeline led worldwide vaccines business development pharmaceutical products appointment lead rd also given overall responsibility nationality gsks oncology business gsk vaccines moroccan belgian american global franchises phd molecular biology appointment date immunology universit libre de bruxelles published may scientific papers presentations prior joining gsk moncef professor immunology university mons belgium committee membership member finance committee external appointments moncef member phrma biotechnology industry organization boards usa member advisory committee director national institutes health also adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef advised us presidents council advisors science technology member board agency science technology research astar january sir deryck maughan skills experience sir deryck wealth international corporate investment senior independent banking experience previously served chairman chief nonexecutive director executive officer citigroup international salomon brothers inc served vice chairman new york stock exchange nationality british external appointments appointment date sir deryck senior adviser former partner kohlberg june senior kravis roberts co nonexecutive director blackrock independent nonexecutive inc thomson reuters trustee british museum director may new york university langone medical center also director committee membership lincoln center member audit risk nominations remuneration finance committees professor sir roy anderson skills experience professor sir roy worldrenowned medical scientist advanced independent nonexecutive knowledge infectious disease epidemiology currently professor director scientific expert infectious disease faculty medicine imperial college london fellow member policy advisory board royal nationality society fellow academy medical sciences royal british statistical society honorary fellow institute actuaries appointment date foreign associate member institute medicine us october national academy sciences french academy sciences professor sir roys background enables bring scientific experience committee membership boards deliberations member nominations finance committees external appointments professor sir roy member international advisory board holdingham group trustee natural history museum london dr stephanie burns skills experience stephanie recognised global business leader served independent nonexecutive chairman president ceo dow corning corporation director retirement end strong scientific background phd organic chemistry organosilicon specialty nationality staunch advocate science education officer american chairman american chemistry council appointment date external appointments february stephanie appointed nonexecutive director corning inc committee membership january appointed director board kellogg member corporate company february sat us presidents export responsibility remuneration council stephanie also officer society chemical industry finance committees america section past honorary president ukbased parent society gsk annual report governance remuneration board board continued stacey cartwright skills experience stacey chartered accountant extensive experience global independent nonexecutive consumer businesses corporate finance served executive director vice president chief financial officer burberry group plc july prior joining burberry group plc stacey held role nationality chief financial officer egg plc british worked various financerelated positions granada appointment date group plc april external appointments committee membership stacey chief executive officer harvey nichols group member audit risk companies role appointed february finance committees lynn elsenhans skills experience lynn wealth experience running global business independent nonexecutive significant knowledge global markets gsk operates director served chair president chief executive officer sunoco inc prior joining sunoco president nationality chief executive officer lynn worked royal dutch shell american joined held number senior roles including appointment date executive vice president global manufacturing july external appointments committee membership lynn nonexecutive director baker hughes inc director member audit risk texas medical center director first tee greater houston corporate responsibility also trustee united way greater houston trustee finance committees rice university judy lewent skills experience judy extensive knowledge global pharmaceutical industry independent nonexecutive corporate finance joined merck co served director chief financial officer retired judy previously served nonexecutive director motorola inc dell inc nationality quaker oats company american external appointments appointment date judy nonexecutive director thermo fisher scientific inc april motorola solutions inc also trustee rockefeller family trust committee membership chairperson audit committee rockefeller financial services life member massachusetts institute technology corporation chairman audit risk member american academy arts sciences judy committee member nonexecutive director purdue pharma inc napp pharmaceutical remuneration finance holdings limited certain mundipharma international limited committees companies dr daniel podolsky skills experience daniel worldrenowned researcher advanced knowledge independent nonexecutive underlying mechanisms disease new therapies gastrointestinal director scientific expert disorders formerly mallinckrodt professor medicine chief gastroenterology massachusetts general hospital harvard nationality medical school previously served chief academic officer american partners healthcare system daniels current responsibilities appointment date leading large academic medical centre give relevant insight july healthcare delivery daniel brings scientific expertise board committee membership audit risk committees deliberations member audit risk external appointments corporate responsibility daniel president university texas southwestern medical finance committees center holds philip obryan montgomery jr md distinguished presidential chair academic administration doris bryan wildenthal distinguished chair medical science member institute medicine us national academy sciences member board southwestern medical foundation director antibe therapeutics inc also member national academies sciences board army science technology gsk annual report tom de swaan skills experience tom long distinguished career european banking independent nonexecutive industry member managing board chief director financial officer abn amro tom held various executive positions dutch central bank nonexecutive director nationality financial services authority financial conduct authority dutch previously nonexecutive director appointment date kpmgs public interest committee also vice chairman january supervisory board chairman audit committee royal ahold committee membership external appointments chairman remuneration tom chairman supervisory board vanlanschot bankiers committee member chairman board directors zurich insurance group audit risk nominations member supervisory board royal dsm finance committees jing ulrich skills experience jing managing director vice chairman asia pacific jpmorgan independent nonexecutive chase advises firms senior global clients across asset director classes building relationships executives asias leading enterprises jing one prominent advisors large global nationality asset management companies sovereign wealth funds multinational american corporations works lines business jpmorgan chase appointment date foster greater crossborder collaboration strengthen senior client july relationships asia pacific rest world committee membership jing managing director chair global markets china member audit risk jpmorgan jing worked finance committees deutsche bank managing director head greater china equities previously held financial positions specialising asia pacific region clsa asia pacific markets emerging markets investors corporation educated harvard stanford universities external appointments jing independent director ermenegildo zegna spa hans wijers skills experience hans broad range business economic political experience independent nonexecutive served chief executive officer chairman akzo nobel director nv hans long distinguished career academia public service strategy consulting served senior nationality vice president boston consulting group dutch external appointments appointment date hans chairman supervisory board heineken nv also april deputy chairman nonexecutive director royal dutch shell committee membership also chairman supervisory board afc ajax member corporate responsibility remuneration finance committees sir robert wilson skills experience sir robert long distinguished career industry mainly independent nonexecutive rio tinto became chief executive officer director executive chairman retirement october sir robert became nonexecutive chairman bg group plc nationality january may also chairman economist british group nonexecutive director appointment date bp diageo boots november stood senior independent nonexecutive director committee membership member audit risk committee may member corporate responsibility nominations external appointments finance committees sir robert senior adviser morgan stanley chairman riverstone energy limited chairman accenture global mining executive council gsk annual report governance remuneration corporate executive team corporate executive team sir andrew witty simon bicknell deirdre connelly roger connor chief executive officer senior vice president president north america president global governance ethics pharmaceuticals manufacturing supply see board assurance deirdre joined gsk president roger president global simon appointed senior vice north america pharmaceuticals manufacturing supply gms president governance ethics february working appointed role assurance january eli lilly company years january working responsible risk management held variety positions year president designate gms compliance strategic auditing including president us operations roger joined gsk senior vice president global simon joined company secretariat commercialisations womans astrazeneca worked became deputy company health senior vice president number roles within finance secretary glaxo wellcome human resources manufacturing strategy including appointed company secretary gsk sites cork ireland glaxosmithkline plc may deirdre native san juan puerto ware uk prior role combined position rico holds bachelors degree gms roger vice president role corporate compliance officer marketing economics office ceo corporate current appointment lycoming college pennsylvania strategy february graduated harvard gaining law degree simon universitys advance management holds degree mechanical qualified barrister programme manufacturing engineering member middle temple queens university belfast deirdre serves director masters manufacturing leadership phrma board board macys cambridge university also inc harvard university public chartered accountant health policy council simon dingemans abbas hussain bill louv david redfern chief financial officer president europe japan senior vice president core chief strategy officer emap business services see board david appointed chief strategy abbas appointed president bill appointed create lead officer may responsible europe emap september core business services cbs proactive exploration new became responsible japan april cbs integrates shared business opportunities strategic march joined company services global support planning leadership president emerging markets functions previously chief dermatology business addition asia pacific june information officer current role appointed chairman board viiv previously abbas spent years bill joined company healthcare ltd april eli lilly held positions vice president medical data including president europe sciences held number previously senior vice vice president europe increasingly senior roles rd president northern europe specific responsibility western responsibility managing gsks european midsize countries africa bill bachelor science degree pharmaceutical businesses middle east areacommonwealth biology college william region prior senior vice independent states central mary master science president central eastern eastern europe regions also held doctor philosophy degrees europe david joined company positions sales marketing across statistics university florida held series finance australasia india roles becoming finance director european business abbas appointed viiv healthcare ltd board october aspen board david bachelor science december degree bristol university uk chartered accountant born madras india abbas degree medicinal chemistry pharmacology loughborough university gsk annual report dr moncef slaoui claire thomas phil thomson chairman global rd senior vice president senior vice president vaccines human resources global communications see board claire appointed senior vice phil appointed senior vice president human resources may president global communications responsible gsks august responsibility environmental sustainability strategy media relations investor relations previously senior vice corporate responsibility internal president human resources communications product pharmaceuticals international communications claire joined company phil joined glaxo wellcome appointed senior vice commercial trainee moving president human resources pharmaceutical brand marketing pharmaceuticals europe product communications successfully led became director media hr function merger relations glaxo wellcome plc took position prior joining company director investor relations gsk worked ford motor company returned corporate holding various positions human media relations vice president resources phil earned degree english claire bachelor science history durham university degree economics management industrial relations university wales claire honoured outstanding european woman achievement dan troy patrick vallance emma walmsley senior vice president president pharmaceuticals president consumer general counsel rd healthcare worldwide dan joined company senior patrick appointed president emma assumed role president vice president general counsel pharmaceuticals rd january consumer healthcare worldwide september prior appointment october joining gsk senior vice president medicines may president consumer previously partner discovery development healthcare europe washington law firm sidley austin llp represented mainly patrick joined company emmas leadership business pharmaceutical companies trade head drug discovery new strategic direction associations matters related focused organisation science become first best fast moving us food drug administration best chance leading consumer healthcare company driven fda government regulations new medicines created science values combining dan formerly chief counsel small multidisciplinary teams called best gsks scientific fda served primary discovery performance units knowledge speed liaison white house transforming way marketing excellence fast us department health human approach late stage clinical trial moving consumer goods world services design execution prior joining gsk emma worked dan graduate cornell prior joining gsk patrick loreal years universitys school industrial clinical academic university college held variety marketing general labor relations earned law london patrick member management roles paris london degree columbia university board agency science new york school law technology research astar based shanghai general director genome manager consumer products research limited loreal china degree classics modern languages oxford university gsk annual report governance remuneration corporate governance corporate governance letter shareholders dear shareholder new style remuneration report pages comprises chairman board committed chairmans statement tom ensuring gsk operates highest de swaan remuneration committee standards corporate governance chairman reflects committees believe governance structure underpins decisions year outlines ability deliver groups strategy committees agenda grow diversified business deliver products value simplify operating n annual report remuneration model sets committee implemented gsks remuneration policy new governance remuneration year way reporting changes propose operate gsks policy light new provisions financial reporting councils update uk remuneration policy report sets corporate governance code updated gsks proposed remuneration policy code commencement new apply three years end remuneration reporting regulations annual general meeting may reviewed governance corporate reporting arrangements updated code annual governance meetings available wwwfrcorguk year pleased chair respect principal areas change governance meetings shareholders set updated code taken uk us alongside judy lewent following actions chair audit risk committee sir deryck maughan senior independent n last years annual report disclosed director sid meetings ahead time diversity policy able discuss broad range governance measurable diversity targets pleased matters shareholders including board report relation gender management dynamics director diversity maintained female induction training development representation board since arrangements succession planning july places gsk firmly whilst imparting details important top ten ftse terms female work undertaken nominations board member representation corporate responsibility committees e nhancements made judy provided overview role audit risk committee report arc activities audit risk committee report pages sir deryck shared insights enhancements include discussion perspectives board governance significant issues relating financial structure shareholders since taking statements committee considered role sid sir robert wilson addressed year arc may report also highlights shareholders following pages outline approach key areas focus committee governance building work undertaken year last years annual report restructure new remuneration reporting corporate governance report year regulations came effect addition consolidating several financial reporting year statutory disclosures shareholder participating member gc information section annual report investor group helped develop pages risk disclosures guidance aimed assisting uk quoted previously appeared corporate companies understand practical governance report incorporated implementation new regulations expanded risk management section introduction regulations pages also provided us opportunity commend report take fresh look present shareholders reporting directors remuneration arrangements sir christopher gent chairman february gsk annual report board report shareholders oversight stewardship future actions board board pleased report full compliance requirements uk corporate governance code board responsible longterm success company corporate governance strategy risk management financial performance accountable shareholders ensuring group appropriately managed governed delivers gsks strategy grow deliver simplify board programme board met six times board member attended scheduled board meetings exception sir deryck maughan tom de swaan hans wijers unable attend one meeting due prior business commitments conveyed views comments chairman matters discussed shared directors meeting board agendas shaped create time strategic discussion debate included deep dive reviews key issues business ensure focused consideration strategic priorities agendas board meetings included following business month strategy board oversight governance risk oversight january review extension operational excellence review financial review internal board review risk programme results outlook evaluation report internal review notice agm secretarys report including controls process reappointment auditors regulatory governance updates march review emap performance strategy preparation agm update secretarys report including deep dive global franchises product regulatory governance updates launch readiness review business development projects may annual global manufacturing preparation agm supply vaccines secretarys report business reviews including regulatory governance updates july deep dive pipeline launches annual north america secretarys report including review talent leadership development rd pharmaceuticals reviews regulatory governance updates strategy review treasury funding pensions review capital licensing strategies proposals review long range forecast october review output annual board annual business reviews review projects cet strategy meeting consumer healthcare transactions approved review group insurance strategy japan board review us pension fund investment secretarys report including hedging strategy regulatory governance updates december deep dive china business secretarys report including europe strategy update review regulatory governance updates review approval plan year board members invited attend audit risk committee meetings risk matters routinely discussed board performance board identified certain actions assist adding value deliberations performance board actions set actions progressachievement external landscape board programme expanded include briefings board members keen supplement understanding external areas dr moncef slaoui members senior team landscape teachins range topics various therapeutic areas board october visited gsks rd facility upper providence design phase iii trials pricing biopharmaceuticals pharmacogenomics part boardcet strategy meeting view first hand emerging technology rd emerging technologies rd manufacturing ii oversight strategy board programme adjusted set aside time board wished spend time business unit strategy competitor deep dive business development reviews year analysis pricing regimes acquisition strategy emerging issues iii board composition nominations committee continues focus longterm nominations committee tasked identifying suitable recruitment nonexecutive directors candidates replace board members due retire next years board pleased welcome new nonexecutive director hans wijers provides experience running global organisations boards deliberations actions set full gsks annual report discusses internally facilitated evaluation boards activities senior independent director gsk annual report governance remuneration corporate governance board report shareholders oversight stewardship future actions continued agms key highlights glance agm held may qeii conference centre agm held may qeii conference centre london london full director attendance sir robert wilson stand board ten years billion votes cast resolution issued service share capital directors stand reelection board sir crispin davis stood nine years service board believes director effective demonstrates directors retired either elected reelected commitment role board receiving least votes cast favour director formally evaluated chairman highest votes favour elect reelect number standing reelection directors lowest votes favour reduce required notice general meeting induction programme hans wijers individually designed facilitated chairman company secretary ii purpose orientate familiarise hans appointed board strategy grow deliver simplify industry organisation governance arrangements iii customised take account experience geographical background business perspectives together committees would serve key elements onetoone induction briefing sessions site visits undertaken hans set contactactivity induction content executive directors gsks strategic financial rd priorities cet members wide spectrum gsk business operations including pharmaceuticals vaccines consumer healthcare businesses strategic development investor relations global communications cr strategies senior executives focused number core functions finance tax treasury audit assurance risk management investor relations company secretary legal regulatory duties uk listed company director corporate governance practices within gsk site visits tours gms rd sites upper merrion upper providence us investor meetings meetings investors requested induction training programme hans continued focus internal management meeting attendance operational site visits order provide hans good perspective management operates provide opportunities meet key talent within gsk well deepen understanding key business issues board performance action points agreed action points arising board evaluation review facilitated senior independent director sir deryck maughan progress disclosed gsks annual report set strategy board would look take longer term view ten years key strategic issues facing company ii board meetings time spent routine matters would managed enable strategicbusiness discussions take priority whilst ensuring critical areas oversight maintained iii nnual boardcet meetings structure format sessions would reviewed ensure appropriately geared realising maximum value terms strategic insights direction setting iv china review appropriate actions would reviewed board implemented necessary conclusion external investigation ropes gray independent review gsk annual report leadership effectiveness senior independent director sir deryck maughan senior independent director sid board since may succeeded sir robert wilson board met six times member attending sid since may sir derycks role act follows sounding board sir christopher trusted intermediary directors also available additional point contact number number shareholders responsibilities include evaluation meetings held whilst meetings performance chairman request chairman board member attended evaluating board committees collaboration sir christopher gent committee chairmen years evaluation conducted sir andrew witty internally sid also works chairman process simon dingemans selection new chairman appropriate chairs dr moncef slaoui nominations committee agreeing recommendation professor sir roy anderson board chairmans successor dr stephanie burns sir deryck maintains understanding issues concerns stacey cartwright major shareholders meetings sir crispin davis reports investor relations team lynn elsenhans judy lewent ceo sir deryck maughan sir andrew responsible management business dr daniel podolsky developing groups strategic direction consideration approval board implementing agreed strategy tom de swaan assisted members corporate executive team cet jing ulrich meets least times year often required hans wijers sir robert wilson short biographies members cet given corporate executive team pages addition scheduled meetings board also met quorate basis three occasions consider corporate transactions company secretary including authorising disposal lucozade ribena company secretary victoria whyte solicitor fellow brands china investigations institute chartered secretaries administrators victoria ir crispin davis retired board may formerly deputy secretary secretary remuneration h ans wijers appointed nonexecutive director committee acted secretary board effect april boards committees since appointment company secretary january sir deryck maughan tom de swaan hans wijers unable attend one board meeting due prior business company secretary supports chairman designing commitments induction new directors delivery corporate governance agenda particular planning agendas chairman annual cycle board committee meetings ensuring information made available board members timely basis sir christopher gents role chairman lead manage company secretary advises directors board procedures business board provide direction focus corporate governance matters arranges non ensuring clear structure effective operation executive directors attend internal management meetings board committees sets agenda board make visits business operations enhance knowledge discussions promote effective constructive debate understanding business support sound decisionmaking process ensuring board receives accurate timely clear information particular company secretary responded various companys performance consultations evolving global governance corporate reporting agenda behalf group engaged sir christopher works closely sir andrew witty ensure shareholders ensure fully understood gsks governance strategies actions agreed board effectively remuneration arrangements implemented provides support advice sir andrew respecting executive responsibility managing group independence division responsibilities chairman ceo agreed board set governance section board considers nonexecutive directors website independent character judgement free business relationship could materially interfere exercise sir christopher responsible shareholders performance judgement chairman satisfied independence test group leads discussions development relations appointment board independence nonexecutive directors served nonexecutive directors board six years subjected rigorous review particular board considered sir deryck maughan sir nonexecutive directors provide strong independent element robert wilson served board nine years board well placed constructively challenge continued demonstrate characteristics independence support management shape proposals strategy challenging management taking part rigorous debate whilst succession planning bring independent possessing outstanding knowledge companys business affairs judgement breadth skills experience gained senior levels international business operations academia gsk annual report governance remuneration corporate governance corporate governance framework board coherent corporate governance framework clearly defined responsibilities accountabilities designed safeguard enhance longterm shareholder value provide robust platform realise groups strategy grow deliver simplify internal control risk management arrangements described pages integral part gsks governance framework board chairman executive directors independent nonexecutive directors audit risk remuneration nominations chief executive committee committee committee officer corporate responsibility finance corporate administration corporate executive committee committee transactions committee team board committees order board operate effectively give full consideration key matters board committees established board summary role board committee set table full terms reference committee available website reports membership work undertaken audit risk remuneration nominations corporate responsibility committees given pages corporate corporate administration audit risk remuneration nominations responsibility finance transactions reviews reviews reviews reviews reviews reviews recommends recommends approves approves financial internal external issues reporting processes board structure size potential annual report matters connection integrity overall executive composition serious impact upon form f administration financial statements remuneration policy board gsks business convening groups system internal board appointment oversight agm preliminary business certain controls identification appropriate fees members quarterly results corporate transactions management chairman board committees reputation announcements risks external cet management internal audit determines approves monitors processes terms service certain major remuneration succession licensing capital proposes executive directors board cet transactions appointment members changes external auditors cet groups investment instrument responsible reviews counterparty limits initiating audit approves tender selection directors external auditors remuneration report remuneration oversight work gsk annual report board induction business awareness training boards diversity policy set details induction programme hans wijers presented gender diversity gsks global workforce see illustrates typical induction format new director responsible business ensure nonexecutive directors develop maintain time allocation greater insight understanding business invited nonexecutive director letter appointment sets attend internal management meetings including meetings terms conditions directorship cet research development executive product executive scientific review board portfolio investment board sir christopher nonexecutive directors expected commercial accountability board risk oversight devote time necessary proper performance compliance council also meet employees informally duties precise timings given vary year year visits groups operations receptions held around board depending companys activities directors expected meetings attend board meetings additional meetings required board kept uptodate legal regulatory governance also expected attend meetings committees matters regular papers company secretary members audit risk committee meetings presentations internal external advisers open directors furtherance risk compliance responsibilities strategy sessions make visits year board briefed various developments operational sites addition board members invited attend narrative executive remuneration reporting going concern risk least one cet meeting year may attend certain research management board diversity impact uk eu reviews development executive operational meetings audit market market abuse insider trading shareholder engagement developments corporate governance board chairmans evaluation including requirements september update uk board carries evaluation performance corporate governance code performance committees every year facilitated board members undertook specific refresher training externally every third year progress board provisions corporate integrity agreement cia outcomes evaluation internally facilitated delivered audit risk committee previous sid sir robert wilson reported new board member part induction programme action points arising evaluation board facilitated receive comprehensive training cia hans wijers taken current sid sir deryck maughan disclosed part training session part induction feedback board evaluation summarised sir christopher also meets director annually oneto board viewed board members effective one basis discuss ongoing training development pharmaceutical industry undergoing fundamental change requirements board worked hard understand opportunities risks poses strategy supportive direction board composition articulated management team debates open robust seek build effective complementary board whose everyone encouraged contribute corporate responsibility capability appropriate scale complexity strategic ethics compliance taken seriously good positioning business process board appointments led balance core values company interests nominations committee described pages shareholders mindful need balance composition board openness sir andrew management team board committees refresh progressively time input viewed board members exemplary ability draw upon experience longer serving directors directors attend management meetings visit sites enhances tapping new external perspectives insights boards competence recent appointees bring boards deliberations board well balanced terms diversity experiences nonexecutive directors drawn wide range industries however desirability adding experienced director backgrounds including pharmaceutical healthcare medical uk listed environment acknowledged research academia retail financial services board committees strong engaged leaders significant appropriate experience complex organisations global reach workloads discharge play important role companys considerable experience pharmaceutical industry governance recent appointees bring new approach group board discussions board diversity committed diversity boardroom similarly committed equal opportunities employees levels organisation diversity inclusiveness workforce promoted throughout gsk believe key requirement effective board comprises range balance skills experience knowledge gender independence individuals prepared challenge work team needs backed diversity personal attributes including character intellect sound judgement honesty courage gsk annual report governance remuneration corporate governance nonexecutive directors led sir deryck met separately relations shareholders without sir christopher present discuss performance considered leadership performance overall contribution work engage effectively shareholders regular high standard communications agm investor relations activities chairmen board committees undertook separate announce financial results quarterly basis annual evaluations committees outcome evaluation results included annual report shareholders receive reported discussed respective committee annual summary advises annual report board notice annual general meeting available website addition sir christopher met nonexecutive directors year sir andrew witty simon dingemans gave independently executive directors presentations institutional investors analysts media full year results also available via webcast accountability teleconference first second third quarter results hold webcast teleconferences audience internal control framework results available website board recognises responsibilities present fair balanced investor relations department offices london understandable assessment groups position prospects philadelphia acts focal point communications investors sir andrew simon sir christopher maintain continuous board accountability reviewing approving dialogue institutional shareholders performance plans effectiveness internal controls operated group including objectives programme regular meetings year financial operational compliance controls risk management held individual meetings investors internal control framework framework operation also hosted approximately group meetings investors whole year continues operate date potential investors approval annual report framework process company secretary acts focal point communications compliance laws regulations reliability financial corporate governance matters also small central reporting effectiveness efficiency operations corporate responsibility cr team coordinates strategy reviewed framework assists identification evaluation policy development reporting specifically respect cr management principal risks required uk corporate matters team communicates socially responsible investors governance code uk code designed manage stakeholders rather eliminate risk achieving business objectives believe framework provides reasonable absolute sir christopher also meets regularly institutional shareholders assurance material misstatement loss hear views discuss issues mutual importance communicates views members board audit risk committee committee receives reports sid nonexecutive directors available meet areas significant risk group related internal controls shareholders following consideration reports committee reports annually board effectiveness controls remuneration committee chairman chairman head human resources held annual meetings major board committee reviewed assessment shareholders november discuss executive remuneration risks framework considered effectiveness system internal controls operation group year addition chairman audit risk committee chair covered annual report date approval sid held separate meetings major uk shareholders board boards review focuses company december major us shareholders january subsidiaries extend material associated undertakings governance matters joint ventures investments although considers risk briefing process place nonexecutive directors companys participation activities established managed sir christopher focus sector specific issues procedures controls place identify entities whose results general shareholder preferences must consolidated groups results believe process followed board reviewing remuneration report system internal controls accords guidance internal remuneration report comprises remuneration committee control issued turnbull committee chairmans annual statement annual report remuneration accordance provisions uk code remuneration policy report set pages provide board responsible determining nature extent significant risks willing take achieving strategic objectives board provides oversight help ensure committee reports group maintains sound risk management internal control systems reports audit risk nominations corporate responsibility committees describing activities review groups risk management approach committees year set pages discussed risk management section pages management principal risk explained pages gsk annual report audit risk committee report ropes gray report directly gsks general counsel chair committee unfettered access law firm partners leading independent investigation addition time continues set aside committee meetings consider matter finally delighted welcome jing ulrich lynn elsenhans new members committee part ongoing refreshment composition committee pleased contribution already made committees deliberations judy lewent audit risk committee chairman membership attendance dear shareholder membership committee together appointment dates attendance meetings set committees agenda included review integrity financial results appropriateness system attendance full internal controls business operations across world meetings management risk well focusing consideration new members committee member since emerging risks judy lewent chairman january april committees report includes descriptions work professor sir roy anderson may undertaken committee year modified stacey cartwright april reflect new audit committee responsibilities reporting requirements uk corporate governance code uk lynn elsenhans january code guidance audit committees issued financial sir deryck maughan january reporting council frc september particular dr daniel podolsky january committee report discusses significant issues tom de swaan january committee considered addressed relation financial jing ulrich may statements outlines committee assisted board sir robert wilson december directors making statement confirming p rofessor sir roy anderson sir robert wilson stood gsks annual report accounts fair balanced members committee may understandable tom de swaan unable attend one sir deryck maughan since start committee board unable attend two committee meetings due prior business considered division work terms risk commitments management agreed board members would invited attend entire committee meetings board continued addition six scheduled meetings committee also met cover risks specifically reserved review ensure quorate basis four occasions review approve matters continuity consistency coverage oversight associated annual report accounts form f preliminary quarterly results announcements completed first full year chair committee time enhanced knowledge understanding board members invited attend committee meetings group meetings range senior executives discuss attendees include issues brought committee management attending cet regular attends risk oversight compliance council management meetings attendee attendee required well connecting network compliance officers chairman group relies oversee drive compliance within gsk ceo cfo matter routine also held precommittee briefing meeting sessions management external auditors generally made general counsel available director senior executive external audit financial controller partner wished discuss particular matters detail head audit assurance company secretary secretary pleased attend alongside chairman senior committee independent director first annual governance meetings chairman research development held major uk shareholders december major us head governance ethics assurance shareholders january opportunity discuss chief medical officer areas mutual importance relation work committee chief product quality officer events year brought evidence vigilance external auditor continuous improvements internal control risk management processes systems must remain high priority committee allegations fraudulent behaviour within business china currently investigation authorities country separately commissioned independent review international law firm ropes gray happened china gsk annual report governance remuneration corporate governance accordance uk code board determined stacey cartwright judy lewent tom de swaan recent relevant financial experience board also agreed stacey judy tom appropriate qualifications background audit committee financial experts defined us sarbanesoxley act determined independent within meaning us securities exchange act amended addition judy lewent sir deryck maughan tom de swaan members remuneration committee allows provide input committees review groups performance oversight risk factors relevant remuneration matters work undertaken committee committee worked largely recurring structured programme activities agreed conjunction committee chair management external auditors start financial year programme comprised standing items committee required consider meeting matters timed coincide key events annual financial reporting cycle business events committee considered discussed made decisions relation number matters year significant set global internal control governance financial reporting compliance external auditors risk matters reviewed integrity draft reviewed global assurance reviewed auditnonaudit considered emerging risks confirmed compliance financial statements business unit expenditure reviewed risk management uk corporate governance appropriateness assurance reports considered auditors report framework compliance code accounting policies reviewed litigation reports regarding findings endorsed review risks discussed annual going concern assumption reviewed internal control annual results approved addition new evaluation exercise r ree cv oie mw ed n dn ed approval framework performed evidencebased e mm oe nr itg oi rn ing g risks register c plo anm tm oi ft ue th ea rg ir mee pd ro vc et ion confirmed compliance assessment external operation committee annual report sarbanesoxley act auditors effectiveness reviewed status clinical reviewed terms form f quarterly external audit study transparency abac reference results announcements reviewed audit process information protection considered approval assurance work risks considered new annual process confirming agreed plan considered qualifications report disclosure recommending expertise reviewed progress requirements including independence auditors external independent new style audit reports annual report fair reviewed corporate balanced integrity agreement cia recommended abac investigations received briefing understandable quarterly compliance appointment approval relation china number group tax treasury reports undertook cia agm committee meetings arrangements training agree auditors reviewed annual progress reinforce committee remuneration global enterprise resource independence approved audit plan planning system committee met audit fee proposal implementation collectively separately set performance external auditors expectations auditors head audit assurance head governance considered initial results ethics assurance audit without members management present reviewed agreed preapproval budget auditors provide nonaudit services respect financial reporting activities committee reviews recommends approval financial results announcements considering quarterly financial results announcements annual financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements gsk annual report significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditors discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis committee considered outcome managements halfyearly reviews current forecast net debt preparation financial positions various financing facilities options available group following review risk statements potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including committee reviewed managements approach timing recognition revenue accruals returns rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external recent government investigations legal counsel together number detailed updates concerning ongoing government investigations china extent china management outlined levels provision considered necessary respect potential adverse determined litigation outcomes also areas including respect china investigation yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions tax issues committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december groups balance sheet included tax payable liability billion impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details provisions pension committee reviewed significant assumptions adopted management valuations postemployment obligations obligations groups largest pension postretirement healthcare schemes uk us together resultant net obligation amounts calculated external actuaries groups net deficit december amounted billion set note financial statements pensions postemployment benefits effectiveness external auditors adhere independence policies including gsks policies evaluating effectiveness audit process prior making isa uki sec requirements recommendation reappointment external auditors deliver focused consistent audit approach globally committee reviews effectiveness performance reflects local risks materiality criteria agrees conjunction management coordinate appropriately gsks audit assurance beginning years audit function part process committee considers feedback provide consistency advice levels prior years external audit gathered client satisfaction survey facilitated auditors client service review team audit partner rotation independent engagement team undertook audit work external auditors required rotate audit engagement survey seeks feedback financial management team partner every five years previous audit partner stepped corporate business unit level covers four key areas position audit gsks financial statements robustness audit process quality delivery quality concluded people quality service reviewed robust review process committee together feedback noted areas improvement implemented involvement ceo cfo select replacement following years audit provided committee satisfied committee approved appointment new audit effectiveness external audit process recommend engagement partner effect financial year reappointment auditors forthcoming agm commencing january details current criteria judging effectiveness external auditors set audit firm tendering deliver smoothrunning thorough efficiently executed audit committee keeps review ongoing legislative proposals audit tendering rotation eu competition provide accurate uptodate knowledge technical issues commission implement become final timely basis proposals effectively superseded frcs complyorexplain serve industry resource communicating best practice approach underpins uk code would otherwise industry trends reporting applied company first time year frc plans withdraw tendering provision gsk annual report governance remuneration corporate governance pricewaterhousecoopers llp remained place auditors auditnon audit service three year comparison graph since groups inception december audit contract put tender period performance reviewed annually committee since time part review implications end previous audit partners five year term committee considered appropriateness putting place tender process included assessing frcs recent guidance subject level change currently underway inside group improvements auditors services including fee levels proposed auditors review concluded tender companys interests time committee consequently approved appointment new audit partner however committee agreed issue reviewed regularly part annual appointment process nonaudit services sarbanesoxley act prohibits engagement external auditors provision certain services legal actuarial internal audit outsourcing financial information systems design external auditors permitted provide nonaudit services committee ensures auditor objectivity audit assurance services independence safeguarded policy requiring preapproval services including tax regulatory compliance committee services total fees nonaudit work treasuryrelated services exceed audit fee except special circumstances code conduct reporting lines would clear advantage companys auditors undertaking additional work services may include audit also number well established policies including auditrelated tax services preapproval detailed code conduct available governance section particular service categories service subject website confidential reporting lines reporting specific budget nonaudit services put investigation unlawful conduct updated version code competitive tender financial service providers line conduct published january groups procurement process unless skills experience fair balanced understandable assessment external auditors make suitable supplier nonaudit service consideration case request proposal one key compliance requirements groups financial submitted relevant cet member cfo approval statements annual report accounts fair balanced understandable coordination review groupwide provision nonaudit services contributions annual report accounts follows well established documented process performed parallel guidelines set groups policy engaging formal process undertaken external auditors external auditors provide nonaudit services include committee received summary approach taken ascertaining skills experience external auditors management preparation gsks annual report make suitable supplier nonaudit services accounts ensure met requirements uk code ensuring adequate safeguards place objectivity enabled committee board confirm independence group audit threatened gsks annual report taken whole fair balanced compromised understandable ensuring fee levels exceed annual committee evaluation audit fee committees annual evaluation carried committee external auditors management report regularly chairman concluded committee continued operate committee regarding extent services provided accordance effectively full participation members executive preapproval fees services performed management attendees members commented favourably committee may also preapprove additional services caseby good level access committee chairman case basis fees paid companys auditor associates set details given note financial terms enhancements committees deliberations statements operating profit agreed heightened focus time management attention key risk areas meetings would assist committees possible accounting firms engaged undertake overall effectiveness nonaudit services gsk annual report nominations committee report search process broad selection criteria generally used focus achieving balance continental european british american emerging markets experience individuals expertise capabilities developed various sectors specialities mwm egon zhender specialise recruitment high calibre nonexecutive directors engaged ensure widest possible pool candidates available select mwm egon zhender provide recruitment consultancy services committee dossiers potential nonexecutive appointees considered committee candidates shortlisted interview merit objective criteria assessing relevant qualifications time commitments interviewing suitable candidates committee pleased recommend board hans wijers potential nonexecutive director appointed board april board considered appointment achieved aim appointing sir christopher gent candidate experience running global companies nominations committee chairman currently intended sir christopher gent step chairman end committee made progress membership search successor membership nominations committee committee together appointment dates attendance meetings board committee changes set boards proactive approach refreshment board resulted orderly changes composition board attendance committees recommendation committee set full meetings members committee member since sir christopher gent sir crispin davis stand reelection agm may chairman since nine years service sir robert wilson stand january december reelection agm ten years service given professor sir roy anderson october number recent appointments longstanding sir crispin davis july board member step board may sir sir deryck maughan july deryck maughan agreed stand reelection shareholders two years stepping board tom de swaan october agm chairman sir deryck conducting search sir robert wilson march chairmans successor sir deryck also provide sir crispin davis retired board may continuity balance composition board given tom de swaan sir deryck maughan unable attend significant knowledge gsks business affairs sir deryck one committee meeting due prior business commitments brought style role senior independent director since succeeded sir robert wilson closure agm may attendees committee meetings may include board confirmed continues demonstrate characteristics independence carrying role regular attends attendee attendee required board chief executive officer tom de swaan succeeded sir crispin davis chairman head human resources remuneration committee judy lewent succeeded tom de company secretary secretary swaan chairman audit risk committee january committee tom de swaan member remuneration appropriate external advisers committee since may continues member audit risk committee judy member audit risk work committee committee since april dr stephanie burns appointed remuneration committee main responsibilities effect may jing ulrich appointed audit main responsibilities committee set risk committee also effect may date professor sir roy anderson sir robert wilson appointment new nonexecutive directors stepped audit risk committee sir robert wilson committees particular area focus search appointed member corporate responsibility new nonexecutive directors phased refreshment committee effect may hans wijers board progressed appointed member remuneration corporate recruiting nonexecutive directors committee evaluates responsibility committees effect october particular skills knowledge independence experience lynn elsenhans appointed member audit risk diversity including gender would benefit balance board committee effect january appropriately appointment gsk annual report governance remuneration corporate governance board diversity corporate responsibility committee report committee responsible developing measurable objectives support implementation boards diversity policy including gender monitoring progress towards achievement objectives may announced aspiration increase female representation board least able report annual report encouraging progress made towards target boards directors women stage part continued refreshment board lynn elsenhans jing ulrich appointed new nonexecutive directors july taking cadre women board pleased delivered early exceeded target set maintained level female representation board level throughout also good representation women management positions illustrated part gender diversity gsks global workforce continue support sir christopher gent efforts increase pipeline women senior positions corporate responsibility committee chairman within gsk also support engagement executive search firms mwm egon zhender signed membership voluntary code conduct gender diversity best practice membership corporate responsibility committee committee together appointment dates attendance committee evaluation meetings set annual evaluation committees effectiveness undertaken committee chairman responses shared attendance committee concluded committee full meetings members committee member since continued operate effectively agreed process committee used identify new appointees much improved sir christopher gent chairman january december dr stephanie burns december lynn elsenhans october dr daniel podolsky july hans wijers october sir robert wilson may hans wijers unable attend one committee meeting due prior business commitments attendees committee meetings include regular attends attendee attendee required chief executive officer chairman global rd vaccines general counsel head governance ethics assurance head global communications head global corporate responsibility company secretary executives independent external corporate responsibility adviser independent external corporate responsibility adviser augment gsks engagement stakeholder opinion may sophia tickell appointed independent external adviser committee position held previously march july ms tickell extensive experience pharmaceuticals industry improving health systems productivity sustainability energy supply distribution climate change policy shorttermism financial markets gsk annual report cofounder director meteos directs people organisational change employee relations pharma futures series aims align better societal inclusion diversity shareholder value holds number board advisory roles leadership development approach performance management ms tickell attended meetings committee provided independent advice guidance corporate social employee health safety wellbeing responsibility matters chairman ceo volunteering main responsibilities planet environmental performance supply chain main responsibilities corporate responsibility committee set committee evaluation committees annual evaluation carried committee committee rolling agenda receives reports chairman concluded committee continued operate members cet senior managers ensure progress effectively full participation members executive meeting gsks corporate responsibility commitments management attendees set within four areas focus reviewed annual basis follows directors report health innovating address currently unmet health needs improving access products irrespective people purposes uk companies act directors live ability pay controlling eliminating diseases report glaxosmithkline plc year ended december affecting worlds vulnerable people comprises pages corporate governance report directors responsibility statements pages behaviour putting interests patients consumers pages investor information entitled first driven values everything backed robust companies act board chosen set policies strong compliance processes strategic report matters required disclosed people enabling people thrive develop directors report considers strategic importance individuals deliver mission company follows planet growing business reducing r isk management objectives policies pages environmental impact across value chain l ikely future developments company throughout committee also reviews approves corporate strategic report responsibility report available reference r esearch development activities pages wwwgskcomresponsibility nclusion diversity work committee p rovision information consultation employees committee focused attention several issues pages including c arbon emissions cr focus area specific topics considered directors report drawn presented health rd investment including diseases accordance reliance upon english company law developing world eg malaria open liabilities directors connection report shall innovation strategy subject limitations restrictions provided law directors report approved duly authorised committee new partnership address access child mortality eg save children partnership board directors february signed behalf behaviour us patient first incentive compensation program selling competency model embedding valuesbased decision making organisation human rights impact assessment sir christopher gent chairman conduct public disclosure clinical research transparency detailed data behind february trial results replacement refinement reduction use animals research development responsibility supply chain standards working practices diversity approach public policy interactions patient advocacy groups gsk annual report governance remuneration directors remuneration report directors remuneration report chairmans annual statement removing business committee reviewed efforts made diversification measure sir andrew team improve performance share plan psp global public health increase transparency deferred annual bonus plan clinical data modernise gsks dabp matching awards made commercial practices interactions onwards business customers ongoing investigation diversification remains important authorities china also considered business mix appropriate committee sir andrew growth still delivered board mindful impact issue without additional focus reputation company specific measure remaining result bonuses awarded performance measures continue lower otherwise might equal weighting change executives continue align effect increasing proportion personal interests shareholders award based tsr adjusted sir andrew elected year free cash flow rd new product defer maximum permitted dear shareholder performance companys dabp december extending time horizons held twice value chairman gsks remuneration introducing additional twoyear gsk shares required companys share committee committee pleased holding period psp awards ownership requirements present directors remuneration report executive directors made seeking remuneration executives related onwards approval agm may line performance annual bonus new remuneration reporting regime committee decided would longterm incentives psp awards dabp directors remuneration report split appropriate award executive matching awards described annual two separate reports annual report directors salary increases report remuneration pages remuneration subject consistent average salary advisory shareholder vote agm budget uk us employees agenda remuneration policy report across business committee held shareholder meetings subject binding vote furthermore committee decided november shared updates remuneration matters last would appropriate key decisions changes months proposals onwards increase annual longterm executive remuneration environment incentive opportunities executive committee continue continued evolve pace directors keep executive remuneration arrangements new reporting regulations offered fresh review also continue opportunity discuss remuneration performance pay regular dialogue shareholders practices policies shareholders group generated best tsr hold annual meetings gsks largest proud track record listening performance since formation investors later listen views views shareholders billion cash returned feedback made number decisions year shareholders determining remuneration committee company take keen relating executive remuneration ensure awards committees view interest external views remuneration incentive arrangements remain appropriate executive team demonstrated strong matters particular consulted gsk longterm interests delivery successful implementation widely remuneration policy shareholders key changes groups strategic priorities particular shareholders feedback input highlighted exceptional year rd productivity responded issues raised reviewed design gsk delivered sales earnings growth pleased receive support investors longterm incentives main line guidance led industry consulted objectives simplification new product approvals new commend reports annual report responding concerns previously raised products strengthen businesses remuneration remuneration policy investors result respiratory vaccines hiv oncology report shareholders approval review investor consultation importantly committee notes agm year changing way substantial future opportunities remain longterm incentives operate group total new molecular entities currently phase iiiii development action also taken streamline tom de swaan increase focus group remuneration committee chairman noncore products assets february divested proceeds billion ongoing organic structural initiatives delivered incremental yearonyear savings around million gsk annual report annual report remuneration total remuneration audited value earned annual longterm total salary benefits bonus incentive pension remuneration awards committee may specific circumstances line stated principles apply clawbackmalus determines appropriate total remuneration executive director set table dr moncef slaoui sir andrew witty simon dingemans chairman ceo cfo global rd vaccines total total total total total total salary benefits total fixed pay pay performance annual bonus including amount deferred value earned lti awards matching awards deferred annual bonus plan na na na performance share plan na total value earned lti awards na total pay performance pension total remuneration notes certain expenses incurred normal course business considered taxable benefits table includes figures restated details provided n analysis value ltis earned sir andrew witty simon dingemans dr moncef slaoui set pages performance period simon dingemans first award dabp ends december earliest period remuneration recorded dabp simon dingemans therefore year ending december full details pensions accrued date executive directors receipt pension gsk given following due consideration committee reduction outstanding awards vesting levels malus applied respect executive directors following sections provide details element total remuneration including intend implement policy gsk annual report governance remuneration directors remuneration report comparator groups pay performance salary committee uses two primary pay comparator groups average salary increase budget employees considering executive pay executive directors approximately uk usa uk crossindustry global pharmaceutical comparator group comparator group committee decided give executive directors salary anglo american france sanofi increases line increases sir andrew witty simon astrazeneca switzerland novartis dingemans dr moncef slaoui received bg group roche holdings base salary increase bhp billiton uk astrazeneca table sets base salaries executive directors bp usa abbvie last two years british american tobacco amgen diageo bristolmyers squibb base salary reckitt benckiser eli lilly change rio tinto johnson johnson sir andrew witty royal dutch shell merck co simon dingemans sab miller pfizer dr moncef slaoui tesco unilever benefits audited vodafone following table shows breakdown grossed cash value amgen abbvie included remuneration benchmarking benefits received executive directors included tsr comparator group onwards financial services companies removed sir andrew simon dr moncef witty dingemans slaoui new regulatory regimes remuneration applied sector make pay structures less comparable sab miller added benefits group employee benefits global pharmaceutical comparator group also used basis travel tsr comparator group features longterm incentive awards international assignment benefits primary pay comparator group executive directors total benefits shown table benefits restated primary pay comparator group uk global employee benefits director crossindustry pharmaceutical travel sir andrew witty international assignment simon dingemans benefits dr moncef slaoui total benefits reviewing ceos remuneration committee also employee benefits include healthcare car allowance personal financial references pay group leading european companies whose advice life assurancedeath service selection based size complexity travel expenses include car travel family spouse partner costs associated accompanying director gsk business summary total package competitive positioning ceo deemed taxable benefits individual total remuneration benchmarking dr moncef slaoui seconded uk november order enable closer vaccines business assumed operational responsibility part group secondment ended december line senior gsk expatriates received appropriate assignment expenses including accommodation location allowance relocation specific financial advice tax equalisation benefits comprise expenses incurred ordinary course business deemed taxable benefits individual included table restated significant changes provision benefits proposed details please refer policy report uk crossindustry global pharmaceutical european crossindustry group group group lower quartile median median upper quartile current position benchmarking includes salary expected value incentives based committees agreed benchmarking methodology gsk annual report pay performance audited annual bonus majority annual bonus opportunity based formal review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multiplier financial measures bonus threshold target maximum payable achievement target bonus threshold reflects stretching nature bonus targets performance targets annual bonus based following performance measures actual targets linked companys financial strategic plan committee believes targets remain commercially sensitive targets therefore disclosed financial performance personal performance sir andrew witty core group operating profit core group profit simon dingemans individual objectives interest tax dr moncef slaoui rd vaccines performance details see policy report financial core group operating profit core group profit interest tax performance companys performance terms core group operating profit core group profit interest tax represented strong delivery group despite unexpected challenges reflected improving balance sales base reflects improvements us european businesses well effective cost control financial efficiencies rd vaccines performance targets year around pipeline growth value exceeded reflects productive period rd output companys history six major new products approved breo ellipta anoro ellipta tafinlar mekinist tivicay well new injectable quadrivalent flu vaccine launched us five additional regulatory filings completed companys pipeline remains extensive new molecular entities nmes phase iiiii clinical development gsk remains track deliver target longterm rate return rd spend targets year around vaccines performance also exceeded reflecting strong sales particular infanrixpediarix fluarix flulaval boostrix table sets matters committee considered respect individual objectives set executive director personal performance sir andrew witty sir andrew continued demonstrate strong leadership gsk remains challenging operating environment healthcare sir andrews remuneration reflects strong delivery groups strategy across areas business subsequent realisation returns shareholders gsk delivered sales earnings growth core eps p cer line market guidance sales growth generated multiple businesses geographies reflecting successful implementation groups strategy source growth broadly year exceptional rd productivity gsk led industry new product delivery six major products approved five additional regulatory filings completed productivity set backdrop continued improvement estimated rate return rd new product launches strengthen businesses respiratory vaccines hiv oncology groups pipeline opportunity also remains substantial total nmes currently phase iiiii development phase iii starts planned ten potential new products sir andrews leadership group generated best tsr performance since formation gsk billion cash returned shareholders fullyear dividend pence share repurchases billion sir andrew continued strengthen focus gsks core business areas group divested noncore products assets proceeds billion gsk also increased shareholding indian consumer subsidiary ongoing organic structural initiatives delivered incremental yearonyear savings around million new efficiencies resulting groups strategic priority simplify business increasingly evident manufacturing supply chain core business services sir andrew continued adopt industryleading positions multiple corporate responsibility issues year gsk widely acknowledged taken innovative steps improve global public health developing countries increase access transparency clinical data modernise commercial practices interactions customers sir andrews request impact ongoing investigation chinese authorities groups subsidiary business china also considered board evaluation performance gsk annual report governance remuneration directors remuneration report performance targets continued personal performance simon dingemans gsk delivered sales earnings growth core eps p cer line market guidance simon dingemans continued drive operating financial efficiencies yearonyear cost savings around million contributing overall performance increased core earnings per share constant currency basis simon drove delivery billion adjusted free cash flow along billion realised divestments gives company flexibility needs protect credit profile fund organic investment restructuring programmes meet commitment growing dividend share buybacks bolton acquisitions also continued achieve reduction effective core tax rate dr moncef slaoui dr moncef slaoui delivered year exceptional performance rd terms approvals filings pipeline detailed leadership vaccines business also delivered solid sales growth despite adverse impact cervarix sales resulting suspension recommendations use hpv vaccines japan successfully established new integrated way working rd parts business create strong new product launch capability following table shows actual bonuses earned compared opportunity opportunity level achieved bonus paid salary salary target maximum sir andrew witty simon dingemans dr moncef slaoui operation annual bonus plan changes proposed operation annual bonus plan inevitably targets linked directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus targets year however details performance achieved disclosed annual report longterm incentive plans audited deferred annual bonus plan matching awards performance share plan levels participation executive table shows performance share plan psp award levels directors shown table together maximum executive director matching awards granted respect deferrals bonuses total bonus deferred award level award level matching shares ads award award base salary base salary sir andrew witty shares sir andrew witty shares simon dingemans shares simon dingemans shares dr moncef slaoui ads dr moncef slaoui ads vesting matching awards performance period ending sir andrew wittys psp awards subject december shown pages twoyear vesting period five years total performance conditions matching awards made psp dabp matching awards subject performance deferred annual bonus plan dabp continued employment performance share plan described gsk annual report awards performance period ending december audited committee reviewed performance psp dabp matching awards granted executive directors performance achieved full three years december actual vesting levels set table committee previously provided estimates vesting awards gsks annual reports estimates based performance achieved time following reflects performance achieved course whole performance period discretion exercised determining vesting levels due commercial sensitivities targets rd new products business diversification disclosed time grant committee committed disclosing time vesting targets shown table performance vesting measures relative weighting performance targets performance achieved maximum award business business diversification measure based aggregate threeyear revenue diversification target vaccines consumer healthcare dermatology emerging markets asia performance pacific japan vesting schedule shown aggregate sales period billion target vesting maximum billion billion billion threshold billion rd new product rd new product performance measure based aggregate threeyear performance revenue target new product sales new products defined products launched performance period two preceding years therefore products launched years included vesting schedule shown aggregate sales period billion target vesting maximum billion billion billion threshold billion adjusted free adjusted free cash flow afcf three years billion line cash flow committees agreed principles included adjustments number material performance distorting items including legal settlements exchange rate movements special pension contributions afcf vesting schedule disclosed time grant threshold award vests achieving afcf billion achieving billion achieving billion maximum achieving billion straightline vesting points relative tsr gsks tsr rank position th comparator group ten pharmaceutical performance companies gsk nine companies vesting schedule comparator group set awards total vesting respect straightline vesting applies points awards performance period ending december audited awards granted executive directors based part performance three years part performance four years portion awards measured four years december lapsed full gsks tsr rank position th comparator group ten pharmaceutical companies gsk nine companies gsk annual report governance remuneration directors remuneration report update performance ongoing awards committee reviewed performance psp dabp matching awards granted executive directors following tables provide estimate vesting taking account performance date actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels awards performance period ending december performance measures relative weighting performance update business business diversification performance awards measures aggregate threeyear sales across vaccines dermatology diversification consumer healthcare emerging markets asia pacific japan threshold performance results vesting maximum performance performance threshold results vesting based aggregate sales based performance measure definitions vesting currently estimated maximum element rd new product rd new product sales performance measures aggregate threeyear sales new products launched threeyear performance performance period preceding two years ie threshold performance results vesting maximum performance threshold results vesting based aggregate sales new products based performance measure definitions vesting currently estimated around threshold adjusted free adjusted free cash flow afcf vesting schedule awards disclosed time grant cash flow threshold award vests achieving afcf billion achieving billion achieving performance billion maximum achieving billion straightline vesting points based adjusted free cash flow based performance measure definitions vesting currently estimated threshold relative tsr period january december gsks tsr rank position th comparator group ten performance pharmaceutical companies gsk nine companies vesting schedule comparator group set awards ranking position remains level vesting would threshold current estimate potential total vesting awards less vesting awards performance period ending december audited performance measures relative weighting performance update business business diversification performance awards measures aggregate threeyear sales across vaccines consumer diversification healthcare emerging markets asia pacific japan threshold performance results vesting maximum performance performance threshold results vesting good sales year business areas based aggregate sales year based performance measure definitions vesting currently estimated maximum element rd new product rd new product sales performance measures aggregate threeyear sales new products launched threeyear performance performance period preceding two years ie threshold performance results vesting maximum performance threshold results vesting strong sales new products year gsk also track deliver target longterm rate return rd spend based aggregate sales new products year based performance measure definitions vesting currently estimated adjusted free adjusted free cash flow afcf vesting schedule awards disclosed time grant cash flow threshold award vests achieving afcf billion achieving billion achieving performance billion maximum achieving billion straightline vesting points based adjusted free cash flow year performance measure definitions vesting currently estimated relative tsr period january december gsks tsr rank position th comparator group ten performance pharmaceutical companies gsk nine companies vesting schedule comparator group set awards ranking position remains level vesting would threshold current estimate potential total vesting awards vesting gsk annual report performance targets awards inevitably measures linked directly strategy commercially sensitive particular committee consider appropriate disclose targets rd new product performance grant may result competitive harm however targets disclosed full gsks annual report end performance period together details extent met committee provide updates estimated vesting targets performance period performance targets vesting schedules set table awards performance period ending december performance measures relative weighting link strategy vesting schedule rd new recognises importance rd future business performance product growth threshold vesting performance revenue target based new product sales maximum rd incentivise better rd performance new products threshold defined products launched performance period two preceding years therefore performance period products launched years included measurement aggregate threeyear revenue target awards new product sales reflect growth historic performance new product sales adjusted free recognises importance effective working capital performance cash flow cash management target vesting performance maximum billion rd billion billion threshold billion straightline vesting points relative tsr focuses delivery value shareholders tsr ranking performance relative tsr using comparator group comprising within comparator rd gsk nine global pharmaceutical companies group vesting relative tsr measured three years using maximum st nd rd twelvemonth averaging period tsr measured th local currency threshold th median th th sr comparator group astrazeneca bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies threshold vesting therefore achieving median performance gsk annual report governance remuneration directors remuneration report historical vesting gsks ltis following table shows historical vesting levels companys longterm incentive plans deferred annual bonus plan matching awards performance share plan share option plan respect awards made executives since deferred annual bonus plan performance share plan share option plan vesting vesting vesting vesting vesting total adjusted free rd new business total year vesting tsr cash flow product diversification vesting eps grant performance period na na na na na na na na na na na na na na na na na na na na na na na deferred annual bonus plan awards subject wholly tsr performance awards subject performance measures psp awards allemployee share plans payments past directors audited executive directors participate various allemployee share julian heslop retired march outstanding balance plans including sharesave sharereward psp award performance period ending december lapsed full performance criteria met sharesave plan uk hm revenue customs approved plan open uk employees participants may save month payments loss office audited net salaries fixed term three years end payments loss office executive directors savings period option buy gsk shares discount market price set launch savings contract sir andrew witty simon dingemans make share ownership requirements monthly contributions sharesave plan align interests executives shareholders sharereward plan uk hm revenue customs approved executives required build maintain significant holdings plan open uk employees terms participants shares gsk time contribute month gross salaries purchase executives required continue satisfy shareholding gsk shares company matches number gsk shares requirements minimum months following retirement bought month arrangement sir andrew witty company simon dingemans contribute month buy shares sharereward plan current share ownership requirements sor set table dilution limits awards made plans incorporate dilution limits share ownership requirements consistent guidelines provided association british ceo x base salary insurers limits rolling ten year period executive directors x base salary plans rolling ten year period executive share plans cet members x base salary estimated dilution existing awards made last ten years december follows shareholdings purpose sor february achievement sor based upon average share price working days preceding date set following gsk employee share plans executive share plans table audited holdings sor purposes increase achievement february december shareholding sor sir andrew witty simon dingemans dr moncef slaoui outstanding share awards still subject performance criteria continued employment included shareholdings purpose sor actual limit actual limit gsk annual report pension audited arrangements current executive directors set table pension arrangements sir andrew witty sir andrew witty member glaxo wellcome defined benefit pension plan accrual rate th final pensionable salary plan closed new entrants since section plan sir andrew member provides normal retirement age maximum pension value rds pensionable salary april pensionable earnings increases limited per annum members including sir andrew simon dingemans simon dingemans member gsk pension plan pension contributions instead receives cash payment lieu pension base salary line gsks defined contribution pension plan rates simon dingemans receives death service illhealth insurance provided part pension plan included employee benefits dr moncef slaoui dr moncef slaoui member us cash balance pension plan supplemental cash balance pension plan provides executive pension credit gsk makes annual contributions dr moncef slaouis pension plans base salary plans provide cash sum retirement fund increases interest rate set annually advance based year us treasury bond rate plan entitlement spouses pension pension increases dr moncef slaoui active member belgium fortis plan may deferred member since plan defined benefit plan lump sum payable normal retirement age company contributions plan dr moncef slaoui also member gsk k savings scheme open us employees executive supplemental savings plan essp savings scheme open executives accrue benefits us government limits imposed gsk k plan contributions plans invested range funds combined contribution rate plans core contributions plus match total base salary bonus less bonus deferred deferred annual bonus plan following table shows breakdown pension values set sir andrew witty simon dingemans dr moncef slaoui pension remuneration values uk defined benefit us defined benefit belgian defined benefit employer cash contributions member contributions total pension remuneration value pension remuneration figures calculated accordance methodology set remuneration regulations calculating defined benefit pension values difference accrued pension accrued pension increased inflation uk defined benefit belgium defined benefit multiplied results negative value deemed zero calculating total values amounts translated euros us dollars using exchange rate b sir andrew details regarding pension values set table accrued pension accrued pension pension remuneration sir andrew witty pa pa value uk funded uk unfunded total ir andrew joined gsk predecessor companies progressed roles increasing seniority within gsk appointed ceo may time built pensionable service different tiers glaxo wellcome pension plan current pension entitlement product service progression within gsk c dr moncef slaoui details regarding pension values set table accrued pension accrued pension pension remuneration dr moncef slaoui pa pa value us funded us unfunded belgium funded us k essp total r moncef slaoui joined gsk predecessor companies progressed number senior roles within gsk appointed chairman research development june time built pensionable service belgium fortis plan us cash balance plan supplemental pension plan annual employer cash contributions made k plan executive supplemental savings plan current pension entitlement product service progression within gsk gsk annual report governance remuneration directors remuneration report performance graph table percentage change remuneration ceo following graph sets performance company relative base salary benefits annual bonus ftse index pharmaceutical performance ceo sir andrew witty comparator group five year period december uk employees graph prepared accordance remuneration regulations indication likely vesting awards reflects salary earned benefits received annual bonus granted companys incentive plans indices earned respect compared wider uk selected comparison purposes reflect index employee population salary increase includes annual salary gsk constituent industry operates review well additional changes year eg promotion increase benefits uk employees reflects change benefits policies levels year reflect changes level benefits individual may received result change role eg promotion uk population considered relevant comparison closely reflects economic environment encountered ceo relative importance pay following table sets percentage changes groups dividends shareholders share buyback total employee pay change total employee pay dividends share buyback glaxosmithkline total return figures table set pages glaxosmithkline pharma peers total return index dividend figure includes supplemental dividend ftse total return index million paid dividends declared respect index comprises astrazeneca bristolmyers squibb eli lilly million million ie increase johnson johnson merck co novartis pfizer roche holdings sanofi timing share buybacks influenced market conditions price remuneration table total employee pay group employees globally external appointments executive directors ceo board encourages executive directors hold one external sir andrew witty directorship become established role ceo single figure broaden experience development help increase remuneration pool candidates nonexecutive directors outside annual bonus award appointments considered nominations committee maximum ensure would cause conflict interest vesting lti awards approved chairman behalf board companys maximum policy remuneration earned appointments may kept bonus amounts include amounts paid individual executive director operational efficiency bonus place years overall dr moncef slaoui received relation maximum receivable subject limit base salary membership qatar biomedical research institute scientific n respect psp award sir andrew also advisory committee external appointments outstanding award share options granted receives remuneration sir andrew witty lapsed full included total vesting simon dingemans hold external appointments percentage due distorting effect aggregating conditional remunerated shares share options respect psp award sir andrew also outstanding award share options granted lapsed full included total vesting percentage due distorting effect aggregating conditional shares share options respect threeyear element psp award respect fouryear element psp award threeyear element psp award dabp matching award n respect fouryear element psp award psp award dabp matching award gsk annual report remuneration committee adviser committee committee access external advice required role committee year committee carried formal review independent role committee set companys remuneration advisers committee result review committee policy gsk able recruit retain motivate decided reappoint deloitte llp provide independent advice executives remuneration policy regularly reviewed executive remuneration committee chairman agrees ensure consistent companys scale scope protocols deloitte provides advice committee operations supports business strategy growth plans satisfied advice received deloitte helps drive creation shareholder value objective independent deloitte member remuneration consultants group terms reference voluntarily operates code conduct relation committees full terms reference available executive remuneration consulting uk code conduct companys website terms reference reviewed found wwwremunerationconsultantsgroupcom least annually last revised december light deloitte provided independent commentary matters best practice new remuneration regulations consideration committee provided updates market practice legislative requirements deloittes fees advice governance provided committee fees board considers members committee charged time materials basis deloitte llp also provided independent nonexecutive directors accordance uk consulting tax assurance services gsk year corporate governance code exception sir christopher however committee satisfied compromise gent chairman company considered independent independence advice received deloitte appointment towers watson provided additional market data committee committee met six times scheduled meetings member attending follows commitment shareholders attendance committee engages regular dialogue shareholders committee full holds annual meetings gsks largest investors discuss member meetings take feedback remuneration policy particular committee members since discusses significant changes policy measures used tom de swaan may assess performance chairman january dr stephanie burns may shareholder votes remuneration matters sir christopher gent january votes judy lewent january total votes total votes total votes withheld sir deryck maughan july agm cast billion million hans wijers october sir deryck maughan hans wijers unable attend one committee meeting due prior business commitments addition six scheduled meetings committee met full three occasions consider remuneration matters review year including review longterm incentive design remuneration report new regulations committee also met quorate basis two occasions approve formal grant longterm incentive awards employees corporate executive team committee meetings usually include closed session members committee present individuals may also invited attend committee meetings year executives committee attendees involved decisions present discussions regarding remuneration attendees committee meetings include regular attends attendee attendee required ceo cfo head human resources head reward secretary committee committee adviser deloitte llp gsk annual report governance remuneration directors remuneration report principal activities matters addressed committees principal activities matters addressed set remuneration month overall incentives governance matters january approve executives remuneration review approve executives review draft remuneration report including salaries ceo cfo bonuses chairman global rd vaccines set bonus objectives remuneration environment update february review lti performance outcomes approve remuneration report approve vesting outstanding lti awards lti awards approve lti measures targets awards grant awards executive directors march remuneration environment update review shareholder feedback including consideration new reporting set committees agenda regulations july update new remuneration reporting review longterm incentive design review agm feedback external regulations including early draft performance measures comparator environment remuneration report group time horizons approve committee evaluation process cet remuneration review review independent adviser july grant interim lti awards executives august grant main share value plan awards executives september review pay comparator groups continuation review longterm review external remuneration incentive design performance measures environment comparator group time horizons october update executives pension update lti vesting awards review chairmans fees arrangements review draft disclosures remuneration report november review terms conditions approve materials annual investor policies meeting november annual meeting investors december annual pay review review feedback shareholder approve executive directors meetings salaries review findings committee evaluation review draft remuneration report gsk annual report nonexecutive directors letters appointment terms engagement nonexecutive directors chairman nonexecutive directors set letters appointment available inspection company aims provide chairman nonexecutive companys registered office agm directors fees competitive paid nonexecutive director initial appointment companies equivalent size complexity subject limits subsequent reappointment subject election thereafter contained gsks articles association periodic reelection shareholders nonexecutive directors letters appointment review chairmans fees contain provision notice periods compensation sir christopher gent took role chairman january appointments terminated chairmans fees last increased january approximately sir following table shows date initial letter appointment christophers total fees delivered shares nonexecutive director deferred steps board fees reviewed nonexecutive director date letter appointment planned increase chairman sir christopher gent may elected increase proportion fees delivered shares professor sir roy anderson september january onwards dr stephanie burns february review nonexecutive director fees stacey cartwright march nonexecutive director fees last increased january lynn elsenhans may increases supplemental fees minimum judy lewent march fees continue delivered shares deferred sir deryck maughan may nonexecutive director steps board dr daniel podolsky july tom de swaan december fees reviewed planned increases jing ulrich may nonexecutive directors fees applying january set hans wijers january sir robert wilson june per annum standard annual cash retainer fee table audited sets value fees benefits supplemental fees received nonexecutive directors form cash chairman audit risk committee shares ads details nonexecutive directors senior independent director scientificmedical experts share allocation plan set chairmen remuneration corporate responsibility committees nonexecutive director undertaking intercontinental travel meetings per meeting ir christopher gent chairman corporate responsibility committee receive additional fee listed restated benefits nonexecutive directors fees fees emoluments cash sharesads benefits total cash sharesads benefits total professor sir roy anderson dr stephanie burns stacey cartwright sir crispin davis lynn elsenhans sir christopher gent judy lewent sir deryck maughan dr daniel podolsky tom de swaan jing ulrich hans wijers sir robert wilson b enefits primarily consist travel subsistence costs incurred normal course business relation meetings board committee matters gskhosted events considered taxable table includes figures restated overseasbased nonexecutive directors includes travel meetings uk b n onexecutive directors paid gbp converted using exchange rate set annually based average rate last quarter year prior payment rate reviewed moves significantly year c j ames murdoch nonexecutive director receive fees benefits however shares built number years nonexecutive directors share allocation plan released year detailed ir crispin davis retired board may hans wijers joined board april gsk annual report governance remuneration directors remuneration report directors interests shares audited following interests directors company office december connected persons shown breakdown share plan interests december total directors interests sharesads options unvested unvested unvested unvested february december january subject subject subject subject vested exercised performance performance performance performance exercised year executive directors shares sir andrew witty simon dingemans dr moncef slaoui ads dr moncef slaoui nonexecutive directors shares professor sir roy anderson dr stephanie burns stacey cartwright tom de swaan sir christopher gent hans wijers sir robert wilson ads dr stephanie burns lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrich u nvested shares ads unvested options held executive directors subject performance reflect bonus deferrals deferred annual bonus plan sharesave awards b one gsk ads represents two gsk shares c otal interests include shares purchased glaxosmithkline sharereward plan shares awarded sir andrew witty simon dingemans respectively plan balance shares within plan follows sharereward plan february december january sir andrew witty simon dingemans dr moncef slaoui participate sharereward plan otal interests include shares ads resulting deferral bonus subsequent reinvestment dividends deferred annual bonus plan totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities deferred annual bonus plan bonus deferrals february december january sir andrew witty shares simon dingemans shares dr moncef slaoui ads e otal interests february include shares ads vested due performance elements performance share plan awards less sold satisfy tax liabilities vested amounts see pages details f f dr moncef slaoui total interests include ads purchased within k plan us executive supplemental savings plan essp ads awarded dr moncef slaouis connected person share value plan svp relevant balances follows dr moncef slaoui february december january us retirement savings plans share value plan executive director dr moncef slaoui eligible receive awards svp svp awards shown reflect holdings dr moncef slaouis connected person also employee gsk awards subject threeyear vesting periods vesting contingent continued employment within gsk gains arising vesting included dr moncef slaouis total remuneration figures year connected person granted ads august grant price face value dr moncef slaouis total interests shares also include psp awards held connected person also employee gsk awards subject performance criteria relevant employees cet december connected person held ads award comprising awards made ads ads including dividend reinvestment gsk annual report g f sir andrew witty simon dingemans unvested options subject performance include holdings respectively december sharesave plan participate terms employees sharesave awards granted sir andrew witty simon dingemans granted options plan december remainder unvested options subject performance relate bonus deferrals structured nilcost options dabp h f executive directors following table provides details vested unexercised options december share option plan sop gsk granted options plan executive directors annual basis number shares option date grant lapse date exercise price sir andrew witty dr moncef slaoui ads vested unexercised options totalling dr moncef slaoui represents ads options held dr moncef slaouis connected person also employee gsk j following table sets details options including nilcost options dabp annual investment plan exercised executive directors simon dingemans exercise options year first nilcost options dabp become exercisable number shares market gain exercise type award date grant option date exercise exercise price price exercise sir andrew witty sop dabp deferral dabp matching dr moncef slaoui annual investment plan k n respect options sop sharesave plans remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration options vested executive directors l f nonexecutive directors total interests include shares ads received part fees share allocation plan see details balances note dividends received shares ads plan converted shares ads december hans wijers joined board april gsk annual report governance remuneration directors remuneration report deferred annual bonus plan matching awards deferred annual bonus plan dabp matching awards made annually executive directors based individuals mandatory deferral voluntary bonus election company match shares ads oneforone depending companys performance threeyear performance period performance conditions vesting levels described pages report awards ukbased executive directors made form nilcost options award vests ukbased executive director may choose exercise award time years date grant awards usbased executive directors made conditional award shares amount remuneration receivable respect matching shares ads calculated using share ads price date relevant award vests executive director chooses exercise nilcost options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision recorded remuneration dividends reinvested nilcost options conditional awards shares made executive directors date vesting following tables provide details executive director respect dabp matching awards market price grant vesting represent closing share price date performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february vested lapsed february vested shares number shares market price vesting gain remuneration remuneration performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february gsk annual report deferred annual bonus plan matching awards continued performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february vested lapsed february vested ads number ads market price vesting gain remuneration performance share plan awards performance share plan psp awards made executive directors annual basis terms psp number shares ads vesting determined following end relevant performance period dependent gsks performance period performance conditions vesting levels described pages dividends reinvested performance shares ads awarded executives throughout performance period date vesting vesting uk participants receive relevant number shares us participants may defer receipt part vested awards amount remuneration receivable respect performance shares calculated using share ads price date relevant psp award vests psp awards made sir andrew witty three year performance periods however deeds award specify awards subject two year vesting period five years total two year period additional performance criteria awards lapse sir andrew dismissed cause remuneration respect awards therefore considered realised full following determination remuneration committee vesting levels initial awards ie full remuneration recognised end threeyear performance period following tables provide details executive director respect psp awards market price grant vesting represent closing share price date executive directors performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration remuneration gsk annual report governance remuneration directors remuneration report performance share plan awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february vested shares number shares market price vesting gain remuneration performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted dividends reinvested vested lapsed unvested february vested shares number ads market price vesting gain remuneration remuneration gsk annual report share allocation plan nonexecutive directors table sets accumulated number shares ads held nonexecutive directors december share allocation plan relation fees received board members together movements accounts year number shares ads december dividends allocated december share allocation plan nonexecutive directors footnote paid reinvested elected shares professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch b tom de swaan sir robert wilson hans wijers c ads dr stephanie burns lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrich ir crispin davis retired board may elected receive shares share allocation plan immediately upon retiring board b j ames murdoch retired board may elected receive shares share allocation plan end first quarter c hans wijers joined board april opening balance recorded date gsk annual report governance remuneration directors remuneration report directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members corporate executive team company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various share plans set table awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb notional shares ads b executive directors eligible receive deferred investment awards participate share value plan february group following interests shares ads company holdings issued various executive share plans described note financial statements employee share schemes interests february shares ads notes owned represents less issued share capital unexercised options deferred annual bonus plan includes shares ads vested unexercised performance share plan includes shares ads vested deferred deferred investment awards notional shares ads share value plan gsk annual report remuneration policy report remuneration policy total remuneration executive director comprises following elements value earned salary benefits annual longterm pension total bonus incentive remuneration awards committee may specific circumstances line stated principles apply clawbackmalus determines appropriate future policy table companys remuneration policy may respect elements outlined table salary benefits international assignment policy purpose link strategy purpose link strategy purpose link strategy provide core reward role levels set recruit retain high calibre gsk may require executive directors relocate individuals execute business strategy order meet business requirements set level appropriate secure retain high calibre individuals needed deliver groups operation operation strategic priorities executive directors eligible receive line policy employees operation benefits line policy employees secondment travel expenses provided may vary location include car executives overseas placement facilitate individuals role experience performance allowances healthcare life assurancedeath relocation process provide continued independently sourced data relevant service provided part standard living assignment comparator groups considered determining individuals pension arrangements personal salary levels international assignment allowances cover financial advice contractual postretirement relocation costs accommodation based salary increases typically take effect first benefits executive directors also eligible size family appropriate security location quarter year participate allemployee share schemes eg allowance relocationspecific tax financial sharesave sharereward plan salaries normally paid currency advice school fees tax equalisation subject terms executive directors home country employees opportunity opportunity order recognise high business travel relocation benefits dependent number formal maximum limit however requirements role executive directors factors home host country family size ordinarily salary increases broadly line also entitled car travel may accompanied duration assignment average increases wider gsk spousepartner business trips workforce benefits include expenses incurred ordinary therefore possible provide typical values course business deemed limits however increases may higher reflect taxable benefits individual change scope individuals role performance measures responsibilities experience salary adjustments benefit provision tailored reflect market none may also reflect wider market conditions practice geography executive geography individual operates director based different policies may apply current future executive directors based salary levels set different country performance measures opportunity overall performance individual key formal maximum limit benefits costs consideration determining salary increases fluctuate depending changes provider cost individual circumstances details current benefits costs set annual report remuneration performance measures none gsk annual report governance remuneration directors remuneration report pension purpose link strategy opportunity us pension arrangements provide competitive pension arrangements existing executive eligible benefits us level retirement income directors follows senior executives sir andrew witty member legacy cash balance pension plan operation glaxo wellcome defined benefit plan supplemental cash balance pension plan pension arrangements structured accrual rate th final pensionable salary including executive pension credit provide accordance plans operated per annum april pensionable maximum contribution base salary country individual likely retire earnings increases limited per annum across pension plans individual chooses become members including sir andrew witty member pension plan cash lieu gsk k plan formerly us relevant pension contribution paid instead simon dingemans member gsk retirement savings plan executive pension plan pension contributions supplemental savings plan core new executive directors uk instead receives cash payment contributions salary bonus entitled either join defined contribution salary lieu pension contribution matched contributions salary pension plan receive cash payment dr moncef slaoui member us cash bonus lieu pension contribution balance pension plans gsk k plan global individual member gsk executive supplemental savings plan legacy defined benefit plan defined also deferred member belgium eligible appropriate equivalent contribution plan alternative pension plan fortis plan arrangement excess arrangement subsequently appointed usuk arrangements policy new external recruit board may remain member plan uk performance measures none salary contribution defined contribution plan matched contributions line policy members plan salary cash payment lieu pension contribution annual bonus purpose link strategy opportunity performance measures incentivise recognise execution threshold maximum bonus opportunities based financial targets individual business strategy annual basis executive directors follows performance objectives rewards achievement stretching annual based core group profit interest threshold maximum financial strategic business targets tax executive directors ceo bonus bonus delivery personal objectives cfo balance based core group base base operating profit executive directors salary salary operation balance based relevant business unit financial operational business targets ceo performance set start year committee cfo individual performance objectives bonus levels determined committee multiplier based achievement chairman global based performance targets rd vaccines individual performance targets applied individual objectives set start bonus awarded performance year committee performance financial operational targets objectives assessed committee executive directors required defer bonus earned shares ads appropriate three years may defer additional bonus earned ie overall maximum deferral deferred shares vest end three year performance period deferred bonus shares eligible dividend equivalents date vesting committee may apply judgement making appropriate adjustments individual annual bonus amounts clawback andor malus provisions apply described gsk annual report deferred annual bonus plan dabp performance share plan psp purpose link strategy opportunity performance measures incentivise recognise delivery dabp three equally weighted performance longer term business priorities financial growth maximum bonus deferral annual bonus measures increases shareholder value compared mandatory additional rd new product performance pharmaceutical companies voluntary adjusted free cash flow addition provide alignment maximum matching opportunity level one shareholder interests retention element share one share basis subject performance relative tsr encourage longterm shareholding criteria three years vests threshold maximum discourage excessive risk taking psp performance normal maximum award limit six times comparator group currently comprising operation base salary per annum maximum initial gsk nine global pharmaceutical dabp value performance shares may companies vesting median rising deferred shares may matched subject granted psp individual vesting upper quartile performance achievement performance conditions one year details unvested three years matching awards may psp rules allow committee awards see pages pages conditional shares nilcost options make awards salary eligible dividend equivalents respect exceptional circumstances performance period current award levels executive psp directors follows conditional awards made annually vesting dependent achievement performance conditions three years salary awards onwards vested awards ceo must held two years ie five cfo years total prior release ceos psp awards subject chairman global rd vaccines additional twoyear vesting period awards eligible dividend equivalents date vesting performance targets dabp psp set start performance period clawback andor malus provisions apply described clawback malus effect annual bonus payable executive directors required defer minimum annual bonus dabp event triggering event eg significant misconduct way violation regulation law significant gsk policy code conduct company ability claw back three years annual deferred bonuses well vested unvested ltis separate recoupment committee established investigate relevant claims misconduct additionally continuity responsibility initiation adverse event emergence problem adverse event taken account assessing annual bonus awards lti vesting levels year problem identified future periods committee may make appropriate adjustments individual annual bonuses well grant vesting levels lti awards reflect thisments individual annual bonus amounts gsk annual report governance remuneration directors remuneration report longterm incentive measures committee selected three equally weighted performance measures focus executive directors longterm remuneration delivery gsks key strategic priorities psp dabp awards made executive directors based rd new product performance adjusted free cash flow relative tsr addition setting robust targets committee implemented number safeguards ensure targets met sustainable way performance reflects genuine achievement targets therefore represents delivery value shareholders performance measure impact acquisition divestment quantified adjusted event major adjustment calculation performance measures disclosed shareholders vesting principal safeguards detailed measure chairman audit risk committee members also members remuneration committee provide input audit risk committees review groups performance oversight risk factors relevant remuneration decisions rationale behind performance measure calculated follows vesting schedules please see annual report remuneration performance measure rationale calculation methodology rd new recognises importance rd future business target based sales new products launched product growth performance period preceding two years performance one key indicators used assess performance aggregate threeyear revenue target reflect growth pharmaceutical industry strength companys product historic performance pipeline rd new product performance measure recognises importance rd future business growth vesting may reduced insufficient progress made included measure order incentivise rd performance performance period towards gsks target return drive development sales new products rd investment committee believes robust appropriate measure committee recognises time time may reflects actual delivery pipeline launch appropriate company respond emerging pandemic excellence supports gsks ethical responsibilities values impact revenue included unless committee considers add shareholder value provided underlying performance sufficiently positive adjusted free recognises importance effective working capital aggregate threeyear adjusted free cash flow target cash flow cash management adjustments may made materially distorting items performance use cash flow performance measure intended may include exchange rate movements major legal taxation recognise importance effective working capital management settlements special pension contributions generating cash assets future valuecreating investments returns shareholders relative tsr focuses delivery value shareholders relative tsr measured three years using month performance committee recognises delivery value averaging period tsr measured local currency shareholders key priority relative total shareholder return peer group global pharmaceutical companies selected order closely align interests executive directors investors committee regularly reviews composition tsr comparator group gsk annual report annual bonus measures annual bonus designed drive achievement gsks annual financial strategic business targets delivery personal objectives majority annual bonus opportunity based formal review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multiplier reasons commercial sensitivity specific personal objectives kept confidential financial performance individual performance committee believes important majority ceo ceo cfos financial targets based core group operating profit individual performance objectives sir andrew witty set smaller element based core group profit interest tax board january year board focuses strategic priorities reflect wider responsibility driving profitable investments developed group following end associates joint ventures financial year board reviews performance generally set objectives determine appropriate bonus payable bonus measures rd employees including dr moncef slaoui performance linked pipeline performance robust governance structure established ensure bonus payable fairly reflects rd executive directors productivity performance ceo sets individual objectives executive directors recognise dr moncef slaouis current dual responsibility global line company strategy makes recommendations rd vaccines element bonus currently based vaccines committee regarding performance objectives performance consistent executive directors element end year recommendations considered bonus also currently based core group profit interest committee determines level bonuses payable tax approach recruitment remuneration committee determines remuneration package new committee mindful sensitivity relating recruitment executive directors casebycase basis depending packages particular buying rights relating role market operate experience previous employment signon payments therefore seek total remuneration levels set reference relevant pay minimise arrangements however certain circumstances comparator group appropriate allow future enable recruitment exceptional talent committee may development role determine arrangements best interests company shareholders arrangements expected new executive directors participate short possible likeforlike basis forfeited awards longterm incentive plans basis existing directors arrangements therefore vary depending plans however exceptional circumstances committee reserves arrangements put place previous employer may flexibility set incentive limit new executive director form cash shares may may subject additional existing limits performance conditions explanations provided committee retains flexibility recognition high payments made either compensation previous remuneration levels variable pay gsks global pharmaceutical competitors forfeited signon payment however committee use flexibility remuneration arrangements newly appointed executive considered best interests company director disclosed soon practicable investors furthermore use flexibility relation appointment external recruits awards line principles future policy table subject performance following policy principles apply roles chairman conditions nonexecutive director pension arrangements external appointments executive chairman director set remuneration policy table fees set level competitive paid companies equivalent size complexity fees paid partly benefits provided line policy existing shares executive directors nonexecutive directors required meet business needs relocation support fee levels new nonexecutive directors set provided line company policy basis existing nonexecutive directors company subject internal appointments entitlements existing local laws regulations fees paid partly shares remuneration elements continue including pension entitlements event nonexecutive director different role outstanding awards however already case responsibilities appointed fee levels benchmarked internal appointments required move executive director set reference comparable roles companies equivalent size contractual terms including termination provisions complexity gsk annual report governance remuneration directors remuneration report loss office payment policy following table sets contractual framework executive directors terms specifically relating termination set detail policy duration company policy fixed term contracts generally contracts new appointments expire line contracts applicable policy retirement age since contracts existing executive directors expire dates shown notice period notice period termination employing company executive director calendar months mitigation ability impose month noncompete period nonsolicitation restriction executive director considered important company ability protect groups intellectual property staff light committee believes would appropriate provide mitigation contracts termination employment event executive directors employment company terminates following policies payments apply element remuneration loss office payment policy termination termination notice months annual salary payable termination company prorated part notice payment period worked termination payment made respect part notice period extends beyond contract expiry date bonus element normally included termination payment however terms contracts seek balance commercial imperatives best practice company enforces noncompete clause current ceo chairman global rd vaccines months ontarget bonus payable redundancy termination notice uk statutory redundancy pay apply us general severance policy apply retirement death illhealth injury disability termination payment lti awards psp dabp matching awards governed plan rules approved shareholders termination notice unvested awards lapse redundancy retirement generally awards vest original timescales subject original performance conditions awards made last months forfeited death illhealth injury disability generally awards vest following end financial year normally taking account performance date awards may prorated time event change control psp dabp matching awards vest taking account performance date normally taking account proportion performance period elapsed alternatively awards may exchanged new awards annual bonus termination notice individual individual serves notice termination date falls december bonus forfeited termination notice company redundancy retirement death illhealth injury disability termination date falls financial year eligible prorated ontarget bonus employed december bonus payable based actual results dabp deferred termination notice deferred shares vest full date termination bonus awards redundancy retirement death illhealth injury disability generally deferred shares vest full end financial year termination date falls benefits generally benefits continue apply termination date termination notice company retirement us executives line policy applicable us senior executives chairman global rd vaccines may become eligible future date receive continuing medical dental insurance terminationretirement termination mutual agreement certain circumstances best interests company board manage proactively succession planning development senior talent pipeline circumstances board may therefore agree executives departure mutual agreement order apply committee need satisfied executive demonstrated performance line expectations required contributed orderly succession completed least years service group termination date case executive director would treated good leaver purposes gsks longterm incentive plans termination date falls financial year would eligible prorated ontarget bonus employed december bonus payable would based actual results case ceo member uk defined benefit pension scheme pension would payable later termination date age without actuarial reduction gsk annual report termination employment continued differences remuneration policy committee anticipate exercise discretion executive directors employees provided psp dabp plan rules respect termination payments however may unforeseen circumstances setting remuneration levels executive directors best interests company shareholders committee considers prevailing market conditions necessary exercise discretion explanations competitive environment comparison remuneration provided executives companies similar size complexity international reach positioning relativities pay executive director leaves company committee employment conditions across broader gsk workforce carry assessment individuals performance conduct time role determined individuals particular committee considers range base salary rises performance conduct contrary legitimate expectations workforces parts gsk ceo cfo company committee reserves right apply chairman global rd vaccines employed considered appropriate mechanisms clawback see relevant comparison populations reflect reduction lapsing outstanding incentive awards malus closely economic environments encountered individuals ensure termination payments best interests principles apply remuneration policy executive company shareholders directors employees although remuneration offered case termination cause payments unvested executive directors policy stronger emphasis awards forfeited except shares deferred dabp performancerelated pay offered employees vest full date termination accrued salary group expenses salary benefits including pension tailored local market service contracts table sets relevant dates current executive annual bonus plan applies wider employee population directors service contracts available review based business individual performance companys registered office office hours combination performancerelated restricted share plans applies wider employee population date effective contract date expiry date notes allemployee share plans available employees uk sir andrew contract amended including hm revenue customs approved uk sharesave witty remove sharereward plans entitlement bonus termination company conducts regular employee surveys include feedback remuneration matters simon dingemans wider organisation aligned performance reward systems values introduced new dr moncef contract replaced performance system formally evaluates employees slaoui principally need also remove entitlement bonus termination senior people disincentivise unethical working practices using clawback mechanism allows us recover performancerelated pay gsk annual report governance remuneration directors remuneration report scenarios future total remuneration ceo charts opposite provide illustrations future total remuneration executive directors respect remuneration opportunity granted policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits pension figures used ie based actual amounts received respect ongoing policy executive director assumed defer annual bonus maximum permitted amount receive corresponding matching award dabp included within value lti awards fixed expected maximum amounts shown value lti awards dabp psp based bonus opportunity relevant multiples cfo salary respectively include amounts respect dividends reinvested factor changes share price vesting period fixed none pay performance annual bonus lti would payable expected annual bonus assumed target financial performance achieved performance executive director would result individual performance multiplier ie increase financial performance element bonus applied results assumed bonus salary sir andrew witty simon dingemans dr moncef slaoui respectively fixed expected maximum lti awards threshold levels vesting assumed maximum chairman global rd vaccines assumed annual bonus would payable maximum level awards dabp psp would vest full fixed expected maximum longterm variable remuneration annual variable remuneration fixed remuneration gsk annual report nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum however fees reviewed annually set competitive paid reference review chairmans performance independently companies equivalent sourced market data size complexity subject remuneration committee responsible evaluating making limits contained gsks articles recommendations board fees payable chairman association chairman participate discussions respect fees fees paid combination cash andor gsk shares ads see details gsks nonexecutive directors share allocation plan basic fee formal maximum however fees reviewed annually set reference independently sourced market data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors minimum delivered form gsk shares ads see details gsks nonexecutive directors share allocation plan supplemental fees provide additional compensation additional fees committee chairmen intercontinental travel senior nonexecutive directors independent director current fee levels set annual excluding chairman taking report remuneration additional board responsibilities undertaking intercontinental travel meetings benefits facilitate execution travel subsistence costs nonexecutive directors incurred responsibilities duties required normal course business relation meetings board committee role matters gskhosted events overseasbased nonexecutive directors includes travel meetings uk nonexecutive directors may time time accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director nonexecutive enhance link least nonexecutive directors total fees excluding directors share directors shareholders gsk chairman paid form gsk shares ads allocated share allocation plan requires nonexecutive directors ads account receive significant part nonexecutive directors may also take opportunity invest part fees form gsk shares balance fees share ads account ads gsk shares ads notionally awarded nonexecutive directors allocated interest accounts set table included directors interests table accumulated balances gsk shares ads together notional dividends accrued paid nonexecutive directors leave board upon leaving nonexecutive directors receive either gsk shares ads cash amount equivalent value gsk shares ads date leaving date payment later letter nonexecutive directors nonexecutive directors subject annual election reelection appointment chairmans terms engagement normally serve longer nine years date first election set letters appointment shareholders general meeting set table chairman subject annual appointment shareholders may serve longer nine years date first election shareholders general meeting gsk annual report governance remuneration directors remuneration report operation scope remuneration policy basis preparation current remuneration policy policy set pages directors remuneration report prepared intended policy gsks executive accordance companies act large nonexecutive directors apply close companys mediumsized companies groups accounts reports annual general meeting may submitted amendment regulations regulations accordance committee approval shareholders committee regulations following parts annual report currently intends operate accordance policy prior remuneration subject audit total remuneration figures annual general meeting exception additional executive directors including details element twoyear holding period performance share plan awards remuneration salary benefits annual bonus longterm incentive apply awards made onwards awards pension nonexecutive directors fees emoluments received year directors interests shares including interests committee written policy principally relation gsk share plans payments past directors payments loss remuneration arrangements ceo cfo chairman global office share ownership requirements holdings rd vaccines whilst taking account possible recruitment opinion thereon expressed remaining sections replacement additional executive director directors remuneration report subject audit operation policy committee intends policy operate pages referred within audited sections period set entirety however may due consideration seek change policy period directors remuneration report approved believes appropriate longterm success board directors signed behalf company consultation shareholders sought shareholder approval general meeting drafting policy committee reserves right make remuneration payments payments loss office including tom de swaan exercising discretions available connection remuneration committee chairman payments notwithstanding line policy february set terms payment agreed policy came effect ii time relevant individual director company opinion committee payment consideration individual becoming director company purposes payments includes committee satisfying awards variable remuneration relation award shares terms payment agreed time award granted committee may also make minor amendments policy set report regulatory exchange control tax administrative purposes take account change legislation without obtaining shareholder approval amendments statement consideration shareholder views committee engages regular dialogue shareholders holds annual meetings gsks largest investors discuss take feedback remuneration policy governance matters annual meetings held november tom de swaan committee chairman shared updates remuneration matters last months proposals onwards particular covered changes performance conditions applying longterm incentives introduction additional twoyear holding period performance share awards ie five years total apply executive directors awards made onwards policies required disclosed remuneration policy report gsk annual report financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report financial statements directors statement responsibilities directors statement responsibilities relation group financial statements directors responsible preparing annual report disclosure information auditors remuneration report group financial statements directors office date report accordance applicable law regulations confirmed uk company law requires directors prepare financial far aware relevant audit information statements financial year law directors companys auditors unaware required prepare group financial statements accordance taken steps ought taken international financial reporting standards ifrs adopted director make aware relevant audit european union preparing group financial statements information establish companys auditors aware directors also elected comply ifrs issued information international accounting standards board iasb company law directors must approve group financial statements confirmation given interpreted accordance unless satisfied give true fair view provisions section companies act state affairs group profit loss group period going concern basis pages contain information performance group preparing financial statements directors required financial position cash flows net debt position borrowing select suitable accounting policies apply facilities information including treasury risk management consistently policies exposures market credit risk hedging activities make judgements accounting estimates reasonable given note financial statements financial instruments prudent related disclosures making enquiries directors reasonable expectation group adequate resources state group financial statements comply ifrs continue operational existence foreseeable future adopted european union ifrs issued iasb reason continue adopt going concern basis preparing subject material departures disclosed explained financial statements group financial statements directors responsible keeping adequate accounting internal control records sufficient show explain companys board audit risk committee reviewed transactions disclose reasonable accuracy time assessment risks internal control framework operates financial position group enable ensure gsk considered effectiveness system internal group financial statements remuneration report comply control operation group year covered report companies act article ias regulation date approval board directors also responsible safeguarding assets group hence taking reasonable steps prevention uk corporate governance code detection fraud irregularities board considers glaxosmithkline plc applies principles provisions uk corporate governance code maintained group financial statements year ended december financial reporting council described corporate comprising principal statements supporting notes governance section pages complied set financial statements pages report provisions board considers annual report taken responsibilities auditors relation group financial whole fair balanced understandable provides statements set independent auditors report pages information necessary shareholders assess groups performance business model strategy group financial statements year ended december required financial conduct authoritys listing rules included annual report published auditors considered directors statement compliance printed form made available website directors relation points uk corporate governance code responsible maintenance integrity annual report specified review website accordance uk legislation governing preparation dissemination financial statements access annual report website available outside uk comparable annual report year ended december legislation may different comprising report directors remuneration report current directors whose names functions listed financial statements additional information investors corporate governance section annual report approved board directors signed behalf confirms best knowledge group financial statements prepared accordance ifrs adopted eu ifrs issued iasb give true fair view assets liabilities sir christopher gent financial position profit group chairman february strategic report risk sections annual report include fair review development performance business position group together description principal risks uncertainties faces gsk annual report independent auditors report members glaxosmithkline plc opinion overview audit approach opinion group financial statements defined materiality give true fair view state groups affairs set certain thresholds materiality helped us december groups profit cash flows determine nature timing extent audit procedures year ended evaluate effect misstatements individually financial statements whole properly prepared accordance international financial reporting standards ifrss adopted based professional judgement determined materiality european union group financial statements whole million represents profit taxation prepared accordance requirements companies act article ias regulation agreed audit risk committee would report misstatements identified audit million opinion read context say well misstatements amount view warranted remainder report reporting qualitative reasons separate opinion relation ifrss issued iasb overview scope audit explained note financial statements group group financial statements consolidation reporting units addition applying ifrss adopted european union comprising groups operating businesses centralised also applied ifrss issued international accounting functions standards board iasb establishing overall approach group audit opinion group financial statements comply ifrss determined type work needed performed issued iasb reporting units us group audit team component auditors within pwc uk pwc network firms operating audited instruction work performed component group financial statements prepared auditors determined level involvement needed glaxosmithkline plc comprise audit work reporting units able conclude group balance sheet december whether sufficient appropriate audit evidence obtained basis opinion group financial statements whole group income statement statement comprehensive income year ended identified reporting units view required audit complete financial information either due size group statement changes equity statement risk characteristics specific audit procedures certain specified cash flows year ended balances transactions performed reporting notes group financial statements include units together additional procedures performed group summary significant accounting policies explanatory level gave us evidence needed opinion information group financial statements whole financial reporting framework applied areas particular audit focus preparation comprises applicable law ifrss adopted preparing financial statements directors made number european union subjective judgements example respect significant accounting estimates involved making assumptions audit financial statements involves considering future events inherently uncertain primarily conducted audit accordance international standards focused work areas assessing directors auditing uk ireland isas uk ireland audit involves judgements available evidence forming judgements obtaining evidence amounts disclosures evaluating disclosures financial statements financial statements sufficient give reasonable assurance financial statements free material misstatement whether audit tested examined information using sampling caused fraud error includes assessment auditing techniques extent considered necessary provide reasonable basis us draw conclusions obtained whether accounting policies appropriate groups audit evidence testing effectiveness controls circumstances consistently applied adequately substantive procedures combination disclosed considered following areas required reasonableness significant accounting estimates made particular focus current year complete list directors risks areas focus identified audit discussed overall presentation financial statements areas focus audit risk committee report matters considered significant issues addition read financial nonfinancial information relation financial statements set annual report identify material inconsistencies audited group financial statements identify information apparently materially incorrect based materially inconsistent knowledge acquired us course performing audit become aware apparent material misstatements inconsistencies consider implications report gsk annual report financial statements independent auditors report independent auditors report continued area focus scope audit addressed area focus rebates discounts allowances returns tested calculation accruals validating assumptions reference third party us pharmaceuticals vaccines business data assessing judgements taken reasonableness historical trends focused area rebates discounts also evaluated design operating effectiveness controls rebates allowances returns arrangements us discounts allowances returns process pharmaceuticals vaccines business complex establishing appropriate accrual requires significant judgement estimates directors directors determined accrual billion necessary december core business services evaluated design tested operating effectiveness key controls part simplification operating model migration centralised processing environment tested accuracy group continued rollout enterprise completeness data migration new erp controls process wide resource planning system erp addition managed directed centrally audit work performed component auditors financial transaction processing centralised bpos bscs performed oversight visits significant entities impacted business process outsourcing locations bpos changes accounting services centralised business service centres bscs consequently year significant change finance function identified heightened risk control design operation might impacted period transition potential implications alleged illegal acts considered ongoing work independent investigators appointed following allegations chinese authorities company assessed whether scope sufficient whether results illegal acts groups chinese business investigation date support directors conclusions identified following risks performed oversight visits china review approach testing results alleged illegal acts might give rise component auditor fines legal penalties event assessed directors determination possible reliably estimate allegations proven financial effect allegations timing appropriately recorded measured financial statements assessed reasonableness assumptions trading forecasts carrying value assets groups directors used support carrying value assets chinese business chinese business supportable light performed additional audit tests certain locations outside china subsequent decline trading designed evaluate whether practices alleged china occurred locations potential impact future business across group illegal acts similar alleged occurred china occurred elsewhere group refer note group financial statements fraud revenue recognition evaluated relevant systems tested internal controls validity presumed risk fraud revenue timing revenue recognised financial statements well completeness recognition isas uk ireland accruals rebates discounts allowances returns also tested journal entries pressure management may feel achieve posted revenue accounts consolidation identify unusual irregular items planned results assessed accounting material new agreements trading arrangements focused validity revenue recognised customers wholesalers oneoff transactions close yearend well accruals performed yearend sales cutoff testing check revenue recorded rebates discounts allowances returns correct period calculations complex involve estimation risk management override internal assessed overall control environment group including arrangements controls staff whistleblow inappropriate actions interviewed senior management isas uk ireland require consider groups internal audit function examined significant accounting estimates risk judgements relevant financial statements evidence bias directors may represent risk material misstatement due fraud also tested journal entries including consolidation entries addition audit work described relation alleged illegal acts fraud revenue recognition gsk annual report going concern information annual report listing rules required review directors isas uk ireland required report statement set relation going concern opinion information annual report nothing report performed review aterially inconsistent information audited noted directors statement directors concluded group financial statements appropriate prepare groups financial statements pparently materially incorrect based materially using going concern basis accounting going concern inconsistent knowledge group acquired basis presumes group adequate resources remain course performing audit operation directors intend least one year date financial statements signed otherwise misleading part audit concluded directors use exceptions report arising responsibility going concern basis appropriate responsibilities financial statements audit however future events conditions predicted statements guarantee groups responsibilities directors ability continue going concern explained fully statement directors opinion matters prescribed responsibilities directors responsible preparation group financial statements companies act satisfied give true fair view opinion information given strategic report responsibility audit express opinion group directors report financial year group financial financial statements accordance applicable law isas statements prepared consistent group financial uk ireland standards require us comply statements auditing practices boards ethical standards auditors report including opinions prepared matters required companys members body accordance chapter report exception part companies act purpose giving opinions accept assume adequacy information explanations received responsibility purpose person companies act required report report shown whose hands may come save opinion received information expressly agreed prior consent writing explanations require audit exceptions report arising responsibility matters reported separately parent company financial directors remuneration statements glaxosmithkline plc year ended companies act required report december information directors opinion certain disclosures directors remuneration remuneration report described audited specified law made exceptions company passed resolution accordance section report arising responsibility companies act senior statutory auditors name stated corporate governance statement listing rules required review part corporate governance statement relating companys compliance nine provisions uk corporate governance code code nothing report performed review pricewaterhousecoopers llp annual report required code chartered accountants statutory auditors provision c directors state consider annual london report taken whole fair balanced understandable february provides information necessary members assess groups performance business model strategy required c code audit risk committee set significant issues considered relation financial statements addressed isas notes uk ireland required report opinion maintenance integrity glaxosmithkline plc statement given directors materially inconsistent website responsibility directors work carried knowledge group acquired course auditors involve consideration performing audit matters accordingly auditors accept responsibility section annual report describing work changes may occurred financial audit risk committee appropriately address matters statements since initially presented website communicated us audit risk committee b legislation united kingdom governing preparation exceptions report arising responsibility dissemination financial statements may differ legislation jurisdiction gsk annual report financial statements consolidated income statement financial statements consolidated income statement year ended december restated restated notes turnover cost sales gross profit selling general administration research development royalty income operating income operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p comparative information restated consistency presentation set note presentation financial statements consolidated statement comprehensive income year ended december restated restated profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement share comprehensive incomeexpense associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial gainslosses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report consolidated balance sheet december restated notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board february signed behalf sir christopher gent chairman gsk annual report financial statements consolidated statement changes equity consolidated statement changes equity year ended december shareholders equity retained non total share share earnings total controlling equity capital premium restated reserves restated interests restated january previously reported prior year adjustment ias january restated profit year comprehensive expense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive incomeexpense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report consolidated cash flow statement year ended december restated restated notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal subsidiary interest associate decrease liquid investments interest received dividends associates joint ventures net cash inflowoutflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares purchase noncontrolling interests increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report financial statements notes financial statements notes financial statements presentation financial statements implementation new accounting standards amendment ias employee benefits issued description business june implemented gsk january glaxosmithkline major global healthcare group amendment eliminates ability defer recognition engaged creation discovery development manufacture gains losses corridor method requires remeasurements marketing pharmaceutical products including vaccines presented comprehensive income requires past overthecounter otc medicines healthrelated consumer service cost recognised income statement year products gsks principal pharmaceutical products include plan amendment rather deferring portion related medicines following therapeutic areas respiratory antivirals unvested benefits requires return plan assets recognised central nervous system cardiovascular urogenital metabolic income statement calculated using rate antibacterials oncology emesis dermatology rare diseases discount rate applied pension obligation makes several immunoinflammation vaccines hiv minor accounting disclosure changes revised standard increased pension charge compliance applicable law ifrs approximately million comparative periods financial statements prepared accordance restated result pension charge increased companies act article ias regulation million million international accounting standards ias international financial addition following new amended accounting standards reporting standards ifrs related interpretations adopted implemented material impact european union current period financial statements also compliance ifrs issued ifrs consolidated financial statements international accounting standards board ifrs joint arrangements composition financial statements ifrs disclosures interests entities consolidated financial statements drawn sterling functional currency glaxosmithkline plc accordance ifrs fair value measurement ifrs accounting presentation financial statements comprise ias presentation items comprehensive income consolidated income statement ias investments associates joint ventures consolidated statement comprehensive income ifrs disclosures offsetting financial assets financial consolidated balance sheet liabilities consolidated statement changes equity group also adopted early amendment ias impairment assets relation recoverable amount disclosures consolidated cash flow statement nonfinancial assets effect january notes financial statements financial period composition group financial statements cover financial year january list subsidiary associated undertakings december comparative figures financial years opinion directors principally affected amount profit january december appropriate net assets group given note principal group january december companies parent company financial statements accounting principles policies financial statements parent company glaxosmithkline plc financial statements prepared using historical prepared accordance uk gaap uk cost convention modified revaluation certain items accounting presentation company balance sheet presented stated accounting policies going concern basis accounting policies given financial statements prepared accordance accounting principles policies groups accounting policies approved board described note accounting principles policies information consolidation application accounting policies including areas estimation judgement given note key accounting consolidated financial statements include judgements estimates assets liabilities results cash flows preparation financial statements conformity company subsidiaries including esop trusts generally accepted accounting principles requires management groups share results net assets associates make estimates assumptions affect reported amounts joint ventures assets liabilities disclosure contingent assets groups share assets liabilities revenue expenses liabilities date financial statements reported joint operations amounts revenues expenses reporting period actual results could differ estimates financial statements entities consolidated made december year gsk annual report accounting principles policies continued consolidation assets liabilities including related goodwill overseas subsidiaries associates joint ventures translated entities group power direct relevant sterling rates exchange ruling balance sheet date activities affect returns group generally results cash flows overseas subsidiaries associates joint control financial operating policies accounted ventures translated sterling using average rates exchange subsidiaries group ability exercise joint exchange adjustments arising opening net assets control rights net assets entities entities profits year retained overseas subsidiaries associates accounted joint ventures group ability joint ventures translated sterling less exchange differences exercise joint control arrangement rights specified arising related foreign currency borrowings hedge assets obligations specified liabilities arrangement groups net investment operations taken separate arrangement accounted joint operation component equity group ability exercise significant influence entities accounted associates results assets translating sterling assets liabilities results cash liabilities associates joint ventures incorporated flows overseas subsidiaries associates joint ventures consolidated financial statements using equity method reported currencies hyperinflationary economies accounting groups rights assets liabilities revenue adjustments made material reflect current price levels expenses joint operations included consolidated loss net monetary assets charged consolidated financial statements accordance rights obligations income statement interests acquired entities consolidated date revenue group acquires control interests sold deconsolidated revenue recognised income statement goods date control ceases services supplied made available external customers transactions balances subsidiaries eliminated orders received title risk loss passed customer profit tax taken sales subsidiaries reliable estimates made relevant deductions relevant products sold customers outside group obligations fulfilled earnings process relevant proportion profits transactions joint ventures regarded complete joint operations associates also deferred products turnover represents net invoice value deduction discounts sold third parties transactions noncontrolling interests allowances given accruals estimated future rebates recorded directly equity deferred tax relief unrealised returns methodology assumptions used estimate rebates intragroup profit accounted extent returns monitored adjusted regularly light considered recoverable contractual legal obligations historical trends past experience goodwill capitalised separate item case subsidiaries projected market conditions market conditions evaluated part cost investment case joint ventures using wholesaler thirdparty analyses market research data associates goodwill denominated currency operation internally generated information value added tax sales acquired taxes excluded revenue cost acquisition fair value net assets group copromotes product counterparty acquired difference recognised directly income records sale group records share revenue co statement promotion income within turnover nature copromotion activities group records costs sales business combinations pharmaceutical turnover includes copromotion revenue business combinations accounted using acquisition million million million addition initial accounting method identifiable assets liabilities contingent eventbased milestone income excluding royalty income arising liabilities acquired measured fair value acquisition date development marketing collaborations groups consideration transferred measured fair value includes compounds products parties recognised turnover fair value contingent consideration milestone income million included turnover consideration transferred together noncontrolling interest royalty income recognised accruals basis accordance exceeds fair value net assets liabilities contingent terms relevant licensing agreements liabilities acquired excess recorded goodwill costs acquisition charged income statement period expenditure incurred expenditure recognised respect goods services received equity subsidiary acquired non supplied accordance contractual terms provision controlling interest recognised either fair value non made obligation exists future liability respect controlling interests share net assets subsidiary past event amount obligation reliably casebycase basis changes groups ownership percentage estimated manufacturing startup costs validation subsidiaries accounted within equity achievement normal production expensed incurred advertising promotion expenditure charged income foreign currency translation statement incurred shipment costs intercompany transfers foreign currency transactions booked functional currency charged cost sales distribution costs sales customers group company exchange rate ruling date included selling general administrative expenditure transaction foreign currency monetary assets liabilities restructuring costs recognised provided retranslated functional currency rates exchange ruling appropriate respect direct expenditure business balance sheet date exchange differences included reorganisation plans sufficiently detailed well income statement advanced appropriate communication affected undertaken gsk annual report financial statements notes financial statements accounting principles policies continued employee share plans incentives form shares provided employees research development share option share award schemes research development expenditure charged income fair values options awards calculated statement period incurred development grant dates using blackscholes option pricing model charged expenditure capitalised criteria recognising asset income statement relevant vesting periods met usually regulatory filing made major group provides finance esop trusts purchase company market approval considered highly probable property plant shares open market meet obligation provide shares equipment used research development capitalised employees exercise options awards costs running depreciated accordance groups policy esop trusts charged income statement shares held environmental expenditure esop trusts deducted reserves transfer made reserves retained earnings vesting environmental expenditure related existing conditions resulting periods related share options awards reflect ultimate past current operations current future proceeds receivable employees exercise benefit discernible charged income statement group recognises liability sitebysite basis reliably property plant equipment estimated liability includes groups portion total costs property plant equipment ppe stated cost also portion potentially responsible parties costs purchase construction less provisions depreciation probable able satisfy respective impairment financing costs capitalised within cost shares cleanup obligation recoveries reimbursements qualifying assets construction recorded assets virtually certain depreciation calculated write cost less residual value legal disputes ppe excluding freehold land using straightline basis provision made anticipated settlement costs legal expected useful life residual values lives reviewed disputes group outflow resources appropriate adjusted annually normal expected useful considered probable reliable estimate made likely lives major categories ppe outcome addition provision made legal expenses freehold buildings years arising claims received disputes respect product leasehold land buildings lease term years liability claims related certain products sufficient history plant machinery years claims made settlements enable management make equipment vehicles years reliable estimate provision required cover unasserted claims certain cases incurred reported ibnr actuarial disposal ppe cost related accumulated depreciation technique used determine estimate impairments removed financial statements group may become involved legal proceedings respect net amount less proceeds taken income statement possible make reliable estimate expected financial effect could result ultimate resolution leases proceedings cases appropriate disclosure leasing agreements transfer group substantially cases would included provision would made costs benefits risks ownership asset treated finance associated claims made group third parties leases asset purchased outright assets charged income statement incurred included ppe computer software capital elements leasing commitments shown obligations finance pensions postemployment benefits leases assets held finance leases depreciated basis costs providing pensions defined benefit schemes consistent similar owned assets lease term shorter calculated using projected unit credit method spread interest element lease rental included income period benefit expected derived statement leases operating leases rental costs employees services consistent advice qualified actuaries charged income statement straightline basis pension obligations measured present value estimated lease term future cash flows discounted rates reflecting yields high quality corporate bonds pension scheme assets measured goodwill fair value balance sheet date goodwill stated cost less impairments goodwill deemed indefinite useful life tested impairment least costs postemployment liabilities calculated annually similar way defined benefit pension schemes spread period benefit expected derived fair value interest acquired entitys assets employees services accordance advice qualified liabilities contingent liabilities exceeds consideration paid actuaries excess recognised immediately gain income statement actuarial gains losses effect changes actuarial assumptions recognised statement comprehensive income year arise groups contributions defined contribution plans charged income statement incurred gsk annual report accounting principles policies continued availableforsale investments liquid investments investments classified available intangible assets forsale investments initially recorded fair value plus intangible assets stated cost less provisions amortisation transaction costs remeasured subsequent reporting impairments dates fair value unrealised gains losses availableforsale investments recognised directly comprehensive income licences patents knowhow marketing rights separately impairments arising significant prolonged decline fair acquired acquired part business combination amortised value equity investment reduce carrying amount asset estimated useful lives generally exceeding years directly charged income statement using straightline basis time available use estimated useful lives determining amortisation charge disposal impairment investments gains losses take account patent lives applicable well value deferred comprehensive income obtained periods nonexclusivity asset lives reviewed reclassified income statement dividends equity investments appropriate adjusted annually contingent milestone recognised income statement groups right payments recognised point contingent event receive payment established equity investments recorded becomes certain development costs incurred group noncurrent assets unless expected sold within one associated acquired licences patents knowhow marketing year rights written income statement incurred unless purchases sales equity investments accounted criteria recognition internally generated intangible asset trade date purchases sales availableforsale met usually regulatory filing made major investments accounted settlement date market approval considered highly probable inventories acquired brands valued independently part fair value businesses acquired third parties brand inventories included financial statements lower value substantial longterm brands cost including raw materials direct labour direct costs either contractual legal nature sold separately related production overheads net realisable value cost rest businesses acquired brands amortised generally determined first first basis prelaunch inventory estimated useful lives years except held asset high probability regulatory considered useful economic life indefinite approval product point provision made carrying value recoverable amount provision costs acquiring developing computer software internal reversed point high probability regulatory approval use internet sites external use capitalised intangible determined fixed assets software site supports significant business system expenditure leads creation trade receivables durable asset erp systems software amortised seven trade receivables carried original invoice amount less ten years computer software three five years provisions doubtful debts provisions made evidence risk nonpayment taking account ageing impairment noncurrent assets previous experience general economic conditions trade carrying values noncurrent assets reviewed receivable determined uncollectable written firstly impairment either standalone basis part larger cash provision available income statement generating unit indication assets might impaired additionally goodwill intangible assets indefinite subsequent recoveries amounts previously provided useful lives intangible assets yet available use credited income statement longterm receivables tested impairment annually provision impairment discounted effect material charged income statement year concerned trade payables impairments goodwill reversed impairment losses trade payables initially recognised fair value held noncurrent assets reversed amortised cost equates nominal value longterm payables change estimates used determine recoverable amounts discounted effect material extent revised recoverable amounts exceed carrying values would existed net depreciation cash cash equivalents amortisation impairments recognised cash cash equivalents comprise cash hand current balances banks similar institutions highly liquid investments investments associates joint ventures joint operations maturities three months less readily convertible investments associates joint ventures carried known amounts cash insignificant risk changes consolidated balance sheet groups share net assets value date acquisition postacquisition retained profits losses together goodwill arising acquisition borrowings group recognises rights assets liabilities revenue borrowings initially recorded amount proceeds expenses joint operations received net transaction costs borrowings subsequently carried amortised cost difference proceeds net transaction costs amount due redemption recognised charge income statement period relevant borrowing gsk annual report financial statements notes financial statements accounting principles policies continued key accounting judgements estimates preparing financial statements management required taxation make estimates assumptions affect amounts current tax provided amounts expected paid applying assets liabilities revenue expenses reported financial tax rates enacted substantively enacted statements actual amounts results could differ balance sheet date estimates following considered key accounting deferred tax provided full using liability method judgements estimates made temporary differences arising tax bases assets liabilities carrying amounts financial statements turnover deferred tax assets recognised extent probable revenue recognised title risk loss passed future taxable profits available customer reliable estimates made relevant deductions temporary differences utilised deferred tax provided relevant obligations fulfilled temporary differences arising investments subsidiaries earnings process regarded complete associates joint ventures except timing reversal gross turnover reduced rebates discounts allowances temporary difference controlled probable product returns given expected given vary temporary difference reverse foreseeable future product arrangements buying groups arrangements deferred tax provided using rates tax enacted purchasing organisations dependent upon submission substantively enacted balance sheet date claims time initial recognition sale accruals made time sale estimated rebates discounts derivative financial instruments hedging allowances payable returns made based available derivative financial instruments used manage exposure market information historical experience market risks principal derivative instruments used gsk foreign currency swaps interest rate swaps forward foreign amounts estimated may fully reflect exchange contracts group hold issue derivative final outcome amounts subject change dependent financial instruments trading speculative purposes upon amongst things types buying group product sales mix derivative financial instruments classified heldfortrading carried balance sheet fair value derivatives level accrual reviewed adjusted regularly light designated hedging instruments classified inception contractual legal obligations historical trends past experience cash flow hedges net investment hedges fair value hedges projected market conditions market conditions evaluated using wholesaler thirdparty analyses market research changes fair value derivatives designated cash flow data internally generated information future events could hedges recognised comprehensive income extent cause assumptions accruals based change hedges effective ineffective portions recognised could affect future results group profit loss immediately amounts deferred comprehensive income reclassified income statement hedged taxation item affects profit loss current tax provided amounts expected paid net investment hedges accounted similar way cash deferred tax provided temporary differences tax flow hedges bases assets liabilities carrying amounts rates enacted substantively enacted changes fair value derivatives designated fair value balance sheet date hedges recorded income statement together changes fair value hedged asset liability deferred tax assets recognised extent probable future taxable profits available changes fair value derivative instruments temporary differences utilised based managements qualify hedge accounting recognised immediately assumptions relating amounts timing future taxable income statement profits factors affecting tax charge future years set discounting note taxation change groups effective tax rate would changed total tax charge year time effect money material balances discounted approximately million current values using appropriate rates interest unwinding discounts recorded finance income finance expense group open tax issues number revenue authorities outflow funds believed probable reliable estimate outcome dispute made management provides best estimate liability estimates take account specific circumstances dispute relevant external advice inherently judgemental could change substantially time new facts emerge dispute progresses details relating significant unresolved disputes set note taxation gsk continues believe made adequate provision liabilities likely arise open assessments open issues exist ultimate liability matters may vary amounts provided dependent upon outcome negotiations relevant tax authorities necessary litigation proceedings gsk annual report k ey accounting judgements estimates pensions postemployment benefits costs providing pensions postemployment continued benefits charged income statement accordance ias employee benefits period benefit legal disputes derived employees services costs assessed group provides anticipated settlement costs basis assumptions selected management outflow resources considered probable reliable estimate assumptions include future earnings pension increases may made likely outcome dispute legal discount rates expected longterm rates return assets expenses arising claims group mortality rates disclosed note pensions estimates take account specific circumstances postemployment benefits dispute relevant external advice inherently judgmental could change substantially time new facts emerge expected longterm rates return bonds determined dispute progresses details status various uncertainties based portfolio mix indexlinked government involved significant unresolved disputes set note corporate bonds equity risk premium added legal proceedings equities companys directors taken legal advice discount rates derived aa rated corporate bond yields established provisions taking account relevant except countries deep market corporate facts circumstances matter accordance bonds government bond yields used sensitivity analysis accounting requirements respect product liability claims provided note pensions postemployment related certain products sufficient history claims made benefits reduction discount rate would lead settlements enable management make reliable estimate increase net pension deficit approximately million provision required cover unasserted claims group increase annual pension cost approximately may become involved legal proceedings respect million selection different assumptions could affect possible make reliable estimate expected financial future results group effect result ultimate resolution proceedings cases appropriate disclosure cases would included provision would made contingent liability quantified december provisions legal disputes amounted billion billion ultimate liability legal claims may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations position could change time therefore assurance losses result outcome legal proceedings exceed amount provisions reported groups financial statements material amount goodwill intangible asset impairments goodwill deemed indefinite life amortised annual impairment tests cash generating units goodwill allocated performed impairment tests based established market multiples riskadjusted future cash flows discounted using appropriate interest rates assumptions used impairment tests set note goodwill case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill impairment tests intangible assets undertaken events occur call question carrying values assets brands amortised subject annual impairment tests valuations impairment tests based established market multiples riskadjusted future cash flows estimated useful life asset limited discounted using appropriate interest rates set note intangible assets assumptions relating future cash flows estimated useful lives discount rates based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests change consequent adverse effect future results group gsk annual report financial statements notes financial statements new accounting requirements exchange rates following new amended accounting standards group uses average exchange rates prevailing issued iasb likely affect future annual reports period translate results cash flows overseas although current forms none expected material subsidiaries joint ventures associated undertakings impact results financial position group sterling period end rates translate net assets undertakings currencies influence amendment ias offsetting financial assets financial translations relevant exchange rates liabilities issued december implemented group january amendment provides additional guidance financial assets financial liabilities average rates may offset us ifrs financial instruments first issued november euro since amended several times standard yen eventually replace ias covers classification measurement derecognition financial assets financial period end rates liabilities together new hedge accounting model iasb us intends expand ifrs add new requirements impairment euro become complete replacement ias due yen course although date mandatory implementation set amendment ias defined benefit plans employee contribution issued november implemented group january amendment provides additional guidance treatment contributions defined benefit plans employees third parties gsk annual report segment information groups operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet individual members cet responsible geographic segment pharmaceuticals vaccines business viiv healthcare consumer healthcare business whole respectively several minor product reclassifications pharmaceuticals consumer healthcare segments made effect january addition amendment ias employee benefits adopted see note presentation financial statements details comparative information restated accordingly rd investment essential sustainability pharmaceutical businesses however segment reporting us europe emerging markets asia pacific japan pharmaceuticals vaccines operating profits exclude allocations globally funded rd well central costs principally corporate functions unallocated manufacturing costs groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis trading unallocated pharmaceuticals vaccines includes canada puerto rico australasia central vaccine tender sales contract manufacturing sales together costs vaccines rd central dermatology costs central manufacturing costs attributed segments pharmaceuticals rd segment responsibility chairman research development reported separate segment corporate unallocated costs represent costs corporate functions restated restated turnover segment pharmaceuticals vaccines usa europe emap japan viiv healthcare trading unallocated pharmaceuticals vaccines turnover consumer healthcare turnover restated restated pharmaceuticals vaccines turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis dermatology rare diseases immunoinflammation pharmaceuticals vaccines viiv healthcare hiv gsk annual report financial statements notes financial statements segment information continued restated restated consumer healthcare turnover category total wellness oral care nutrition skin health us pharmaceuticals viiv healthcare made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated pharmaceuticals vaccines usa europe emap japan viiv healthcare pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines operating profit consumer healthcare operating profit segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restated restated pharmaceuticals vaccines usa europe emap japan viiv healthcare pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report segment information continued ppe intangible asset goodwill impairment segment restated restated pharmaceuticals vaccines usa europe emap japan viiv healthcare pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines impairment consumer healthcare impairment segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment restated restated pharmaceuticals vaccines usa europe emap japan viiv healthcare pharmaceuticals rd trading unallocated costs pharmaceuticals vaccines impairment reversals consumer healthcare impairment reversals segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals gsk annual report financial statements notes financial statements segment information continued restated net assets segment pharmaceuticals vaccines usa europe emap japan viiv healthcare pharmaceuticals rd trading unallocated assets pharmaceuticals vaccines net operating assets consumer healthcare net operating assets segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets trading unallocated pharmaceuticals consumer healthcare segments include assets centrally managed pharmaceutical vaccine consumer healthcare manufacturing operations depreciation totalling million million million recovered standard cost product charged businesses geographical information uk regarded groups country domicile restated restated turnover location customer uk usa rest world external turnover turnover location subsidiary uk usa rest world turnover including intersegment turnover uk usa rest world intersegment turnover uk usa rest world external turnover gsk annual report segment information continued restated restated operating profit location uk usa rest world total operating profit restated net operating assets location uk usa rest world net operating assets restated noncurrent assets location uk usa rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating income impairment equity investments disposal equity investments disposal businesses assets legal settlements gain settlement preexisting collaborations acquisition hgs gain acquisition shionogiviiv healthcare joint venture fair value remeasurements contingent consideration recognised business combinations fair value adjustments derivative financial instruments expenseincome disposal businesses assets legal settlements includes gain disposal lucozade ribena business suntory million gain sale worldwide intellectual property rights excluding certain emap markets anticoagulant products business aspen group million fair value remeasurements contingent consideration recognised business combinations arose principally contingent consideration payable acquisition former shionogiviiv healthcare joint venture gsk annual report financial statements notes financial statements operating profit restated restated following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets goodwill net reversals net foreign exchange losses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries auditrelated assurance services including attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services addition fees paid respect gsk pension schemes audit services gsk annual report employee costs restated restated wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance charge pension postemployment costs includes credit million following restructuring us postretirement medical obligations charge includes credit million following change policy relating discretionary pension increases certain uk pension schemes introduction limit future pensionable pay increases uk schemes set note pensions postemployment benefits cost sharebased incentive plans analysed follows share value plan performance share plan share option plans plans average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans gsk annual report financial statements notes financial statements major restructuring costs major restructuring costs charged arriving operating profit include restructuring costs arising operational excellence programme initiated expanded major change programme initiated following acquisition human genome sciences inc hgs august following acquisition stiefel laboratories inc july total restructuring costs million incurred million incurred operational excellence programme million major change programme following areas restructuring pharmaceuticals business europe leading staff reductions sales force administration projects rationalise core business services simplify eliminate processes leading staff reduction support functions transformation manufacturing vaccines businesses deliver step change quality cost productivity rationalisation consumer healthcare business costs million incurred restructuring programme related integration hgs remaining costs million incurred restructuring programme related integration stiefel business analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs asset impairments million million million noncash charges totalling million million million noncash items principally accelerated depreciation asset lives shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees finance income interest income arising cash cash equivalents availableforsale investments loans receivables realised gains liquid investments fair value adjustments derivatives fair value profit loss derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias gsk annual report finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss unwinding discounts provisions movements amounts owed noncontrolling interests finance expense derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense associates joint ventures december group held one significant associate aspen pharmacare holdings limited aspen summarised income statement information respect aspen set turnover profit taxation comprehensive income total comprehensive income results aspen included summarised income statement information represent estimated earnings aspen group year adjusted transactions gsk aspen amounts relating joint ventures principally arise interest one joint venture japan vaccine co ltd daiichi sankyo co ltd aggregated financial information respect associated undertakings joint ventures set associates share turnover share tax profits share comprehensive income share total comprehensive income joint ventures share turnover share tax losses share comprehensive income share total comprehensive income sales joint ventures associates gsk annual report financial statements notes financial statements taxation restated restated taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation deferred tax credit arises predominantly result non cash items related continuing restructuring supply chain intellectual property ownership reconciliation taxation rate group profits uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits intercompany stock profit impact sharebased payments reduction tax rate unrecognised losses permanent differences reassessments prior year estimates disposal associate tax unremitted earnings restructuring tax rate group operates countries tax rate differs uk tax rate impact overseas taxes overall rate tax shown group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate current period intercompany profit ifrs reduced increase decrease arising changes location workinprogress finished goods restated restated tax items charged equity statement comprehensive income current taxation share based payments deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements availableforsale investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax share based payments gsk annual report taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues ongoing requirement gsk group continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate aggregate amount unremitted profits balance sheet date approximately billion billion uk legislation relating company distributions provides exemption tax repatriated profits subject certain exceptions provision deferred tax liabilities million million made respect withholding taxation would arise distribution profits certain overseas subsidiaries unprovided deferred tax unremitted earnings december estimated million million relates taxes payable repatriation levied overseas tax jurisdictions provision made grounds group able control timing reversal remaining temporary differences probable reverse foreseeable future movement deferred tax assets liabilities pensions post manu share accelerated intra employment legal facturing stock option net offset capital group benefits tax restruct valuation award temporary within total allowances intangibles profit restated losses disputes uring adjustments schemes differences countries restated deferred tax assets previously reported prior year adjustment ias r deferred tax assets january deferred tax liabilities january january exchange adjustments creditcharge income statement credit equity charge comprehensive income acquisitions transfer current tax december deferred tax assets december deferred tax liabilities december deferred tax charge income relating changes tax rates million million deferred tax credit million deferred tax credit deferred tax movements arise origination reversal temporary differences net temporary differences mainly include accrued expenses tax deduction available paid basis gsk annual report financial statements notes financial statements taxation continued tax losses recognised unrecognised trading losses expiring within years years available indefinitely december deferred tax asset addition group capital losses approximately billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses factors affecting tax charge future years global organisation many factors could affect future effective tax rate group mix profits across different territories transfer pricing disputes tax authorities location research development activity significant impact groups effective tax rate changes tax legislation territories group business operations could also impact groups effective tax rate december uk government announced part ongoing phased reduction main rate corporation tax main rate reduce effect april march reduction main rate corporation tax announced take effect april deferred tax movements reflect reduction uk tax rate effect april effect april substantively enacted earnings per share restated restated pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted gsk annual report dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paidpayable pence paidpayable pence first interim july july july second interim october october october third interim january january january fourth interim april april april annual total supplemental april total ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december gsk annual report financial statements notes financial statements property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer fromto assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment million million net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million million rd million million sga million million include million million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million gsk annual report goodwill cost january exchange adjustments additions business combinations note transfer assets held sale movements contingent consideration balances cost december net book value january net book value december movement contingent consideration balance mainly arises respect acquisition pfizer incs hiv business april carrying value goodwill translated yearend exchange rates made balances arising acquisition following businesses cash generating unit stiefel laboratories inc us europe emap human genome sciences inc us europe emap japan pharmaceuticals vaccines reliant pharmaceuticals inc us pharmaceuticals vaccines id biomedical corporation us europe emap japan pharmaceuticals vaccines sirtris pharmaceuticals inc us europe emap japan pharmaceuticals vaccines domantis limited us europe emap japan pharmaceuticals vaccines glaxosmithkline kk japan pharmaceuticals vaccines cns inc consumer healthcare pfizer hiv business viiv healthcare maxinutrition group holdings limited consumer healthcare polfa poznan sa europe pharmaceuticals vaccines certain businesses ucb sa emap pharmaceuticals vaccines novamin technology inc consumer healthcare others goodwill arising acquisition stiefel allocated us europe emap cash generating units impairment testing purposes benefits acquired business split cash generating units goodwill arising acquisitions human genome sciences id biomedical sirtris pharmaceuticals domantis split us europe emap japan pharmaceutical vaccines cash generating units impairment testing purposes either benefit acquired businesses split cash generating units acquired businesses generate independent cash flows total goodwill allocated us pharmaceuticals vaccines amounted million million amounts allocated cash generating units significant relative total balance gsk annual report financial statements notes financial statements goodwill continued recoverable amounts cash generating units assessed using either fair value less costs disposal model value use model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value posttax cash flows discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks fair value less costs disposal calculated using similar discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis higher fair value less costs disposal value use key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows years terminal growth rate discount rate terminal growth rate discount rate us pharmaceuticals vaccines pa europe pharmaceuticals vaccines pa emap pharmaceuticals vaccines pa japan pharmaceuticals vaccines pa viiv healthcare pa pharmaceuticals vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rates used fair value less costs disposal calculations cash generating units reflect impact future generic competition take account new product launches pharmaceutical vaccines cash generating units comprise collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill gsk annual report intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs reclassifications transfer fromto assets held sale cost december exchange adjustments capitalised internal development costs additions business combinations capitalised borrowing costs additions disposals asset writeoffs transfer tofrom assets held sale cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs impairment december exchange adjustments impairment losses disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software includes million million internally generated costs charge impairments year includes impairments lovaza reflecting reassessment groups expectations likelihood potential generic competition chemocentryx retigabine panmiraflair carrying value december intangible assets impairments charged reversed year following impairments reversals million million gsk annual report financial statements notes financial statements intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses restated restated cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development net book value includes million million internally generated costs note acquisitions disposals gives details additions business combinations year book values largest individual items follows dolutegravir benlysta flulavalfluviral selzentry arzerra okairos technology platform lovaza duac toctino fraxiparine others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident biotene corega poligrip others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using five year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement december investments joint ventures principally arise interest one joint venture japan vaccine co ltd daiichi sankyo co ltd joint venture holds development commercial rights existing preventative vaccines parent companies supply vaccines including human papillomavirus hpv vaccine rotavirus vaccine seasonal flu vaccine mumps vaccine diphtheria pertussis dtp vaccine measles rubella vaccine mrv japan group held one significant associate december aspen pharmacare holdings limited december group owned million shares aspen aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets investment market value million million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors year group disposed shareholding see note summarised balance sheet information respect aspen set noncurrent assets current assets current liabilities noncurrent liabilities net assets summarised balance sheet information respect aspen based preliminary results information analysts forecasts available december adjustments transactions gsk aspen reconciliation summarised financial information carrying amount aspen investment set january profit year comprehensive income exchange adjustments dividends paid movements december interest associated undertaking goodwill carrying value december gsk annual report financial statements notes financial statements investments january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures equity investments converted subsidiary acquisition business disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million increase arising additions fair value adjustments additions year include investments theravance inc theravance million net fair value movements include increase value investment theravance million although gsk owns common stock theravance accounted equity investment due voting restrictions contained gsks governance agreement theravance prevent group exerting significant influence disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement investments include assets impaired carrying value assets december calculated follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report trade receivables trade receivables net provision bad doubtful debts prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million provision bad doubtful debts million provision million due state hospital authorities greece ireland italy portugal spain trade receivables also include million million due associates joint ventures receivables includes million nil due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits increase cash cash equivalents reflects disposal proceeds million largely received towards end assets held sale land buildings plant equipment vehicles intangible assets noncurrent assets transferred assets held sale expected carrying amounts recovered principally disposal sale considered likely held lower carrying amount fair value less costs sell gsk annual report financial statements notes financial statements trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals december payables include million respect maximum potential amount payable noncontrolling shareholders gsk pharmaceuticals ltd groups pharmaceuticals subsidiary india voluntary open offer purchase additional shares announced december purchase expected complete first half december payables include million respect maximum potential amount payable noncontrolling shareholders gsk consumer healthcare ltd groups consumer healthcare subsidiary india see note customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers including million million respect us pharmaceuticals vaccines accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group trade payables include million million due associates joint ventures pensions postemployment benefits restated restated pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes net reduction postretirement healthcare schemes cost arises restructuring us postretirement medical obligations reduction uk pension scheme cost relates oneoff adjustments arising capping future pensionable salary increases change basis future discretionary pension increased rpi cpi certain legacy plans details see costs defined benefit pension postretirement healthcare schemes charged income statement follows restated restated cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans also updated return seeking assets liability matching assets uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group restructured us postretirement medical obligations active retired members age current plan participants paid medical expenses excess covered medicare part part b well prescription drugs new arrangement participants instead eligible receive amount age health reimbursement account based years service subject inflation linked maximum per year already retired age also given option switch new arrangement impact change credit income statement million similar reduction postretirement obligation group changed policy towards granting discretionary pension increase smithkline beecham defined benefit schemes year group also introduced limit uk defined benefit schemes per year rate pensionable pay may increase group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report financial statements notes financial statements pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service costcredit net interest cost expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group restated restated restated restated restated amounts charged operating profit current service cost past service creditcost net interest cost remeasurements recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group restated restated restated restated restated amounts charged operating profit current service cost past service creditcost net interest cost gains losses settlement remeasurements recorded statement comprehensive income past service credit million includes amount million relation restructuring us postretirement medical obligations past service credit million reflects adjustments million related capping future pensionable salary increases change basis future discretionary pension increases rpi cpi certain legacy plans details see amounts included within past service costs include nil million million augmentation costs arising major restructuring programmes see note provisions gsk annual report pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table restated restated recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed assets listed unlisted fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets december uk scheme purchased insurance contract guarantee payment specified pensioner liabilities included within assets present value scheme obligations table value million million million additional insurance contracts also purchased countries included within assets table value million million million october uk schemes entered repurchase agreements gain exposure indexlinked gilts related loan also included within assets value million nil nil uk usa rest world goup restated restated restated restated december equities listed property unlisted corporate bonds listed government bonds listed assets listed unlisted fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report financial statements notes financial statements pensions postemployment benefits continued uk usa rest world goup restated restated restated restated december equities listed property listed corporate bonds listed government bonds listed assets listed unlisted fair value assets present value scheme obligations recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk usa rest world group group restated restated restated restated restated movements fair values assets assets january exchange adjustments interest income remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income remeasurement employer contributions scheme participants contributions benefits paid settlements curtailments assets december exchange adjustments interest income expenses remeasurement employer contributions scheme participants contributions benefits paid assets december uk defined benefit schemes include defined contribution sections account balances totalling million december million million group made special funding contributions uk pension schemes totalling million million million nil million million million us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreements following valuation additional contributions expected million contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report pensions postemployment benefits continued postretirement pensions benefits uk usa rest world group group restated restated restated restated restated movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost movements remeasurement scheme participants contributions benefits paid obligations december uk defined benefit schemes include defined contribution sections obligations totalling million december million million defined benefit pension obligation analysed follows restated restated funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter us postretirement healthcare scheme amended see details impact change oneoff reduction postretirement obligation million december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report financial statements notes financial statements pensions postemployment benefits continued movement net defined benefit liability follows fair value present value net assets obligation total january restated exchange adjustments service cost past service cost interest incomecost settlements curtailments remeasurements return plan assets excluding amounts included interest loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid december exchange adjustments service cost past service cost interest incomecost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid december exchange adjustments service cost past service cost interest incomecost remeasurements return plan assets excluding amounts included interest loss change demographic assumptions loss change financial assumptions experience losses employers contributions scheme participants contributions benefits paid expensesother movements december remeasurements included within postretirement benefits detailed lossgain change demographic assumptions gainloss change financial assumptions experience gainslosses gsk annual report pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs revisions ias decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report financial statements notes financial statements provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements december settled within one year settled one year december legal disputes nature groups business number group involved substantial number legal matters may subject negotiation litigation disputes including notification possible claims set many years litigation proceedings including various appeal note legal proceedings provisions legal disputes procedures often take many years reach resolution outof include amounts relating product liability principally relating court settlement discussions also often protracted avandia paxil poligrip antitrust principally relating group potential settlement discussions number wellbutrin flonase lamictal government investigations disputes amounts provided based principally relating colorado investigation settlement current assessment progress disputes estimates avandiarelated investigations average wholesale price awp billion amount provided december nominal price investigations contract terminations self settled within one year insurance environmental cleanup property rental december expected million charge year million million net reversals million provision made legal disputes estimated insurance recoveries primarily related provisions reimbursed third party insurers amount included within product liability cases regarding paxil poligrip receivables balances note noncurrent assets products various government investigations note trade receivables discussion legal issues see note legal proceedings discount provisions decreased nil million calculated using riskadjusted projected cash flows riskfree rates return movement includes decrease nil million arising change discount rate year respect product liability claims related certain products sufficient history claims made settlements enable management make reliable estimate provision required cover unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations gsk annual report provisions continued major restructuring programmes october group announced operational excellence programme improve effectiveness productivity operations see note major restructuring costs addition group initiated major change restructuring programme focused opportunities simplify supply chain processes build groups capabilities manufacturing rd restructure european pharmaceuticals business provisions staff severance payments made management made formal decision eliminate certain positions communicated groups employees affected appropriate consultation procedures completed appropriate provision made staff severance payments made immediately pension augmentations arising staff redundancies nil million charged year transferred pension obligations provision shown note pensions postemployment benefits asset writedowns recognised impairments property plant equipment note property plant equipment majority amounts provided expected utilised next two years employee related provisions employee related provisions include obligations certain medical benefits disabled employees spouses usa december provision benefits amounted million million employee benefits reflect variety provisions severance costs jubilee awards longservice benefits provisions included provisions insurance provisions million million onerous property lease provisions million million number provisions including vehicle insurance regulatory matters noncurrent liabilities accruals deferred income payables increase payables primarily arises contingent consideration million relating acquisition share shionogiviiv healthcare joint venture previously held shionogi co ltd gsk annual report financial statements notes financial statements contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december nil nil financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings bank loans overdrafts commercial paper obligations finance leases us us medium term note new york stock exchange us us medium term note london stock exchange longterm borrowings us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases net debt gsk annual report net debt continued current assets longterm borrowings liquid investments classified availableforsale investments yearend gsk longterm borrowings billion december included us treasury notes billion billion billion falls government bonds effective interest rate liquid investments due five years average effective preswap interest december approximately approximately rate notes issue december approximately liquid investment balances december earning approximately interest floating fixed rates amount million longterm borrowings repayable five years carry interest million respectively million million effective rates repayment dates effective interest rate cash cash equivalents range december approximately approximately cash cash equivalents december earning pledged assets interest floating fixed rates amount million group pledged investments us treasury notes par million respectively million million value million million million million security irrevocable letters credit issued groups gsks policy regarding credit quality cash cash behalf respect groups selfinsurance activity provisions equivalents referred note financial instruments respect selfinsurance included within provisions legal related disclosures disputes discussed note provisions shortterm borrowings december million groups cash balance held escrow account connection groups offer gsk billion billion us commercial paper purchase shares indian pharmaceutical subsidiary addition programme billion billion issue million million assets included note december billion billion gsk also noncurrent assets form part net debt billion five year committed mediumterm facilities pledged collateral future rental payments operating billion billion day committed facilities lease arrangements entered human genome sciences inc facilities put place september prior acquisition group september respectively undrawn december liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts december weighted average interest rate commercial paper borrowings december finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations gsk annual report financial statements notes financial statements share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december december december number shares issuable employee share schemes note number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million million shares cancelled monthly purchases shares follows average share price excluding number shares commission stamp duty march may june july august september october november december total details substantial shareholdings refer gsk annual report movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included total retained non translation earnings fair value controlling exchange restated reserve interests restated january exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary december exchange movements overseas net assets december exchange movements overseas net assets december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial gains defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive incomeexpense year retained non earnings controlling total restated reserves interests restated items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expenseincome year gsk annual report financial statements notes financial statements movements equity continued retained non earnings controlling total restated reserves interests restated items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement share comprehensive expense associates joint ventures items reclassified income statement exchange movement overseas net assets noncontrolling interests actuarial losses defined benefit plans deferred tax actuarial movements defined benefit plans comprehensive expense year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report related party transactions gsk held interest aspen pharmacare holdings limited december gsk sold million shares representing aspens share capital million gsk distributed million million products aspens extensive distribution network december balance due gsk aspen million million balance payable gsk aspen million million december gsk completed sale worldwide intellectual property rights excluding certain emap markets anticoagulant products business aspen group together related inventory manufacturing site consideration million million deferred receivable may viiv healthcare shire canada joint venture dissolved gsk acquired net assets former partnership subsidiary viiv healthcare ulc viiv canada owns operates business former partnership december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million vaccine products joint venture december balance due gsk jvc million balance payable gsk jvc nil aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows restated restated profit tax tax profits share tax profits associates joint ventures finance income net finance expense depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increasedecrease inventories decrease trade receivables increase receivables increase trade payables increase payables decrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report financial statements notes financial statements reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash bank overdrafts cash inflow liquid investments net increase longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year january december exchange reclassifications acquisitions cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper european us medium term notes debt due one year european us medium term notes net debt information significant changes net debt see note net debt gsk annual report acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions year gsk completed acquisition three businesses cash including okairos ag european based biopharmaceutical company focused development specific vaccine technology prophylactic therapeutic fields acquired may total purchase price businesses million included million cash acquired million contingent consideration fair value book value adjustments fair value net assets acquired intangibles property plant equipment inventory trade receivables assets including cash cash equivalents deferred tax provision trade payables goodwill cash consideration paid contingent consideration total consideration acquisitions made beginning year estimated group turnover would increased approximately million year okairos fully integrated gsk business practicable separately identify impact group profit year acquisitions occured shortly end year material impact group profit year goodwill arising acquisitions reflects potential business synergies value workforce acquired majority goodwill expected deductible income tax purposes results acquisitions reported within us europe emap japan trading unallocated pharmaceuticals vaccines consumer healthcare operating segments transactions accounted using acquisition accounting method acquisition costs expensed totalled million contingent consideration january exchange adjustments additions remeasurement goodwill remeasurement income statement settlement december disposals lucozade ribena december gsk completed sale lucozade ribena business including manufacturing site related inventory suntory beverage food ltd million cash recognised profit disposal operating income million lucozade ribena sales excluding retained markets totalled million year ending december cash consideration net assets sold inventory property plant equipment goodwill disposal costs profit disposal gsk annual report financial statements notes financial statements acquisitions disposals continued anticoagulant business december gsk completed sale anticoagulant business comprising worldwide intellectual property rights excluding china india pakistan fraxiparine arixtra together related inventory manufacturing site aspen group consideration million million received cash million deferred million deferred consideration receivable relates inventory manufacturing site receivable million consideration receivable relates inventory subject true upon final transfer inventory profit disposal million recognised operating income worldwide sales fraxiparine arixtra excluding retained markets million year ending december cash consideration cash consideration receivable net assets sold inventory property plant equipment intangible assets goodwill disposal costs total profit disposal deferral profit profit recognised year gsk holds investment aspen pharmacare holdings limited aspen accounted investment associate million total profit disposal representing gsks continuing interest shareholding aspen therefore deferred investments associates joint ventures november gsk sold one third shareholding aspen representing issued share capital company million cash december gsk held aspen continued recognise investment aspen associate cash consideration net book value shares reclassification exchange comprehensive income reclassification fair value movements comprehensive income profit disposal business associates acquisitions joint disposals ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired contingent consideration cash consideration paid net cash acquired total cash proceeds receivable cash proceeds deferred net cash proceeds disposals gsk annual report acquisitions disposals continued acquisitions human genome sciences inc august gsk completed acquisition issued share capital human genome sciences inc hgs us based biopharmaceutical company focused development protein antibody drugs treatment immunoinflammation diseases cash goodwill arising acquisition business reflected potential business synergies realisation full value benlysta albiglutide darapladib assets simplifying optimising rd commercial manufacturing operations complete ownership assets goodwill recognised expected deductible income tax purposes results acquired business reported part us europe emap japan trading unallocated costs operating segments transaction accounted using acquisition accounting method proforma turnover hgs business full year million gsk recorded turnover million hgs products hgs products fully integrated gsk business practicable separately identify impact acquisition group profit year acquisition costs expensed arising acquisition amounted million fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax asset trade liabilities goodwill cash consideration paid gain settlement preexisting collaborations total consideration shionogiviiv healthcare joint venture october gsk acquired share shionogiviiv healthcare joint venture previously held shionogi co ltd assets acquired included investigational medicine dolutegravir early stage integrase inhibitor compounds development total consideration comprised equity stake viiv healthcare gsks existing investment joint venture contingent consideration payable cash future together deferred tax asset loss settlement preexisting relationships contingent consideration payable based percentage future sales performance compounds developed joint venture become marketed products total amount payable unlimited results acquired business reported part viiv healthcare transaction accounted using acquisition accounting method acquisition costs expensed arising acquisition amounted million gsk annual report financial statements notes financial statements acquisitions disposals continued fair value book value adjustments fair value net assets acquired intangible assets deferred tax provision negative goodwill consideration settled shares viiv healthcare contingent consideration deferred tax contingent consideration fair value investment joint venture converted subsidiary loss settlement preexisting relationships total consideration acquisitions gsk completed two smaller acquisitions cash total cash consideration paid million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision trade liabilities goodwill cash consideration paid contingent consideration fair value equity investment converted subsidiary gain settlement preexisting relationships total consideration acquisitions made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions market participants none goodwill recognised expected deductible income tax purposes results acquisitions reported part europe pharma research development reportable operating segments group recognised settlement gain million result measuring fair value relationships existed prior acquisition date gain recognised operating income income statement acquisition costs expensed arising acquisitions totalled million gsk annual report acquisitions disposals continued investments associates joint ventures gsk made cash contributions million shionogiviiv healthcare joint venture prior acquisition subsidiary made cash investments million new joint venture group held share gsk also made cash investments million associates human shionogi total associates genome viiv joint business joint sciences venture acquisitions acquisitions ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired contingent consideration cash consideration paid net cash acquired acquisitions year gsk completed four subsidiary acquisitions cash total purchase price million included million cash acquired fair value book value adjustments fair value net assets acquired intangible assets property plant equipment trade receivables assets including cash cash equivalents deferred tax provision liabilities goodwill cash consideration paid fair value investment joint venture converted subsidiary total consideration acquisitions made beginning year estimated group turnover would increased million year subsidiaries fully integrated gsk business practicable separately identify impact acquisitions group profit year goodwill arising acquisitions reflects potential business synergies sales growth increase gsks market presence following acquisitions businesses addition goodwill million recognised respect fair value adjustments prior year acquisitions none goodwill recognised expected deductible income tax purposes results acquisitions reported part us europe emap japan trading unallocated pharmaceuticals vaccines consumer healthcare operating segments group recognised loss million result remeasuring fair value associate held prior acquisition date loss reported loss disposal interest associates income statement acquisition costs expensed arising acquisitions totalled million investments associates joint ventures gsk made cash contributions million joint venture group share made cash investments associates totalling million transferred million equity investment associates group increased shareholding gsk annual report financial statements notes financial statements acquisitions disposals continued disposals gsk disposed one subsidiary cash outflow disposal million net cash disposed february gsk disposed entire shareholding quest diagnostics inc us clinical laboratory business listed new york stock exchange sale comprised secondary public offering accompanying repurchase shares quest diagnostics together generated profit disposal million tax associates joint acquisitions ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired deferred consideration cash consideration paid net cash acquired net cash outflowproceeds disposals net cash disposed noncontrolling interests group one subgroup material noncontrolling interests viiv healthcare limited subsidiaries viiv healthcare group focused research development worldwide commercialisation hiv medicines summarised financial information respect viiv healthcare group set turnover profit taxation comprehensive expense total comprehensive income total comprehensive incomeexpense year attributable noncontrolling interests dividends paid noncontrolling interests noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets noncontrolling interests attributable subgroup net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decreaseincrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments acquisitions noncontrolling interests february gsk increased shareholding glaxosmithkline consumer healthcare ltd india representing increase shares held price inr per share million carrying amount noncontrolling interests acquired million december gsk announced voluntary open offer increase stake glaxosmithkline pharmaceuticals limited pharmaceuticals subsidiary india representing maximum increase shares held shares price inr per share offer period began february expected close march announcement offer obliged gsk complete purchase price offered risks rewards ownership shares deemed passed gsk date carrying amount noncontrolling interest deemed acquired million obligation million pay noncontrolling shareholders recorded payables see note december gsk annual report commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangements adimab llc immunicore ltd morphosys ag new arrangements offset reduced commitments due prior year transactions including amendments agreements chemocentryx inc panmira pharmaceuticals llc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report financial statements notes financial statements f inancial instruments related disclosures liquidity risk gsks policy borrow centrally order meet anticipated gsk reports sterling pays dividends sterling profits funding requirements cash flow forecast funding role corporate treasury monitor manage external requirements monitored tmg monthly basis internal funding requirements financial risks support strategy diversify liquidity sources using range strategic objectives gsk operates global basis primarily facilities maintain broad access funding markets subsidiary companies manages capital ensure subsidiaries able operate going concerns optimise december gsk billion borrowings repayable returns shareholders appropriate balance debt within one year held billion cash cash equivalents equity treasury activities governed policies approved liquid investments billion held centrally board directors recently july including disposal proceeds received end december gsk also access shortterm finance billion treasury management group tmg meeting chaired chief billion us commercial paper programme billion financial officer takes place monthly basis review treasury billion issue programme december activities members receive management information relating gsk billion five year committed mediumterm activities internal audit reviews treasury internal control facilities billion billion day committed facilities environment regularly facilities put place september september gsk uses variety financial instruments finance operations respectively undrawn december gsk derivative financial instruments manage market risks considers level committed facilities adequate given operations derivatives principally comprising forward current liquidity requirements foreign currency contracts interest rate swaps used swap gsk billion european medium term note programme borrowings liquid assets currencies required group december billion notes issue purposes manage exposure financial risks changes programme group also us shelf registration foreign exchange rates interest rates statement december billion billion gsk hold issue derivatives speculative purposes notes issue programme gsks longterm borrowings treasury policies specifically prohibit activity mature dates transactions financial instruments undertaken manage gsks longterm credit ratings remained unchanged since risks arising underlying business activities speculation february gsks current ratings stable outlook standard poors negative outlook moodys investors capital management service moodys groups shortterm credit ratings gsks financial strategy supports groups strategic priorities p standard poors moodys respectively regularly reviewed board gsk manages capital structure group appropriate mix debt equity market risk gsks financial architecture designed support delivery groups strategy enhance returns shareholders interest rate risk management four key priorities delivering sustainable sales growth improving gsks objective minimise effective net interest cost operating leverage improving financial efficiency converting balance mix debt fixed floating interest rates time earnings cash free cash flow generated policy interest rate risk management limits amount returned shareholders reinvested bolton acquisitions floating interest payments prescribed percentage operating wherever attractive returns available gsk continues profit apply strict financial returnsbased criteria cash flow gsk uses interest rate swaps redenominate one bonds return investment order allocate capital assess floating interest rates duration swaps matches investment opportunities whilst protecting credit profile duration principal instrument interest rate derivative business remains highly cash generative gsk instruments accounted fair value hedges relevant generated billion free cash flow addition group liability realised billion divestments returned total billion shareholders billion dividends billion share repurchases net debt end year billion reduction billion compared previous year gsk expects deliver continued dividend growth part longterm share buyback programme targeting share repurchases billion depending market conditions capital structure group consists net debt billion see note net debt shareholders equity billion see consolidated statement changes equity total capital including provided noncontrolling interests billion billion gsk annual report f inancial instruments related disclosures corporate treasurys usage limits monitored daily corporate compliance officer cco operates independently continued corporate treasury breach limits would reported cfo immediately cco also monitors credit rating foreign exchange risk management counterparties changes ratings occur notifies corporate foreign currency transaction exposures arising internal treasury changes made investment levels external trade flows generally hedged groups objective authority limits appropriate addition relationship banks minimise exposure overseas operating subsidiaries credit ratings reviewed regularly report presented annually transaction risk matching local currency income local tmg approval currency costs possible gsks internal trading transactions matched centrally intercompany payment terms managed gsk actively manages exposure credit risk reducing surplus reduce foreign currency risk foreign currency cash flows cash balances wherever possible part treasury strategy hedged selectively management corporate treasury regionalise cash management concentrate cash centrally tmg possible gsk manages cash surpluses much possible gsk continued maintain conservative borrowing requirements subsidiary companies centrally using approach counterparty risk throughout period table forward contracts hedge future repayments back sets credit exposure counterparties rating liquid originating currency order reduce foreign currency translation investments cash cash equivalents derivatives gross exposure group seeks denominate borrowings asset position derivative contract considered currencies principal assets cash flows primarily purpose table although isda agreements amount denominated us dollars euros sterling certain borrowings risk net position counterparty table e swapped currencies required borrowings sets groups financial assets liabilities offset basis denominated swapped foreign currencies match billion bank balances deposits invested aaaa investments group overseas assets may treated hedge rated counterparties december significantly higher relevant assets forward contracts major currencies equivalent december result disposal also used reduce exposure groups investment overseas proceeds received end december compared last assets see net investment hedges section note year significantly higher amount bank balances details tmg reviews ratio borrowings assets major deposits held aa rated counterparties whilst amount currencies monthly significantly decreased aa rated counterparties result gsks bank balances deposits held citibank credit risk shifted due moodys upgrading citibank nas rating group considers maximum credit risk december million december million total million invested baabbb rated counterparties groups financial assets exception investments includes bank balances deposits hdfc bank state bank comprising equity investments bear equity risk rather credit india bbva venezuela halk emirates bank counterparties risk see details groups total financial assets used either local cash management purposes local december gsks greatest concentration credit risk investment purposes gsk sole shareholder billion billion hsbc aaaa including disposal proceeds received end december million invested babb rated counterparty relates investment pakistan government treasury bills treasuryrelated credit risk million held unrated bank islandsbanki gsk sets global counterparty limits gsks banking used cash management purposes iceland investment counterparties based longterm credit ratings moodys standard poors aaaa aaaa aa aa aabaabbbbaabbb baabbb babb total unrated bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total aaaa aaaa aa aa aabaabbbbaabbb baabbb babb total unrated bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys standard poors using published conversion tables gsk annual report financial statements notes financial statements f inancial instruments related disclosures following methods assumptions used estimate fair values continued cash cash equivalents approximates carrying amount gsks centrally managed cash reserves amounted billion december available within months excludes liquid investments based quoted market prices calculated billion centrally managed cash held viiv healthcare based observable inputs case marketable securities owned subsidiary group invested centrally managed liquid based principal amounts case nonmarketable assets bank deposits aaaaaa rated us treasury securities short repricing periods treasury repo money market funds bear credit exposure investments equity investments traded active market us government aaaaa rated determined reference relevant stock exchange quoted bid price equity investments determined reference wholesale retail credit risk current market value similar instruments reference outside usa customer accounts discounted cash flows underlying net assets groups trade receivables balance shortterm loans overdrafts commercial paper approximates usa line pharmaceutical companies group carrying amount short maturity sells products small number wholesalers addition instruments hospitals pharmacies physicians groups sales three largest wholesalers amount approximately longterm loans based quoted market prices case groups us pharmaceuticals vaccines turnover december european us medium term notes fixed rate group trade receivables due three borrowings level fair value measurement approximates wholesalers totalling million million group carrying amount case floating rate bank loans exposed concentration credit risk respect loans wholesalers one encounters financial contingent consideration business acquisitions january difficulty could materially adversely affect groups financial based present values expected future cash flows results interest rate swaps foreign exchange contracts based groups credit risk monitoring activities relating present value contractual cash flows using market sourced data wholesalers include review quarterly financial information exchange rates interest rates balance sheet date standard poors credit ratings development gsk internal receivables payables approximates carrying amount risk ratings establishment periodic review credit limits however group believes credit risk provision companyowned life insurance policies based cash required excess normal provision bad doubtful debts surrender value see note trade receivables lease obligations approximates carrying amount fair value financial assets liabilities fair value investments gsk shares table presents carrying amounts fair december employee share ownership plan values groups financial assets liabilities december esop trusts held gsk shares carrying value million december million fair value million fair values financial assets liabilities included million based quoted market price shares represent price would received sell asset paid transfer purchases esop trusts satisfy future exercises options liability orderly transaction market participants awards employee incentive schemes carrying value measurement date lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings gsk annual report financial instruments related disclosures continued carrying fair carrying fair value value value value notes cash cash equivalents e availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables certain noncurrent assets scope ias b financial assets fair value profit loss noncurrent assets scope ias ab derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts e commercial paper total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss trade payables provisions certain noncurrent liabilities scope ias ac derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities reconciled relevant notes gsk annual report financial statements notes financial statements financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies noncurrent liabilities classified level comprise contingent consideration business acquisitions level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss trade payables noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration liabilities businesses acquired year equity investment converted subsidiary acquisition business equity investment additions equity investment disposals transfers level exchange december net losses million million attributable level financial instruments held end year reported operating income million million arose remeasurement contingent consideration liabilities principally contingent consideration payable acquisition former shionogiviiv healthcare joint venture net gains million nil reported selling general administration net gains nil million attributable level equity investments held end year reported comprehensive income fair value movements availableforsale investments gsk annual report financial instruments related disclosures continued net liability position million million respect financial instruments measured using level valuation methods december includes million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid several years vary line sales tivicay dolutegravir regulatory approval product obtained usa canada year european union january table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuation liability increasedecrease financial liability lossgain income statement change key inputs increase sales forecasts decrease sales forecasts increase market interest rates decrease market interest rates b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies assets include tax receivables pension surplus balances prepayments outside scope ias fair value fair value loans financial loans financial profit loss receivables instruments total profit loss receivables instruments total trade receivables note noncurrent assets note following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days provision bad doubtful debts made total million million balance million million relates receivables due state hospital authorities greece ireland italy portugal spain total receivables due state hospital authorities countries current past due net provisions million million c trade payables provisions noncurrent liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities liabilities include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias fair value fair value financial financial profit loss liabilities instruments total profit loss liabilities instruments total trade payables note provisions note noncurrent liabilities note gsk annual report financial statements notes financial statements financial instruments related disclosures continued derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities fair value hedges interest rate swaps principal amount million million net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments analysed current noncurrent total foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts consisting primarily foreign currency swaps net liability fair value million million asset less million liability december fair value million net liability million asset less million liability million net liability fair value increase due additional hedging intercompany loans deposits external debt legal provisions designated accounting hedges fair value movements taken income statement period offset exchange gains losses related intercompany lending borrowing external debt legal provisions fair value hedges group designated series interest rate swaps fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance expense carrying value bonds designated hedging relationship includes million million designated hedged item fair value hedge relationship net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro japanese yen foreign operations shown table carrying value bonds designated hedging relationship includes million million designated hedging instrument net investment hedge relationship cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges foreign exchange exposure arising euro us dollar denominated coupon payments relating groups european us medium term notes december group designated cash flow hedge foreign exchange exposure arising recognition liability denominated indian rupee groups consolidated financial statements addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued year disclosed note balance reclassified finance costs life bonds gsk annual report financial instruments related disclosures continued e offsetting financial assets liabilities following tables set financial assets financial liabilities subject offsetting enforceable master netting arrangements similar agreements amounts set financial assets liabilities groups balance sheet set trade receivables trade payables derivative financial assets derivative financial liabilities amounts offset balance sheet could offset certain circumstances also set gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilites bank loans overdrafts gross financial assets liabilities set balance sheet primarily relate cash pooling arrangements banks amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party gsk annual report financial statements notes financial statements financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing group holds interest rate swaps designated fair value hedges convert million fixed rate debt maturity less one year million maturity one two years floating rate exposure g sensitivity analysis foreign exchange interest rate sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations december financial instruments affected market risk include cash cash equivalents borrowings trade receivables payables derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes foreign exchange interest rates foreign exchange sensitivity table shows indicative basis groups sensitivity foreign exchange rates us dollar euro yen financial instruments three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies concluded cent yen movement rates sterling reasonable analysis financial instruments considered sensitive foreign exchange rates functional currency entity holds obligations finance leases intercompany loans fully hedged maturity certain nonderivative financial instruments net debt excluded present material exposure foreign exchange sensitivity group assets liabilities financial instruments included calculation movement income statement table relates primarily cash cash equivalents intercompany loans deposits intercompany trading balances hedging instruments legal provisions trade receivables payables denominated functional currency entity holds whilst hedging instruments provide economic hedges related remeasurement provisions included calculation increase increase income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following decrease income million million million us dollar euro yen exchange rates respectively million million nil gsk annual report financial instruments related disclosures continued movements equity table relate hedging instruments foreign exchange derivatives external debt designated net investment hedge hedge group assets denominated euro yen decrease decrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increase equity nil million million us dollar euro yen exchange rates respectively nil million million table presents groups sensitivity foreign exchange rates based composition net debt shown note adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows increase increase decrease decrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would following impact net debt million million million us dollar euro yen exchange rates respectively million million million interest rate sensitivity table shows indicative basis groups sensitivity interest rates floating rate sterling us dollar euro financial instruments issued debt bank borrowings cash cash equivalents liquid investments gsk considered movements interest rates last three years concluded basis points increase reasonable benchmark debt bank borrowings maturity less one year floating rate calculation interest rate movements derivative financial instruments designated fair value hedges deemed immaterial effect group income statement due compensating amounts carrying value debt basis points movement interest rates deemed material effect equity increase increase decrease decrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates increase interest income due higher levels indicative cash balance sheet date interest rates could decreased basis points currently less maximum increasedecrease income would therefore limited million nil million sterling us dollar euro interest rates respectively million nil nil h contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report financial statements notes financial statements financial instruments related disclosures continued contractual cash flows nonderivative financial liabilities derivative instruments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities billion year results principally increase billion forecast future cash flows respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purposes table though practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year increased compared december due higher levels hedging intercompany loans external debt reflected increased principal amounts shown table receivables payables receivables payables due less one year one two years gross contractual cash flows employee share schemes group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline plc grant price savingsrelated share option schemes share award schemes addition gsk operates performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options employees cost scheme readily equates potential gain made employee grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving grants share option schemes awards performance share plan normally granted employees acquire shares ads gsk plc circumstances settled cash options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant share options awarded directors cet subject performance criteria option pricing purposes valuing options awards arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives savingsrelated share options share award schemes years years years weighted average share price grants year shares ads plans dividends reinvested gsk annual report employee share schemes continued volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value january options granted options exercised options lapsed december options granted options exercised options lapsed december options granted options exercised options lapsed december range exercise prices options outstanding year end weighted average market price exercise weighted average remaining contractual life years years years options outstanding share option share option savingsrelated december schemes shares schemes ads share option schemes weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year options exercisable share option share option savingsrelated schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december december december gsk annual report financial statements notes financial statements employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted onwards directors members cet performance conditions based four equally weighted measures three year performance period first measure based achievement adjusted free cash flow targets second measure based relative tsr performance comparator group remaining two measures based businessspecific performance measures business diversification rd new product performance details calculation measures see remuneration report pages awards granted directors members cet award based achievement adjusted free cash flow targets three year measurement period remaining award based relative tsr performance comparator group half tsr element award measured three years half four years awards made eligible employees performance conditions consist two parts applies award first part performance condition compares gsks eps growth increase uk retail prices index three year measurement period second part performance condition based strategic operational business measures three year measurement period specific employees business area fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december year shares ads awarded dividends reinvested included share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december gsk annual report employee share schemes continued employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report financial statements notes financial statements principal group companies following represent principal subsidiaries associates glaxosmithkline group december details given principal country operation location headquarters business sector business activities equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford setfirst limited phch h brentford glaxosmithkline trading services limited iv ph e brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph austria vienna glaxosmithkline pharma gmbh ph belgium wavre glaxosmithkline pharmaceuticals sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch marly le roi viiv healthcare sas ph st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h munich glaxosmithkline gmbh co kg ph h greece athens glaxosmithkline aebe phch italy verona glaxosmithkline spa ph milan glaxosmithkline consumer healthcare spa ch netherlands zeist glaxosmithkline bv ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph republic carrigaline smithkline beecham cork limited ph p r ireland dublin glaxosmithkline consumer healthcare ireland limited ch dublin glaxosmithkline ireland limited ph dungarvan stafford miller ireland limited ch p dungarvan glaxosmithkline dungarvan limited ch p sligo stiefel laboratories ireland limited ph p romania brasov europharm holding sa phch bucharest glaxosmithkline gsk srl ph russian moscow glaxosmithkline trading zao ph e federation spain madrid glaxosmithkline sa ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa research triangle park stiefel laboratories inc ph p marietta corixa corporation ph p r philadelphia glaxosmithkline llc phch e p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc phch f research triangle park viiv healthcare company ph rockville human genome sciences inc ph p r gsk annual report principal group companies continued americas location subsidiary sector activity canada mississauga glaxosmithkline inc ph p mississauga glaxosmithkline consumer healthcare inc ch laval id biomedical corporation quebec ph e p r mexico mexico city glaxosmithkline mexico sa de cv phch e p asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h r hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ch e p india mumbai glaxosmithkline pharmaceuticals limited ph p gurgaon glaxosmithkline consumer healthcare limited ch e p r malaysia selangor glaxosmithkline consumer healthcare sdn bhd ch pakistan karachi glaxosmithkline pakistan limited phch e p r philippines makati glaxosmithkline philippines inc phch e singapore singapore glaxo wellcome manufacturing pte ltd ph e p r singapore glaxosmithkline pte ltd phch e south korea seoul glaxosmithkline korea limited ph ch r thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae phch e p nigeria lagos glaxosmithkline consumer nigeria plc ii phch e p south africa johannesburg glaxosmithkline south africa pty limited phch e p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch e p middle east africa location associate sector activity south africa johannesburg aspen pharmacare holdings limited iii phch p r exempt provisions section companies amendment act ireland ii c onsolidated subsidiary accordance section companies act grounds dominant influence iii equity accounted grounds significant influence iv ncorporated ireland directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiaries associates attached companys annual return filed uk registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial statements notes financial statements legal proceedings october district court issued ruling construed claims patent manner arzerra would group involved significant legal administrative infringe patent genentech biogen idec stipulated proceedings principally product liability intellectual property tax judgment infringement filed appeal claim antitrust governmental investigations well related private construction issue united states court appeals litigation group makes provision proceedings federal circuit december appeal heard regular basis summarised note accounting principles november court affirmed district courts claim policies note provisions group may become construction giving effect genentech stipulation patent involved significant legal proceedings respect infringed genentech filed request rehearing en banc possible make reliable estimate expected financial effect may denied july ending case could result ultimate resolution proceedings avodartjalyn cases appropriate disclosures cases would november banner pharmacaps inc banner notified included provision would made group filed abbreviated new drug application respect legal proceedings described anda market generic version avodart dutasteride provision made group unable usa banners notification contained paragraph iv certification make reliable estimate expected financial effect alleging two patents expiring one patent expiring stage group believe information amount patent covering compound dutasteride sought plaintiffs known would meaningful invalid infringed banners proposed generic dutasteride respect legal proceedings due number product group subsequently received similar notices factors including limited stage proceedings anchen pharmaceuticals anchen apotex apotex roxane entitlement parties appeal decision clarity theories laboratories roxanne watson laboratories inc watson liability damages governing law intellectual property claims mylan pharmaceuticals inc mylan variously challenging either include challenges validity enforceability groups patent patents patents various products processes well assertions december anchen notified group filed noninfringement patents loss cases anda jalyn paragraph iv certification alleging could result loss patent protection product issue patent invalid unenforceable infringed jalyn consequences loss could significant decrease combination dutasteride tamsulosin covered sales product could materially affect future results three patents cover avodart subsequently group received operations group similar notices impax laboratories inc impax watson legal expenses incurred provisions related legal claims challenging one patents covering jalyn charged selling general administration costs provisions group filed suit anchen banner impax mylan roxanne made taking appropriate legal specialist advice watson united states district court district outflow resources considered probable reliable delaware infringement avodart jalyn patents estimate made likely outcome dispute certain applicable cases consolidated trial august product liability claims group make provision group filed separate suit apotex sufficient history claims made settlements enable court infringement patent case management make reliable estimate provision required consolidated original case generic cover unasserted claims december groups defendants may court ordered apotex aggregate provision legal disputes including tax case would stayed pending entry judgment banner matters described note taxation billion et al case january group anchen settled ultimate liability legal claims may vary amounts provided litigation terms would allow anchen enter market dependent upon outcome litigation proceedings jalyn fourth quarter earlier certain investigations possible settlement negotiations circumstances group previously settled earlier patent groups position could change time therefore challenge avodart teva pharmaceuticals teva terms assurance losses result outcome allow teva launch generic dutasteride product legal proceedings exceed material amount fourth quarter earlier certain circumstances amount provisions reported groups financial accounts tevas generic dutasteride product approved fda happen could material adverse impact december results operation group reporting period trial consolidated case generic defendants judgments incurred settlements entered held january august district court significant matters described upheld validity patent banner impax mylan roxanne intellectual property watson appealed decision favour group court appeals federal circuit august arzerra february federal circuit entered decision favour march genentech biogen idec filed suit group affirming decision district court group united states district court southern district california alleging groups sale arzerra ofatumumab approved us food drug administration fda treatment refractory chronic lymphocytic leukaemia cll induces contributes infringement patent claims treatment cll anticd monoclonal antibody group counterclaimed patent invalid infringed gsk annual report benlysta separate component decision judge ruled september uk court appeal refused appeal eli lupin generic version trizivir infringe patent lilly company eli lilly asserting human genome sciences trial teva stipulated generic version epzicom would infringe inc hgs uk patent ep benlysta invalid patent district court enjoined teva launching grounds lacked necessary information required work generic epzicom product parties appealed invention described claims covered antibodies judgements antibody claim insufficiency argument uk high court february viiv healthcare received notice lupin uk supreme court previously decided patent valid filed anda containing paragraph iv certification epzicom grounds uk supreme court refused eli alleging three patents listed orange book epzicom lilly petition appeal result uk litigation either invalid unenforceable infringed patents relate ended validity hgs patent affirmed method treating hiv using double combination expiring uk courts hemisulfate salt abacavir expiring eli lilly separately requested declaration uk high certain crystal form lamivudine expiring court supplementary protection certificate spc filed lexiva hgs extend uk patent based upon future eli lilly marketing april ranbaxy laboratories limited ranbaxy notified authorisation antiblys antibody invalid viiv healthcare filed paragraph iv certification alleging litigation pending patent claiming polymorphic form fosamprenavir calcium september court justice european union active ingredient lexiva invalid infringed patent cjeu heard arguments question meaning expires viiv healthcare sue patent protected basic patent handed guidance july mylan pharmaceuticals inc mylan notified viiv december cjeu answer question whether healthcare filed anda lexiva paragraph iv eli lillys antibody protected hgs patent confirmed certification asserting patents claiming active ingredient functional definition product spc sought expiring ii polymorphic form active ingredient sufficient principle claims patent relate implicitly expiring invalid unenforceable infringed mylan necessarily specifically active ingredient covered second generic company file anda lexiva first spc uk high court must implement guidance generic company challenge basic compound patent cjeu decide case hearing date yet set active ingredient august viiv healthcare outcome litigation effect groups ability market benlysta licensor vertex pharmaceuticals incorporated filed patent infringement suit mylan patent claiming active epzicomtrizivir ingredient patent claiming polymorph united november groups affiliate viiv healthcare states district court district delaware mylan subsequently received notice teva pharmaceuticals usa inc teva filed filed declaratory judgment action viiv healthcare alleging anda paragraph iv certification epzicom polymorph patent invalid infringed viiv healthcare combination lamivudine abacavir certification challenged stipulated noninfringement patent claiming polymorph patent covering hemisulfate salt abacavir parties filed consent judgment december expires viiv healthcare sue teva patent polymorph patent trial scheduled may june viiv healthcare received notice teva infringement basic active ingredient patent lexiva amended anda epzicom contain paragraph iv october ranbaxy filed petition inter parties review certification two additional patents listed orange book united states patent trademark office uspto alleging alleging patents invalid unenforceable infringed basic compound patent covering active ingredient invalid patents challenged new certification relate method march uspto granted petition inter parties treating hiv using combination expiring certain review proceeding settled october terms crystal form lamivudine expiring august viiv confidential healthcare filed suit teva combination patent united states district court district delaware lovaza march group received notice teva pharmaceuticals may viiv healthcare received notice lupin ltd usa inc teva par pharmaceuticals inc par apotex inc lupin filed anda containing paragraph iv certification trizivir triple combination lamivudine azt abacavir apotex filed andas paragraph iv certification alleging alleging three patents listed orange book trizivir two patents covering lovaza omegaacid ethyl esters invalid unenforceable infringed patents expire march invalid unenforceable infringed patents relate april group licensee patents method treating hiv using triple combination expiring marketing rights usa puerto rico pronova hemisulfate salt abacavir expiring certain biopharma norge pronova owner patents sued teva crystal form lamivudine expiring june viiv par apotex united states district court district healthcare filed suit lupin patent covering triple delaware group party suits combination united states district court district delaware district court consolidated discovery teva march pronova entered agreement apotex epzicom case viiv healthcares patent infringement suit settle patent litigation usa related lovaza lupin relating trizivir cases involve patent settlement grants apotex licence enter us market covering combination lamivudine abacavir generic version lovaza first quarter terms settlement confidential december united states district court district delaware upheld validity us patent expiry date march covers combination lamivudine abacavir epzicom triple combination lamivudine abacavir zidovudine trizivir gsk annual report financial statements notes financial statements trial involving teva par held march april february group reached agreements settle may district court held patent valid infringed substantial majority federal state cases pending us september court appeals federal circuit fourteen purported class actions avandia pending canada ruled pronova patent litigation regarding lovaza group reached agreement principle resolve reversing district courts ruling court found asserted single purported consumer class action israel claims pronovas us patent invalid remanded approved court group notified individual case district court orders enter judgment favour claims uk lawyers representing claimants uk anda filers patent litigation us made application high court overall litigation expired earlier court found unnecessary subject group litigation order court listed reach issues regarding patent october pronova application hearing date june filed combined petition panel rehearing rehearing en banc number purported class actions seeking economic court appeals federal circuit court denied damages behalf third party payers consumers asserting petitions january thereby affirming claims arising various state federal laws including september decision federal circuit court racketeer influenced corrupt organizations act rico state pronova group also received paragraph iv notices unfair trade practices andor consumer protection laws addition endo pharmaceuticals endo sandoz inc sandoz strides three subrogation actions initiated united health group inc arcolab ltd strides trygg pharma trygg advising humana medical plan humana brought submitted abbreviated applications fda generic group one putative class action brought mdl court form lovaza pronova chose assert patents endo humana concerns medicare advantage claims briefing sandoz strides trygg awaiting ruling litigation action threshold class certification issues remains pending teva par court appeals federal circuit two state court actions concern nonmedicare group aware fda approved generic advantage claims actions stayed midjune copies lovaza date determine whether private lien resolution program resolve claims veramyst november group received notice sandoz inc paxilseroxat paxil cr filed anda paragraph iv certification veramyst group received numerous lawsuits claims alleging fluticasone furoate nasal spray challenging three patents listed use paxil paroxetine caused variety injuries orange book veramyst invalid unenforceable lawsuits recent years alleged use paxil infringed three patents expire december pregnancy resulted birth child birth defects group filed suit sandoz united states district health issues lawsuits claims alleged patients court district delaware three patents stay took paxil committed attempted commit suicide acts fda approval sandozs generic product place violence patients suffered symptoms discontinuing earlier court decision adverse group may trial treatment paxil scheduled begin december pregnancy august group sandoz settled litigation terms would allow sandoz enter market generic competitor group reached agreements settle substantial veramyst third quarter earlier certain majority us claims relating paxil use pregnancy circumstances february number claims related use pregnancy still pending including several scheduled trial product liability philadelphia state court mass tort program mtp matters preclinical clinical trials conducted development dismissed without payment us united states potential products determine safety efficacy court appeals third circuit ruled june products use humans following approval regulatory glaxosmithkline llc delaware citizen purposes diversity bodies notwithstanding efforts drugs vaccines jurisdiction us federal courts result ruling introduced marketplace unanticipated safety issues group seeking remove federal court numerous cases may become claimed evident group recently filed philadelphia mtp certain cases set currently defendant number product liability lawsuits related trial mtp november thomasswindle groups pharmaceutical vaccine consumer healthcare matter pennsylvania superior court upheld summary judgment products significant matters described favour group based expiration statute group able make reliable estimate expected limitations december plaintiffs case financial effect matters discussed category petitioned allowance appeal pennsylvania supreme included provision matters provision legal court group plans oppose petition allowance disputes also noted note provisions appeal currently trials scheduled two proposed one certified class actions canada avandia bartram action certified british columbia group named product liability lawsuits behalf national class action relates cardiovascular defects appeal individuals asserting personal injury claims arising use certification decision dismissed october avandia federal cases filed group part parties therefore proceed commence discovery multidistrict litigation proceeding pending united states district court eastern district pennsylvania mdl court cases also filed number state courts gsk annual report singh action alberta also proposed national class action february vast majority individual cases previously seeks certify class relating birth defects generally pending mdl mtp dismissed fewer certification motion likely scheduled time ten active cases mdl one active case mtp still also one inactive proposed national class action british pending group scheduled trial columbia held abeyance november one individual lawsuit well five purported proceedings move forward certification class actions asserting consumer fraud claims also filed canada individual lawsuit resolved one acts violence class actions dismissed leaving four putative class actions february pending matters including two remain pending canada filed unfiled claims lawsuits appeal one pending united states court turkey uk elsewhere group voluntarily withdrew appeals ninth circuit pending floridas zinccontaining formulations super poligrip market early second district court appeal concerning allegations patients took paxil committed attempted commit suicide acts violence sales marketing regulation group able make reliable estimate expected discontinuation financial effect matters discussed category uk late public funding withdrawn included provision matters provision legal claimants received funding pursue litigation alleging disputes except noted matters group paxilseroxat caused suffer withdrawal reactions made provision also noted note provisions dependency majority claimants discontinued claims june group informed legal aid china investigation agency laa formerly legal services commission june number groups pharmaceutical offices considering whether discharge public funding certificate china visited government authorities peoples following recommendation special cases review panel republic china prc july ministry public case poor prospects success remaining claims security china released statement confirming ongoing police prosecuted pending outcome laas decision investigation alleged serious economic crimes gsk china prc acting various government agencies continues poligrip investigation alleged crimes violations law gsk chinas beginning number product liability lawsuits claims operations group takes allegations seriously filed group state federal courts continuing cooperate fully chinese authorities usa including purported class actions alleging zinc investigation super poligrip causes copper depletion permanent neurologic injury federal cases consolidated denture cream group informed us department justice us adhesive multidistrict litigation mdl united states district securities exchange commission uk serious fraud court southern district florida established office regarding investigation possible time june group procter gamble defendants make reliable estimate financial effect could result litigation included mdl four purported class matters actions asserting economic loss claims state consumer colorado investigation protection laws claims medical monitoring original four july group announced reached putative class actions dismissed putative agreement united states government multiple states class action filed puerto rico removed federal district columbia conclude groups significant court transferred mdl remains pending ongoing united states federal government investigations specifically february two current exceptions one state court case united states department justices investigation pennsylvania one state court case small claims court groups sales marketing practices relating nine largest tennessee state court cases consolidated selling products begun february ii department philadelphia state court mass tort program mtp justices investigation possible inappropriate use nominal price exception medicaid rebate program iii department justices investigation development marketing avandia settlement payment billion settlement resolved criminal civil liabilities related investigations payment covered groups existing provisions funded existing cash resources date states district columbia agreed join federal settlement agreement receive portion share settlement payment agreement gsk annual report financial statements notes financial statements group notified consortium state attorneys cidra thirdparty payer litigation general investigating conduct underlying july number major us healthcare insurers filed suit nonavandia federal state sales marketing settlements group philadelphia pennsylvania county court determine company violated state unfair deceptive trade common pleas seeking compensation reimbursements made practices statutes states known participating medicines manufactured groups former cidra plant investigation puerto rico insurers claim group knowingly illegally marketed sold adulterated drugs manufactured avandiarelated matters conditions noncompliant cgmp thirdparty noted july group reached agreement insurers unlawfully induced pay us government number states district columbia resolve federal governments avandia investigation suit alleges us federal various state law causes settlement resolved claims federalstate medicaid programs action august group removed case november group agreed pay million settle united states district court eastern district pennsylvania claims states district columbia state moved dismiss complaint oral argument motion consumer protection laws regarding marketing promotion dismiss held february motion currently avandia consideration district court manufacturing issues groups plant cidra subject federal state group agreed pay million resolve individual claims group resolved us federal government lawsuits filed attorneys general offices kentucky louisiana group compliance obligations maryland mississippi new mexico south carolina utah west corporate integrity agreement us government virginia asserting various statutory common law claims relating development marketing avandia regard paxilseroxat state louisiana groups products states group settled lawsuit filed new york state participated federal government settlement attorney generals office alleging group failed disclose group also defending action county santa clara data use paxil children adolescents california brought californias consumer protection group made class settlements lawsuits brought laws seeking civil penalties restitution pretrial activities consumers thirdparty payers respectively economic scheduled occur q case proceeds trial damages allegedly resulting prescriptions paxil children mdl court send case back california federal court adolescents group denied liability settlements bench trial plaintiffs voluntarily dismissed similar purported class action filed behalf governmental entities paid prescriptions two native american groups cherokee nation oklahoma paxil minors remains similar purported class action mississippi band choctaw indians filed lawsuits canada seeking economic damages behalf individuals respective tribal courts alleging common law claims including fraud purchased paxil use patients age negligence breach warranty unjust enrichment cherokee certification application part purported class action nation matter relates sale marketing avandia whereas adjourned permit filing evidence likely choctaw complaint relates avandia group products resume average wholesale price secdoj fcpa enquiry number states respective attorneys general us securities exchange commission sec us counties new york state filed civil lawsuits state department justice doj initiated industrywide enquiry federal courts group many pharmaceutical whether pharmaceutical companies may engaged companies claiming damages restitution due average violations us foreign corrupt practices act fcpa relating wholesale price awp andor wholesale acquisition cost wac sale pharmaceuticals including argentina brazil canada price reporting pharmaceutical products covered states china germany italy poland russia saudi arabia group medicaid programmes cases alleged group reported one companies asked respond enquiry caused reported false awp wac prices turn cooperating sec doj group informed allegedly caused state medicaid agencies reimburse providers doj sec investigation china operations money covered medicines agencies intended chinese government initiated states sought recovery behalf states payers cases behalf instate patients consumers group antitrustcompetition resolved awp claims state medicaid programmes almost group able make reliable estimate expected states groups settlement agreement financial effect matters discussed category federal government announced september multiple included provision matters provision legal additional settlements since litigation concerning awp issues disputes except noted matters group continuing two states illinois wisconsin made provision also noted note provisions hiv division enquiry july group received subpoena eastern district new yorks us attorneys office regarding sales marketing practices three hiv products well educational programmes grants payments physicians regarding drug used treat hivinfected adults september group advised us government concluded investigation declined intervene qui tam lawsuit filed united states district court eastern district new york suit dismissed matter concluded gsk annual report eu sector enquiry flonase european commission launched enquiry purported direct indirect purchaser class actions filed investigate possible anticompetitive conditions pharmaceutical united states district court eastern district sector final report pharmaceutical sector inquiry pennsylvania alleging group illegally maintained monopoly power published july announced final report market flonase charged plaintiffs supracompetitive commission decided continue monitoring patent settlement prices additionally suit filed roxane laboratories inc agreements originator generic companies relating generic competitor seeking lost profits groups alleged eu markets result group provided input reports actions unlawfully delaying roxanes entry market published february predicate allegations filing group group received questionnaire relating patent settlements allegedly sham citizen petitions subsequent litigation group responded commission february december group reached agreement settle provision made matter litigation direct purchasers payment million eu enquiry tyverb combivir agreement settle indirect purchaser class indirect purchasers payment million december group viiv healthcare received request information european commission regarding court approved class action settlements application direct pharmacy distribution groups product matter concluded tyverb viiv healthcares product combivir group viiv lamictal healthcare provided requested information provision made matter purported direct indirect purchaser class actions filed united states district court district new jersey alleging uk office fair trading competition act investigation group teva pharmaceuticals unlawfully conspired august uk office fair trading oft launched delay generic competition lamictal resulting formal investigation group pharmaceutical overcharged separate count accuses group monopolising companies potential infringement competition act market district court recently denied motion investigation focuses whether litigation settlements purported direct purchaser class reconsideration order group potential suppliers generic paroxetine formulations granting gsks motion dismiss december plaintiffs entered object effect filed notice appeal united states court appeals prevention restriction distortion competition uk ii third circuit group also plans move purported group infringed dominant position making payments indirect purchaser class dismissed following outcome potential suppliers generic paroxetine aim restricting direct purchaser case development full generic competition uk group nevada vaccines antitrust litigation terminated agreements issue oft investigation covers issues also investigated european vaccine center forprofit vaccination centre las vegas commission respect paroxetine european nevada alleges group along vendor engaged union also part european commission price discrimination providing lowerpriced vaccine products pharmaceutical sector enquiry march commission southern nevada health district b entity entitled announced formally concluded enquiry lowerpriced pharmaceutical products us federal action march oft decided focus investigation healthcare program allegedly creating competitive disadvantage potential anticompetitive aspects paroxetine settlement resulting antitrust injury vaccine center complaint agreements dropped investigation relation potential alleges violation sherman act robinsonpatman act abuse dominance however february oft decided claim nevada state law group responded reopen dominance aspects matter complaint trial date yet set group cooperated oft investigations since wellbutrin sr outset april oft issued statement december january february lawsuits objections setting decision oft would propose several purported class actions filed make allowing affected parties make representations united states district court eastern district pennsylvania proposed decision ofts core theory harm group behalf direct indirect purchasers transfer value originator company potential competitor wellbutrin sr complaints alleged violations us antitrust laws made return restrictions potential competitor entering sham litigation fraud patent office group market necessarily restricts competition delays true obtaining enforcing patents covering wellbutrin sr generic competition accompanying price reduction complaints followed introduction generic competition includes situation value transferred context wellbutrin sr april district appellate court rulings settling patent litigation oft states would generic manufacturer infringe groups patents propose fine gsk details provided fine might calculated august gsk submitted response november district court approved groups rebutting ofts arguments october settlement certified class direct purchasers gsk presented case oft oral hearing settlement concluded january group hearing gsk also responded writing followup questions reached agreement principle settle claims indirect oft indicated decide proceed purchasers million district court approved case q final decision likely issued october settlements matter concluded ofts decision may appealed competition appeal tribunal provision made matter gsk annual report financial statements notes financial statements wellbutrin xl addition private litigant suits december us actions filed biovail corporation biovail sec filed formal complaint stiefel charles stiefel group united states district court eastern district united states district court district florida alleging pennsylvania purported classes direct indirect purchasers stiefel principals violated federal securities laws inducing allege unlawful monopolisation antitrust violations stiefel employees sell shares employee stock plan back related enforcement biovails wellbutrin xl patents company greatly undervalued price without disclosing filing biovail citizen petitions direct indirect employees company sold matter purchaser classes certified district court granted likewise stayed pending ruling finnerty appeal groups motion partial summary judgment primarily immunity group made provision stiefel litigation grounds november district court also granted benlysta securities litigation groups motion stay proceedings except limited november class action suit filed united amount ongoing discovery light us supreme courts states district court district maryland alleging human grant petition ftc v watson reverse payment patent genome sciences inc hgs certain individual officers litigation case directors group made statements clinical trials december district court held hearing benlysta failed disclose suicides among trial participants connection remaining issue case possible withholding information defendants caused hgs antitrust liability arising settlement underlying patent stock artificially inflated harming anyone purchased hgs infringement litigation court recently ordered parties stock inflated price submit plan additional discovery proceedings november second action filed federal remaining issue court two cases combined may group commercial corporate hgs filed motions dismiss suits oral argument heard september march court ruled favour group able make reliable estimate expected gsk hgs motions matter concluded financial effect matters discussed category included provision respect matters provision environmental matters legal disputes set note provisions group notified potential responsibility relating provision made following matters except past operations past waste disposal practices certain sites indicated primarily usa matters subject securitieserisa class actions litigation including proceedings initiated us federal state governments waste disposal site remediation costs tort stiefel actions brought private parties july class action suit brought behalf current group advised may responsible party former employees stiefel laboratories inc stiefel filed approximately sites appear national priority united states district court southern district florida list created comprehensive environmental response complaint alleges stiefel officers directors violated compensation liability act superfund proceedings us employee retirement income security act erisa federal seek require operators hazardous waste facilities state securities laws inducing stiefel employees sell transporters waste sites generators hazardous shares employee stock plan back stiefel greatly waste disposed sites clean sites reimburse undervalued price without disclosing employees stiefel us government cleanup costs instances sold group july district group involved alleged generator hazardous waste court denied plaintiffs motion class certification october district court granted defendants motions summary although superfund provides defendants jointly judgment dismissing one remaining plaintiffs severally liable clean costs proceedings frequently litigation trial claims one plaintiff timothy finnerty took resolved basis nature quantity waste disposed place may resulted million jury verdict favour generator site groups proportionate liability mr finnerty securities claims group appealed cleanup costs substantially determined verdict oral argument appeal scheduled february sites referred separately group settled mr finnertys erisa claims groups potential liability varies greatly site site additionally stiefel complete defence verdict fried case cost investigation study remediation sites could tried federal court florida october remaining case time significant group routinely accrues amounts related florida martinolich stayed pending outcome share liability matters finnerty appeal addition finnerty two matters appeal eleventh circuit bacon summary judgment granted plaintiffs favour mackay summary judgment granted stiefels favour discovery continues georgia new york suits lawsuits involve claims similar brought finnerty gsk annual report financial statements glaxosmithkline plc prepared uk gaap directors statement responsibilities disclosure information auditors relation companys financial statements directors office date report confirmed directors responsible preparing parent company far aware relevant audit information glaxosmithkline plc financial statements remuneration companys auditors unaware report accordance applicable law regulations taken steps ought taken uk company law requires directors prepare financial director make aware relevant audit statements financial year law directors information establish companys auditors aware elected prepare parent company financial statements information accordance united kingdom accounting standards applicable law united kingdom generally accepted accounting confirmation given interpreted accordance practice company law directors must approve provisions section companies act parent company financial statements unless satisfied going concern basis give true fair view state affairs company period making enquiries directors reasonable expectation company adequate resources continue operational preparing financial statements directors required existence foreseeable future reason continue select suitable accounting policies apply adopt going concern basis preparing financial statements consistently uk corporate governance code make judgements accounting estimates reasonable board considers glaxosmithkline plc applies principles prudent provisions uk corporate governance code maintained state regard parent company financial statements financial reporting council described corporate applicable uk accounting standards followed subject governance section pages complied material departures disclosed explained parent provisions board considers annual report taken company financial statements whole fair balanced understandable provides directors responsible keeping adequate accounting information necessary shareholders assess groups records sufficient show explain companys performance business strategy transactions disclose reasonable accuracy time required financial conduct authoritys listing rules financial position company enable ensure auditors considered directors statement compliance parent company financial statements remuneration report relation points uk corporate governance code comply companies act also responsible specified review safeguarding assets company hence taking reasonable steps prevention detection fraud irregularities parent company financial statements year ended sir christopher gent december comprising balance sheet year ended chairman december supporting notes set pages february report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended december included annual report published printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic report risk sections annual report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report financial statements glaxosmithkline plc prepared uk gaap independent auditors report members glaxosmithkline plc report parent company financial statements matters required report exception opinion adequacy accounting records information explanations received opinion parent company financial statements defined companies act required report opinion g ive true fair view state parent companys affairs december received information explanations require audit h ave properly prepared accordance united kingdom generally accepted accounting practice adequate accounting records kept parent company returns adequate audit received h ave prepared accordance requirements branches visited us companies act parent company financial statements part opinion read context say directors remuneration report audited remainder report agreement accounting records returns audited exceptions report arising responsibility parent company financial statements prepared directors remuneration glaxosmithkline plc comprise companies act required report parent company balance sheet december opinion certain disclosures directors remuneration notes parent company financial statements specified law made exceptions include summary significant accounting policies report arising responsibility explanatory information information annual report financial reporting framework applied isas uk ireland required report preparation comprises applicable law united kingdom opinion information annual report accounting standards united kingdom generally accepted aterially inconsistent information audited parent accounting practice company financial statements applying financial reporting framework directors pparently materially incorrect based materially inconsistent made number subjective judgements example respect knowledge parent company acquired course significant accounting estimates making estimates performing audit made assumptions considered future events otherwise misleading audit financial statements involves exceptions report arising responsibility conducted audit accordance international standards auditing uk ireland isas uk ireland audit involves responsibilities financial statements audit obtaining evidence amounts disclosures financial statements sufficient give reasonable assurance financial responsibilities directors statements free material misstatement whether caused explained fully directors statement responsibilities fraud error includes assessment set directors responsible preparation parent company financial statements satisfied w hether accounting policies appropriate parent give true fair view companys circumstances consistently applied adequately disclosed responsibility audit express opinion parent company financial statements accordance applicable law reasonableness significant accounting estimates made isas uk ireland standards require us comply directors auditing practices boards ethical standards auditors overall presentation financial statements report including opinions prepared addition read financial nonfinancial information companys members body accordance chapter annual report identify material inconsistencies part companies act purpose audited parent company financial statements identify giving opinions accept assume responsibility information apparently materially incorrect based purpose person report materially inconsistent knowledge acquired us shown whose hands may come save expressly course performing audit become aware apparent agreed prior consent writing material misstatements inconsistencies consider implications report matter reported separately group financial statements opinions matters prescribed companies act glaxosmithkline plc year ended december opinion company passed resolution accordance section information given strategic report directors companies act senior statutory auditors report financial year parent company name stated financial statements prepared consistent parent company financial statements pricewaterhousecoopers llp part directors remuneration report audited chartered accountants statutory auditors properly prepared accordance companies act london february gsk annual report company balance sheet uk gaap december notes fixed assets investments e debtors f cash bank current assets creditors amounts due within one year g net current assets net assets capital reserves called share capital h share premium account h reserves profit loss account equity shareholders funds financial statements pages approved board february signed behalf sir christopher gent chairman glaxosmithkline plc registered number gsk annual report financial statements glaxosmithkline plc prepared uk gaap notes company balance sheet uk gaap expenditure expenditure recognised respect goods services received presentation financial statements supplied accordance contractual terms provision made obligation exists future liability respect description business past event amount obligation reliably glaxosmithkline plc parent company gsk major global estimated healthcare group engaged creation discovery development manufacture marketing pharmaceutical investments subsidiary companies products including vaccines overthecounter otc medicines investments subsidiary companies held cost less healthrelated consumer products provision impairment preparation financial statements impairment investments financial statements prepared going concern carrying value investments reviewed impairment basis drawn accordance uk generally accepted indication investment might impaired accounting practice uk gaap uk accounting provision resulting impairment review charged presentation december comparative figures income statement year concerned december appropriate comparative figures reclassified ensure consistent presentation current year share based payments information issuance company subsidiaries grant permitted section companies act profit companys shares represents additional capital contributions loss account company presented annual company subsidiaries additional investment report subsidiaries results corresponding increase shareholders company included group accounts glaxosmithkline equity additional capital contribution based fair value plc publicly available advantage taken grant issued allocated underlying grants vesting period exemption provided frs cash flow statements revised taxation prepare cash flow statement exemption provided frs related party disclosures disclose related party current tax provided amounts expected paid applying transactions within group tax rates enacted substantially enacted balance sheet date accounting convention standards company accounts taxation deferred accelerated balance sheet prepared using historical cost reason timing differences originated convention complies applicable uk accounting standards reversed balance sheet date deferred tax assets recognised extent considered recoverable accounting principles policies future taxable profits preparation balance sheet conformity generally accepted accounting principles requires management make deferred tax measured average tax rates expected estimates assumptions affect reported amounts apply periods timing differences expected assets liabilities disclosure contingent assets reverse deferred tax liabilities assets discounted liabilities date balance sheet actual amounts could differ estimates financial guarantees liabilities relating guarantees issued company behalf balance sheet prepared accordance subsidiaries initially recognised fair value amortised companys accounting policies approved board described life guarantee note b c perating profit b accounting policies fee relating audit foreign currency transactions company charged operating profit foreign currency transactions recorded exchange rate ruling date transaction forward rate hedged dividends forward exchange contract foreign currency assets liabilities directors declared four interim dividends resulting dividend translated rates exchange ruling balance sheet date year pence pence increase dividend forward rate details see note group financial statements dividends dividends paid received dividends paid received included accounts period related dividends actually paid received gsk annual report notes company balance sheet uk gaap continued e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments f debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings g creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company outstanding guarantees billion debt instruments amounts due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note f gsk annual report financial statements glaxosmithkline plc prepared uk gaap notes company balance sheet uk gaap continued h share capital share premium account share ordinary shares p premium number share capital authorised december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes share capital cancelled december december december number shares issuable outstanding options number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes total million shares purchased company cost million million shares cancelled company expects make share repurchases billion exact amount timing purchases whether shares held treasury shares cancelled determined company dependent market conditions factors shares purchased period january february reserves profit reserves loss account total january profit attributable shareholders dividends shareholders shares purchased cancelled held treasury share capital contribution relating share based payments december profit attributable shareholders dividends shareholders shares purchased cancelled held treasury share capital contribution relating share based payments december loss glaxosmithkline plc year million million profit dividends million million gave retained loss million million profit cost shares purchased cancelled held treasury shares million profit loss account reserve december stood million million million unrealised million gsk annual report investor information section quarterly trend five year record product development pipeline products competition intellectual property risk factors share capital share price dividends tax information shareholders annual general meeting us law regulation shareholder services contacts glossary terms index gsk annual report investor information financial record financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating income operating profit net finance costs profit disposal interest associates joint ventures share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report investor information financial record pharmaceuticals vaccines turnover therapeutic area total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera valtrex zovirax zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza metabolic antibacterials augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatology bactroban duac rare diseases flolan volibris immuno inflammation benlysta pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix viiv healthcare hiv cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report pharmaceuticals vaccines turnover therapeutic area total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antivirals hepsera valtrex zovirax zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare metabolic avandia products antibacterials augmentin oncology emesis arzerra promacta tyverbtykerb votrient dermatology bactroban duac rare diseases flolan volibris immuno inflammation benlysta pharmaceuticals vaccines boostrix cervarix fluarix flulaval hepatitis infanrix pediarix nimenrix rotarix synflorix viiv healthcare hiv cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report investor information financial record viiv healthcare turnover total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer combivir epivir epzicomkivexa selzentry trizivir total usa europe emap rest world therapeutic area restated growth growth growth growth growth major products cer cer cer cer cer combivir epivir epzicomkivexa lexiva selzentry trizivir five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board restated restated restated restated turnover division pharmaceuticals vaccines pharmaceuticals vaccines consumer healthcare group turnover geographic region usa europe emap japan group turnover segment usa europe emap japan viiv healthcare hiv trading unallocated pharmaceuticals pharmaceuticals vaccines consumer healthcare gsk annual report five year record continued restated restated restated restated pharmaceuticals vaccines turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis dermatology rare diseases immunoinflammation pharmaceuticals vaccines viiv healthcare hiv consumer healthcare turnover total wellness oral care nutrition skin health restated restated restated restated financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share restated restated financial results core turnover operating profit profit taxation profit taxation pence pence pence core earnings per share core diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted restated restated restated restated return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report investor information financial record five year record continued restated restated restated restated balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees usa europe emap japan manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average average rate year calculated average pm buying rates day year feb jan dec nov oct sep high low pm buying rate february us gsk annual report pipeline products competition pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party month first submission phase evaluation clinical pharmacology usually conducted volunteers month first regulatory approval maa first eu phase ii determination dose initial evaluation efficacy conducted approval letter small number patients bla biological licence application phase iii large comparative study compound versus placebo andor established maa marketing authorisation application europe treatment patients establish clinical benefit safety nda new drug application usa po month eu positive opinion maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla respiratory phosphoinositide kinase inhibitor idiopathic pulmonary fibrosis soluble epoxide hydrolase inhibitor copd phosphoinositide kinase inhibitor asthma copd cathepsin c inhibitor bronchiectasis tumour necrosis factor receptor domain antibody acute lung injury danirixin cxcr chemokine receptor antagonist copd fluticasone furoate glucocorticoid agonist longacting beta agonist copd vilanterol muscarinic acetylcholine antagonist umeclidinium muscarinic acetylcholine antagonist beta agonist copd ii tolllike receptor agonist asthma ii sodium channel blocker cough ii recombinant human angiotensin converting enzyme acute lung injury ii fluticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma ii umeclidinium antagonist losmapimod p kinase inhibitor oral copd also acute coronary syndrome ii mepolizumab il monoclonal antibody nasal polyposis ii mepolizumab il monoclonal antibody severe asthma also eosinophilic granulomatosis iii polyangiitis relvarbreo ellipta longacting beta agonist glucocorticoid agonist copd mortality outcomes iii vilanterol fluticasone furoate vilanterol longacting beta agonist copd iii fluticasone furoate glucocorticoid agonist asthma submitted oct incruse ellipta muscarinic acetylcholine antagonist copd also hyperhidrosis submitted po feb apr umeclidinium anoro ellipta muscarinic acetylcholine antagonist longacting copd approved po feb dec umeclidinium beta agonist vilanterol relvarbreo ellipta longacting beta agonist glucocorticoid agonist asthma approved nov vilanterol fluticasone furoate relvarbreo ellipta longacting beta agonist glucocorticoid agonist copd approved nov amay vilanterol fluticasone furoate paediatric vaccines rsv recombinant respiratory syncytial virus prophylaxis maternal immunisation rsv recombinant viral vector respiratory syncytial virus prophylaxis pneumoniae next recombinant conjugated streptococcus pneumoniae disease prophylaxis ii generation mmr live attenuated measles mumps rubella prophylaxis iii us nov mosquirix recombinant malaria prophylaxis plasmodium falciparum iii na malaria rtss nimenrix conjugated neisseria meningitis groups c w approved apr menacwytt disease prophylaxis ii us vaccines hiv recombinant hiv disease prophylaxis nthi recombinant nontypeable haemophilus influenzae prophylaxis hepatitis c recombinant viral vector hepatitis c virus prophylaxis ii hiv recombinant hiv disease immunotherapy ii tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpes zoster prophylaxis iii flu pre pandemic hn inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis approved na nov flu vaccine inactivated split quadrivalent seasonal influenza prophylaxis approved feb dec use brand name approved regulatory authorities gsk annual report investor information pipeline products competition pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla antigenspecific cancer immunotherapeutic prame recombinant treatment resectable nonsmall cell lung cancer ii immunotherapeutic magea recombinant treatment bladder cancer ii immunotherapeutic wt immunotherapeutic recombinant treatment breast cancer ii magea recombinant treatment melanoma iii immunotherapeutic magea recombinant treatment nonsmall cell lung cancer iii immunotherapeutic hiv viiv healthcare hiv integrase inhibitor longacting hiv infections ii parenteral formulation dolutegravir abacavir hiv integrase inhibitor reverse hiv infections fixed dose combination submitted soct soct sulphate lamivudine transcriptase inhibitors fixed dose combination tivicay dolutegravir hiv integrase inhibitor hiv infections approved jan aug oncology bromodomain inhibitor nut gene midline carcinoma trametinib akt protein kinase inhibitor cancer mek inhibitor focal adhesion kinase inhibitor cancer phosphatidylinositol kinase inhibitor cancer erbb monoclonal antibody cancer fibroblast growth factor ligand trap cancer afuresertib akt protein kinase inhibitor multiple myeloma votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer mk pd monoclonal antibody afuresertib akt protein kinase inhibitor ovarian cancer ii foretinib mesenchymalepithelial transition factor nonsmall cell lung cancer ii cmet kinase inhibitor mekinist trametinib mek inhibitor braf protein kinase colorectal cancer ii tafinlar dabrafenib inhibitor human antiegfr panitumumab monoclonal antibody revoladepromacta thrombopoietin receptor agonist acute myeloid leukaemia ii eltrombopag revoladepromacta thrombopoietin receptor agonist aplastic anaemia ii eltrombopag revoladepromacta thrombopoietin receptor agonist myelodysplastic syndromes ii eltrombopag tafinlar dabrafenib braf protein kinase inhibitor nonsmall cell lung cancer ii arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia use relapsed patients iii arzerra ofatumumab cd human monoclonal antibody diffuse large b cell lymphoma relapsed patients iii arzerra ofatumumab cd human monoclonal antibody follicular lymphoma refractory relapsed patients iii mekinist trametinib mek inhibitor braf protein kinase metastatic melanoma adjuvant therapy iii tafinlar dabrafenib inhibitor tyverbtykerb lapatinib human epidermal growth factor receptor breast cancer neoadjuvant adjuvant therapy iii epidermal growth factor receptor egfr dual kinase inhibitor votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii arzerra ofatumumab cd human monoclonal antibody chronic lymphocytic leukaemia first line therapy submitted oct oct votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy submitted aug mekinist trametinib mek inhibitor metastatic melanoma approved feb may mekinist trametinib mek inhibitor braf protein kinase metastatic melanoma approved feb ajan tafinlar dabrafenib inhibitor revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia approved sep nov eltrombopag tafinlar dabrafenib braf protein kinase inhibitor metastatic melanoma approved aaug amay tyverbtykerb lapatinib egfr dual kinase inhibitor metastatic breast cancer combination trastuzumabapproved jul gsk annual report pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla cardiovascular metabolic prolyl hydroxylase inhibitor topical wound healing selective androgen receptor modulator heart failure prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii perioperative risk reduction ileal bile acid transport inhibitor type diabetes ii camicinal motilin receptor agonist delayed gastric emptying ii losmapimod p kinase inhibitor acute coronary syndrome also copd ii retosiban oxytocin antagonist threatened preterm labour ii darapladib lppla inhibitor atherosclerosis also diabetic macular oedema iii eperzan albiglutide glp agonist type diabetes submitted po jan jan immunoinflammation janus kinase jak inhibitor ulcerative colitis il receptor monoclonal antibody autoimmune disease macrophage targeted histone deacetylase rheumatoid arthritis inhibitor janus kinase jak inhibitor systemic lupus erythematosus also psoriasis ii mor granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody belimumab b lymphocyte stimulator monoclonal transplant rejection also myaesthenia gravis ii antibody iv benlysta belimumab b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc benlysta belimumab b lymphocyte stimulator monoclonal vasculitis iii antibody iv sirukumab il human monoclonal antibody sc rheumatoid arthritis iii rare diseases sap monoclonal antibody amyloidosis exvivo stem cell gene therapy metachromatic leukodystrophy ii exvivo stem cell gene therapy wiscottaldrich syndrome ii ozanezumab neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis ii monoclonal antibody exvivo stem cell gene therapy adenosine deaminase severe combined immune iii deficiency adascid mepolizumab il monoclonal antibody sc eosinophilic granulomatosis polyangiitis iii also severe asthma volibris ambrisentan endothelin antagonist chronic thromboembolic pulmonary hypertension iii infectious diseases antiviral maturation inhibitor hiv infections nsb polymerase inhibitor hepatitis c polypeptide deformylase inhibitor bacterial infections ii type topoisomerase inhibitor bacterial infections ii tafenoquine aminoquinoline plasmodium vivax malaria ii relenza iv zanamivir neuraminidase inhibitor iv influenza iii neurosciences lppla inhibitor alzheimer 's disease h receptor antagonist multiple sclerosis ii myelinassociated glycoprotein monoclonal stroke ii antibody belimumab b lymphocyte stimulator monoclonal myaesthenia gravis also transplant rejection ii antibody iv ofatumumab cd human monoclonal antibody sc multiple sclerosis also pemphigus vulgaris ii rilapladib lppla inhibitor alzheimer 's disease ii gsk annual report investor information pipeline products competition pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla ophthalmology beta amyloid monoclonal antibody geographic retinal atrophy ii darapladib lppla inhibitor diabetic macular oedema also atherosclerosis ii dermatology stearoyl coa desaturase inhibitor topical acne vulgaris umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis also copd janus kinase jak inhibitor psoriasis also lupus ii nonsteroidal antiinflammatory atopic dermatitis psoriasis ii ofatumumab cd human monoclonal antibody sc pemphigus vulgaris also multiple sclerosis ii toctino alitretinoin retinoic acid receptor modulator chronic hand eczema iii na duac low dose clindamycinbenzoyl peroxide gel acne vulgaris approved mar na brand names appearing italics trademarks either owned andor licensed glaxosmithkline associated companies optionbased alliances third parties include assets phase phase ii development company disease area phase cancer research uk cancer dynavax technologies cutaneous systemic lupus erythematosus ii isis pharmaceuticals transthyretinmediated amyloidosis iiiii hepatitis b oncomed pharmaceuticals oncology iii shionogi bacterial infection two assets gsk annual report pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands usa eu respiratory anoro ellipta umeclidinium bromide copd spiriva onbrez nce nce vilanterol terfenatate device device avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired diskus device diskus device hfadevice hfadevice formulation formulation relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate us copd flutiform dulera nce nce device device seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expired onbrez diskus device diskus device hfadevice formulation ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice formulation formulation antivirals relenza zanamivir influenza tamiflu expired valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired requip xl ropinirole parkinsons disease mirapex expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi lovaza omega acid ethyl esters high triglycerides tricor expired na see risk factors details uncertainty timing followon competition generic competition possible see note financial statements legal proceedings gsk annual report investor information pipeline products competition pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands usa eu antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections oncology arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia imbruvica mekinist trametinib metastatic melanoma yervoy zelboraf na promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura hepatitis c mabtherarituxan associated thrombocytopenia tafinlar dabrafenib mesylate metastatic melanoma yervoy zelboraf yet granted tykerbtyverb lapatanib advanced metastatic herceptin breast cancer kadcyla positive patients votrient pazopanib soft tissue sarcoma yondelis sutent metastatic renal cell nexavar afinitor carcinoma rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta belimumab systemic lupus erythematosus vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis b polio hepatitis b pentaxim pentavac haemophilus influenzae haemophilus influenzae hexaxim type b type b cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtypes fluzone influvac subtype b antigens aggripal fluad intenza flumist fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtypes vaxigrip qiv subtype b antigens fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip none none virus subtypes fluzone influvac subtype b antigens aggripal fluad intenza flumist pandemrix derived split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis adjuvant prepandrix derived split inactivated pandemic hn aflunov vepacel influenza virus antigen influenza prophylaxis adjuvant synflorix conjugated pneumococcal invasive pneumococcal prevenar prevnar na polysaccharide disease pneumonia acute otitis media gsk annual report pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands usa eu hiv combivir lamivudine zidovudine hivaids truvada atripla expired expired stribild combination combination compleraeviplera epivir lamivudine hivaids truvada atripla expired expired stribild compleraeviplera epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaids isentress prezista reyataz kaletra trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera generic competition commenced consumer healthcare products competition brand products application markets competition total wellness panadol tablets caplets infant drops paracetamolbased treatment global except usa reckittbenckisers nurofen headache joint pain fever cold symptoms nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin cq original lozenge withdrawal aid johnson johnsons nicabate quitting smoking nicorette europe also nicorette retailers brands us eno effervescent rapid relief antacid global hypermarcas estomazil tums chewable tablets pfizers gelusil sanofis rolaids johnson johnsons mylanta oral care sensodyne toothpastes toothbrushes prevention dental global colgatepalmolives mouthwashes sensitivity colgate pro relief polident denture adhesive denture improve comfort global procter gambles fixodent poligrip cleanser fitted dentures reckittbenckisers kukident corega clean dentures steradent aquafresh toothpastes toothbrushes prevention caries gum global colgatepalmolives colgate mouthwashes disease bad breath procter gambles crest oralb parodontax toothpastes mouthwashes help stop bleeding gums global colgatepalmolivess gum health colgate progum nutrition horlicks malted milkbased drinks nutrition uk ireland india mondelezs bournvita foods nestles milo maxinutrition sports nutrition protein nutrition uk myprotein powder bars optimum nutrition skin health physiogel moisturising creams face body care dry germany france italy loreals la roche posay lotions cleansers sensitive irritated skin poland spain beiersdorfs eucerin pierre fabres avene oilatum emollient bath creams soothing treatment eczema uk poland reckittbenckisers e shampoo dry skin conditions markets sanofis emolium gsk annual report investor information principal risks uncertainties principal risks uncertainties risk factors principal risks discussed risks uncertainties moreover rules regulations change governmental relevant business financial condition results operations interpretation rules regulations evolves nature may affect performance ability achieve objectives particular risk may alter changes certain regulatory regimes factors believe could cause actual us healthcare system may substantial change results differ materially expected historical results failure comply applicable law regulation could materially adversely affect financial results operate global basis industry highly competitive highly regulated competitors may make similarly business exposes us litigation government significant product innovations technical advances may investigations including limited product liability litigation intensify price competition light competitive environment antitrust litigation sales marketing litigation litigation continued development commercially viable new products government investigations including related provisions may make development additional uses existing products critical unfavourable outcomes increases related costs ability maintain increase overall sales insurance premiums could materially adversely affect financial results detail status various uncertainties developing new pharmaceutical vaccine products costly involved significant unresolved disputes potential litigation lengthy uncertain process however product candidate set note legal proceedings may fail stage including significant group economic human resources invested competitors products uk regulations require discussion mitigating activities company pricing strategies failure part develop commercially takes address principal risks uncertainties summary successful products develop additional uses existing mitigation activities accompanies principal risk represent products could materially adversely affect financial results main actions taken manage principal risks principal risk factors uncertainties listed order must also adapt comply broad range laws significance regulations requirements apply research development manufacturing testing approval distribution sales marketing pharmaceutical vaccine consumer healthcare products affect cost product development also time required reach market uncertainty successfully patient safety strategic priority deliver products value grow diversified global company risk definition failure appropriately collect review follow report adverse events chief medical officer cmo responsible medical governance potential sources could compromise ability conduct group global policy policy safeguarding human robust safety signal detection interpretation ensure subjects clinical trials patients take products appropriate decisions taken respect riskbenefit profile paramount importance cmo authoritative role evaluating products including completeness accuracy product labels addressing matters human safety individual medical officers pursuit additional studiesanalyses appropriate groups substantial global safety pharmacovigilance keep track adverse issues reported products course clinical studies risk impact group product approved marketing group extensive impacts risk include potential harm patients reputational postmarketing surveillance signal detection system information damage product liability claims litigation governmental possible side effects medicines received several sources including investigation regulatory action fines penalties loss unsolicited reports health professionals patients regulatory product authorisation authorities medical scientific literature media policy employees required report immediately issues relating safety context quality medicines country managers responsible monitoring exception tracking training helps assure collection preclinical clinical trials conducted development safety information reporting information relevant central safety investigational pharmaceutical vaccine consumer healthcare products department accordance group policy legal requirements determine safety efficacy products use humans notwithstanding efforts make determine safety products information changes benefitrisk profile one groups appropriate preclinical clinical trials unanticipated side effects medicines result certain actions characterise communicate may become evident products widely introduced minimise risk proposed actions discussed regulatory authorities marketplace questions may raised ongoing safety include modifying prescribing information communications surveillance postmarketing studies also governmental agencies physicians healthcare providers restrictions product thirdparties may analyse publicly available clinical trial results prescribingavailability help assure safe use sometimes carrying clinical trials certain cases may appropriate stop clinical group currently defendant number product liability lawsuits trials withdraw medicine market groups global including class actions involve significant claims damages related safety board gsb comprising senior physicians representatives products litigation particularly us inherently unpredictable supporting functions integral component system gsb class actions seek sweep together persons prescribed including subsidiary boards dedicated consumer healthcare products products increase potential liability claims pain suffering vaccines reviews safety investigational marketed products punitive damages frequently asserted product liability actions across group authority stop clinical trial deemed allowed represent potentially openended exposure thus possibly harmful human volunteers could materially adversely affect groups financial results addition medical governance framework within group mitigating activities described group uses several mechanisms foster early constructed system medical governance help ensure evaluation mitigation resolution disputes arise potential safety efficacy pharmaceuticals vaccines consumer claims even arise goal programmes create healthcare products group produces culture early identification evaluation risks claims actual potential order minimise liability litigation gsk annual report intellectual property strategic priority deliver products value grow diversified global company risk definition depend certain key products significant portion sales failure appropriately secure protect intellectual property rights timing impact entry usa major markets europe followon product seretideadvair uncertain us patent risk impact compositions containing combination active substances seretideadvair expired although us patent loss patent protection including reducing scope patent rights component advair diskus device continues august compulsory licensing government forces manufacturer able predict generic competitor seretideadvair license patents specific products competitor could materially may enter us market adversely affect financial results markets absence adequate patent data exclusivity protection could limit opportunity generic drug manufacturers also exhibited readiness market rely markets future sales growth products could generic versions many important products prior also materially adversely affect financial results expiration patents efforts may involve challenges validity enforceability patent assertions generic product context infringe patents result may continue involved legal proceedings involving patent challenges may materially innovative pharmaceutical vaccine consumer healthcare adversely affect financial results moreover usa become products company seek obtain appropriate intellectual property increasingly common patent infringement actions prompt claims protection products ability obtain enforce patents antitrust laws violated prosecution patent proprietary rights regard products critical litigation involving defence patent claims direct business strategy success pharmaceutical vaccine products indirect purchasers payers typically filed class actions usually protected copied generic manufacturers relief sought may include treble damages restitution claims period exclusivity provided issued patent related intellectual similarly antitrust claims may brought government entities property rights regulatory data protection orphan drug private parties following settlement patent litigation alleging status following expiration certain intellectual property rights generic settlements anticompetitive violation antitrust laws manufacturer may lawfully produce generic version product successful antitrust claim private party government entity may face technological regulatory barriers marketing could materially adversely affect financial results operate markets intellectual property laws patent offices expiration dates patents major products may affect still developing governments may unwilling grant dates generic versions products may introduced set enforce intellectual property rights fashion similar developed pages legal proceedings involving patent challenges regions eu japan usa developing countries set note financial statements legal proceedings reduced threatened reduce effective patent protection pharmaceutical products generally particular therapeutic areas facilitate early competition within markets generic manufacturers mitigating activities global patents group focuses securing protecting patent face competition manufacturers proprietary generic rights global group maintains internal processes designed help pharmaceutical products major markets introduction generic ensure successful procurement enforcement defence patents products particularly usa highest turnover goal maintaining exclusive rights markets products margins typically leads dramatic loss sales reduces revenues margins proprietary products global patents group monitors new developments international pharmaceutical vaccine products million annual patent law help ensure appropriate protection assets sometimes global sales certain products generic competition acting trade associations work local governments seek usa markets europe may also experience secure effective balanced intellectual property protection designed impact sales one products due expiry loss patent meet needs patients payers supporting longterm protection product marketed competitor similar product class investment innovation treatment similar disease condition gsk annual report investor information principal risks uncertainties product quality strategic priority deliver products value grow diversified global company risk definition adopted single quality management system qms failure ensure product quality throughout manufacturing defines quality standards systems businesses associated distribution processes resulting noncompliance good pharmaceuticals vaccines consumer healthcare products manufacturing practice gmp regulations rd investigational materials qms broad scope covering endtoend supply chain starting materials distributed product risk impact applicable throughout complete lifecycle products rd mature commercial supply failure ensure product quality could far reaching implications terms health patients customers product recalls qms periodically updated based experience evolving potential damage reputation well regulatory legal regulatory agency expectations requirements improved scientific financial consequences could materially adversely affect understanding help ensure operations comply gmp financial results requirements globally support delivery consistent reliable products large network quality compliance professionals context aligned business unit provide oversight assist delivery quality performance operational compliance management patients consumers healthcare professionals trust quality oversight activities accomplished hierarchy quality products point use failure ensure product quality council meetings staff trained help ensure standards well enterprise risk applicable across business activities expected behaviours based values followed product quality may influenced many factors including product process understanding consistency manufacturing components implemented riskbased approach assessing managing compliance gmp accuracy labelling reliability security thirdparty suppliers provide materials used finished products supply chain embodiment overarching quality culture contract manufacturers making products expected comply internal external environment continues evolve new standards identified group audited help provide products new markets new legislation introduced particularly assurance expected standards met around security supply good distribution practice product chief product quality officer oversees activities gsk standards quality council serves forum escalate emerging risks share experiences handling quality issues businesses mitigating activities help ensure lessons learned assessed deployed globally medicines development scientists adopt principles quality preparation implementation new legislation regularly design new products devise control strategies deployed reviewed gsk quality council advocacy communication throughout product lifecycle help ensure consistency reliability programmes used maintain awareness external environment performance supply convey consistent messages across group emphasis quality performance metrics culture right first time gsk annual report supply chain continuity strategic priority simplify operating model deliver products value risk definition failure small number singlesource thirdparty suppliers failure deliver continuous supply compliant finished product service providers fulfil contractual obligations timely manner result regulatory noncompliance physical disruption risk impact logistics manufacturing sites may result delays service interruptions interruption supply exclusion healthcare programmes could impact patient access products expose us litigation regulatory mitigating activities action materially adversely affect financial results particular incurring fines disgorgement result noncompliance supply chain model designed help ensure supply quality manufacturing practice regulations could also materially adversely security products globally closely monitor delivery affect groups financial results result reputational damage products help ensure customers medicines vaccines products need safety stocks backup supply context arrangements high revenue medicallycritical products place practical help mitigate risk addition supply chain operations subject review approval standing manufacturing external suppliers routinely monitored various regulatory agencies effectively provide licence operate order identify manage supply base risks failure manufacturing distribution facilities suppliers key services materials could lead litigation regulatory action practical dependencies single sources critical items product recalls seizures interruption supply delays removed reliance single source components approval new products revocation licence operate reduced several key products qualification alternative pending resolution manufacturing logistics issues materials help improve supply chain robustness materials services provided thirdparty suppliers necessary supply chain operating model modified commercial production products including active strengthen link commercial forecasting manufacturing pharmaceutical ingredients api antigens intermediates commodities action time decrease risk associated demand components necessary manufacture packaging many fluctuations impacting ability supply writeoffs associated pharmaceutical vaccine consumer healthcare products product exceeding expiry dating new model node thirdparty services procured services provided supply chain optimised help ensure adequate safety clinical research organisations support development key products stock balancing working capital associated endtoend important continuous operation businesses although supply chain undertake business continuity planning single sourcing certain components bulk api finished products services creates risk failure supply event regulatory noncompliance physical disruption manufacturing sites logistics financial reporting disclosure strategic priority simplify operating model risk definition mitigating activities failure report accurate financial information compliance group maintains control environment designed identify material accounting standards applicable legislation errors financial reporting disclosure design operating effectiveness key financial reporting controls periodically tested risk impact provides us assurance controls key financial noncompliance existing new financial reporting disclosure reporting disclosure processes operated effectively requirements changes recognition income expenses keep uptodate latest developments financial reporting could expose us litigation regulatory action could materially requirements working external auditor advisors adversely affect financial results help ensure adherence relevant reporting disclosure requirements context shared accountability financial results across new revised accounting standards rules interpretations issued businesses financial results reviewed approved regional time time international accounting standards board management reviewed financial controller could result changes recognition income expense chief financial officer cfo allows financial controller may materially adversely affect financial results cfo assess evolution business time group also required laws various jurisdictions evaluate performance plan significant judgments reviewed publicly disclose financial results regulators routinely review confirmed senior management financial statements listed companies compliance accounting regulatory requirements group believes complies appropriate regulatory requirements concerning financial statements disclosures however subject investigation potential noncompliance accounting disclosure requirements potential restatements previously reported results could subject significant penalties gsk annual report investor information principal risks uncertainties tax treasury strategic priority simplify operating model risk definition liquidity risk managed diversifying liquidity sources using failure comply tax law significant losses due treasury range facilities maintaining broad access funding markets activities order meet anticipated future funding requirements also hold significant amounts cash investments invested line risk impact strict investment guidelines changes tax laws application respect matters interest rate risk managed limiting amount floating rate transfer pricing foreign dividends controlled companies rd interest payments prescribed percentage operating profit tax credits taxation intellectual property restriction tax relief mix debt fixed floating interest rates monitored regularly allowed interest intragroup debt could impact effective tmg tax rate significant losses may arise treasury activities foreign currency transaction risk arising internal external trade inconsistent application treasury policies dealing settlement flows generally hedged internal trading transactions errors counterparty defaults changes tax laws matched centrally manage intercompany payment terms application failure comply tax law significant losses due reduce foreign currency risk foreign currency cash flows treasury activities could materially adversely affect financial hedged selectively management treasury results tmg possible manage cash surpluses borrowing requirements subsidiary companies centrally order reduce context foreign currency translation exposure seek denominate groups treasury group deals high value transactions mostly borrowings currencies principal assets cash flows foreign exchange cash management transactions daily basis tmg reviews ratio borrowings assets major currencies monthly groups effective tax rate driven rates tax jurisdictions higher lower uk addition many counterparty risk managed setting global counterparty limits jurisdictions currently offer regimes encourage innovation banking investment counterparties based long investment science providing tax incentives rd term credit ratings moodys standard poors treasurys tax credits lower tax rates income derived patents usage limits monitored daily corporate compliance furthermore international business face risks associated officer cco operates independently corporate treasury intragroup transfer pricing cco also monitors credit rating counterparties changes ratings occur notifies treasury changes tax charge included financial statements best estimate made investment levels authority limits appropriate tax liability pending audits tax authorities submit tax returns according statutory time limits engage tax authorities help monitor government debate tax policy key jurisdictions ensure tax affairs current exceptional cases matters deal proactively potential future changes tax law tax settled agreement tax authorities may risk managed set policies procedures help ensure resolve disputes formal appeals proceedings consistency compliance tax legislation engage advisors international business also subject range duties legal counsel review tax legislation applicability taxes carrying similar types risk business increased focus tax position multinational attempt mitigate risk aggressive tax authority audits businesses consequence challenging economic date possible tax affairs working environment priority placed g addressing proactively tax authorities possible also moved allegations tax avoidance seen increase audits centralised simplified intellectual property ownership governments seek raise revenues corporate taxes trading model model centralises pharmaceutical intellectual line taxes customs duties property uk reducing complexity intercompany arrangements enabling us drive bilateral advance pricing mitigating activities agreements apas uk jurisdictions treasury operate profit centre enter operate apas give greater certainty application transfer financial derivative transactions speculative purposes pricing direct tax affairs hence reduce risks internal transactions financial instruments undertaken manage structures enhanced centralised team risks arising underlying business activities treasury activities dedicated specialists responsible managing transactional tax governed policies approved board directors reporting compliance compliance regularly reviewed treasury management group tmg chaired cfo gsk annual report antibribery corruption strategic priority grow diversified global company risk definition mitigating activities failure foster culture within group bribery code conduct values behaviours commitment zero corruption unacceptable adopt measures embed procedures tolerance integral mitigate risk group prevent bribery corruption employees complementary enterprisewide abac programme designed respond threat workers third party interactions investigate allegations risk bribery corruption builds groups values bribery corruption remediate issues identified comply existing standards form comprehensive practical approach applicable antibribery corruption abac legislation compliance complex risk area abac programme supported toplevel commitment risk impact global policy proportionate procedures including speak failure comply applicable local international abac procedure ongoing training communications including legislation could expose group associated persons confidential reporting line ongoing risk assessment monitoring governmental investigation regulatory action civil criminal investigations third party due diligence including contracting liability well damage groups reputation shareholder value requirements monitoring oversight addition programme licence operate could materially adversely mandates enhanced controls interactions government officials affect financial results undertaking business development transactions programme governance provided groups abac oversight committee context includes representation key functional areas like large organisations group faces risk fraud additionally dedicated abac team responsible driving members staff nature scale geography international implementation evolution programme response business activities increase possibility bribery corruption developments internal external environment capability risk additionally healthcare industry highly regulated includes abac investigations team empowered review bribery overseas markets operations emerging markets corruption allegations make recommendations remedial action susceptible bribery corruption risks improvement supported network functional experts legal compliance audit assurance groups continually benchmark abac programme use external expertise review help improve elements programme gsk annual report investor information principal risks uncertainties commercial practices scientific engagement strategic priority deliver products value grow diversified global company risk definition mitigating activities failure engage commercial andor scientific activities committed legitimate scientific engagement ethical consistent letter spirit legal industry groups responsible commercialisation medicines support mission requirements relating marketing communications improve quality human life enabling people medicines associated therapeutic areas appropriate interactions feel better live longer accomplish mission engage healthcare professionals hcps patients legitimate healthcare community various ways advance scientific transparent transfer value knowledge well provide important information medicines risk impact obligation learn scientific engagement interactions failure comply applicable laws rules regulations may result provide accurate complete information appropriate governmental investigation regulatory action legal proceedings channels careful correct nonpromotional manner researchers brought group governmental private plaintiffs hcps healthcare organisations hcos external experts failure provide accurate complete information related engage fairly compensated services expertise products may result incomplete awareness benefitrisk profile provided however payments must excessive must never medicines possibly suboptimal treatment patients perceived inducement reward prescribing consequences could materially adversely affect financial products results practices found misaligned values promotion approved medicines helps ensure hcps globally could also result reputational damage dilute trust established access information need patients access key stakeholders medicines need medicines prescribed used manner provides maximum healthcare benefit patients context committed communicating information related approved group disseminates information products products responsible legal ethical manner promotion nonpromotional scientific engagement latter interaction exchange information group taken action levels group enhance improve partners external communities order advance scientific standards procedures scientific engagement promotional medical understanding including appropriate development interactions based values transparency respect integrity use products management disease patient care patient focus policies standards governing promotional distinct promotional activities may take place activities scientific engagement undertaken group authorisation new product indication must conducted behalf activities conduct worldwide must conform strictly accordance promotional laws codes groups high ethical medical scientific standards local standards policy differ global standards stringent two applies legal regulatory financial reputational risks group promotional materials activities must reviewed approved activities perceived exceeding proper according groups standards conducted accordance boundaries inappropriately influencing hcps paid local laws regulations help ensure materials billion resolve government investigations usa focused activities fairly represent products services group large part promotional practices necessary disciplined including termination employees engaged misconduct broadened ability claw back remuneration senior management event misconduct recent years taken several steps feel industry leading various areas commercial practices scientific engagement examples group stance recognised industryleading include removing prescriptionvolume incentives compensation sales representatives us global standards scientific engagement gsk annual report research practices strategic priorities deliver products value grow diversified global company risk definition also committed reporting results human subject failure protect inform patients involved human clinical trial research used evaluate products regardless whether research conduct objective ethical preclinical clinical trials using outcomes perceived positive negative believe sound scientific principles guarantee integrity discovery preclinical fundamental advancement medical science helps clinical development data manage human biological samples inform prescribers patients products according established ethical standards regulatory expectations committed making data publicly available enable valid scientific treat animals ethically practice good animal welfare appropriately research respect human biological samples committed disclose human subject research medicinal products ensure managing samples manner respects rights integrity regulatory filings data publish research clinical participants well meeting applicable legal regulatory ethical obligations risk impact implement controls help ensure trials conducted impacts risk include harm patients reputational damage accordance good clinical practice gcp guidelines failure obtain necessary regulatory approvals products developed international conference harmonisation governmental investigation legal proceedings product liability suits based principles contained world medical association claims damages regulatory action fines penalties declaration helsinki ethical principles medical research loss product authorisation could materially adversely involving human subjects affect financial results established office animal welfare ethics strategy oawes led chief animal welfare ethics strategy help context ensure humane responsible care animals increase research relating animals humans raise ethical concerns knowledge application nonanimal alternatives group attempt proactively address animal studies remain oawes embeds framework animal welfare governance explores vital part research many cases method opportunities crossindustry data sharing creates consistency used investigate effects potential new medicine metrics rs replacement refinement reduction animals living body tested humans generally mandated research conducts quality assessments regulators ethically imperative animal research also provide report results human subject research medicines critical information causes diseases develop vaccines publicly accessible clinical study register website countries require additional animal testing even medicines governmentrequired repositories submit human research approved use elsewhere results manuscripts publication peer reviewed scientific clinical trials healthy volunteers patients used assess journals committed expanding register include demonstrate investigational products efficacy safety clinical study reports system introduced allow evaluate product approved marketing also researchers request access anonymised patientlevel data work human biological samples samples fundamental groups clinical trials subject review scientific validity discovery development safety monitoring products independent panel certain conditions integrity data essential success stages global human biological samples management hbsm research data lifecycle design generation recording management governance framework place oversee ethical lawful analysis reporting storage retrieval research data acquisition management human biological samples governed legislation regulatory requirements global hbsm network champions hbsm activities provides experienced group support internal sample custodians best research data supporting documents core components practice various stages pipeline progression decisionmaking also form content regulatory submissions poor data integrity continuing enhance data integrity controls remains important compromise research efforts priority scientific data misrepresentation discovered relation nature medicine publication took immediate innate complexities interdependencies required action retract publication full analysis incident regulatory filings particularly given global research scientific data misrepresentation discovered undertaken development footprint currently rapid changes submission based analysis improved controls implemented requirements developing countries increasing complexity across rd meeting regulatory requirements chief regulatory officer oversees activities regulatory mitigating activities governance board includes promoting compliance proactively address ethical concerns raised research relating regulatory requirements groupwide standards making regulatory animals humans transparent practices services efficient agile aligning regulatory regularly engaging academics scientists regulators policymakers capabilities international business needs enterprise industry colleagues stakeholders request advice help local levels ensure best practice committed acting ethically providing animals health wellbeing reducing number animals finding alternatives use animals gsk annual report investor information principal risks uncertainties environment health safety sustainability strategic priorities grow diversified global company risk definition mitigating activities failure ethically manage environment health safety management ehss risk fundamental performance sustainability ehss consistent groups objectives policies reputation committed appropriately managing ehss risk relevant laws regulations embedded importance mission improve quality human life enabling people feel better live longer risk impact operate rigorous procedures help us eliminate hazards failure manage ehss risks could lead significant harm people practicable protect employees health wellbeing right environment communities operate fines failure culture essential starting point employment practices meet stakeholder expectations regulatory requirements litigation designed create work place culture employees feel regulatory action could materially adversely affect valued respected empowered inspired achieve goals financial results continuing efforts improve environmental sustainability reduced water consumption hazardous waste energy context consumption actively manage environmental remediation group subject health safety environmental laws obligations help ensure practices environmentally sustainable various jurisdictions laws impose actual potential compliant obligations remediate contaminated sites also identified potentially responsible party us ehss performance results shared public year comprehensive environmental response compensation liability corporate responsibility report act number sites remediation costs relating use ownership sites failure manage environmental risks properly could result litigation regulatory action additional remedial costs may materially adversely affect financial results see note financial statements legal proceedings discussion environmental related proceedings involved routinely accrue amounts related liabilities matters information protection strategic priorities simplify operating model risk definition mitigating activities risk groups business activity critical sensitive computer group global information protection policy supported systems information available needed accessed dedicated programme activity increase focus authorised deliberately changed corrupted information security group established office chief information security officer provide strategy direction oversight risk impact enhancing global information security capabilities failure adequately protect critical sensitive systems assess changes information protection risk environment information may result inability maintain patent rights loss briefings government agencies subscription commercial commercial strategic advantage damage reputation threat intelligence services knowledge sharing business disruption including litigation regulatory sanction fines pharmaceutical crossindustry companies could materially adversely affect financial results aim use industry best practices part information security policies processes technologies invest strategies context commensurate changing nature security threat rely critical sensitive systems data corporate landscape strategic plans sensitive personally identifiable information intellectual also subject various laws govern processing property manufacturing systems trade secrets personally identifiable information pll help ensure compliance potential malicious careless actions expose computer crossborder pii transfer requirements groups binding systems information misuse unauthorised disclosure corporate rules bcrs approved uk information commissioners office human resource research activities data bcrs make possible transfer pii internationally groups entities without individual privacy agreements european union country gsk annual report crisis continuity management strategic priorities deliver products value grow diversified global company risk definition mitigating activities inability recover sustain critical operations following disruption group place crisis management business continuity respond crisis incident timely manner regardless cause plans critical business operations plans include authorised response recovery strategies key areas responsibility risk impact clear communication plans established ccm failure manage crisis continuity management ccm effectively governance board representatives across group lead prolonged business disruption greater damage provide vital information ccm programme team regarding new groups assets risk medicines supply disruption patients threats acquisitions significant business organisational changes could materially adversely affect financial results delays dedicated team ccm experts supports business rd activities delivery products consumers responsibilities include coordinating crisis management business patients rely could also expose us litigation regulatory continuity training facilitating exercises monitoring provide action materially adversely affect financial results lead global consistency alignment centrally storing monitoring reputational damage plan updates crisis management plans business continuity plans supporting critical business processes help ensure context appropriate level readiness response capability maintained patients consumers healthcare professionals rely products also develop maintain partnerships external bodies like readily available needed even event crisis business continuity institute un international strategy international operations partners maintain disaster risk reduction helps improve business continuity vast global footprint exposing people facilities operations initiatives disaster prone areas information technology potential disruption resulting natural continually improve training programmes tools based event eg storm earthquake manmade event eg civil unrest learning plan activations example indepth video case studies terrorism global emergency eg global public health emergency created share lessons learned responded japan earthquake us superstorm sandy regularly evaluate introduce new tools improve ccm practices gsk annual report investor information shareholder information shareholder information share capital control share buyback programme board authorised issue allot ordinary shares details issued share capital number shares held article companys articles association power treasury december found note article authority company make purchases financial statements share capital share premium account shares subject shareholder authorities shares listed london stock exchange also sought annual basis annual general meeting agm quoted new york stock exchange nyse form shares purchased company may cancelled held american depositary shares ads ads represents two treasury shares ordinary shares details listed debt listed refer continued longterm buyback programme note financial statements net debt million shares purchased total cost million holders ordinary shares entitled receive dividends shares purchased period january february declared companys annual report attend speak period february february million general meetings company appoint proxies exercise shares purchased cost million voting rights programme covers purchases shares cancellation restrictions transfer limitations holding held treasury shares accordance authority renewed ordinary shares requirements obtain approval prior shareholders agm may company transfers ordinary shares carry special rights regard authorised purchase maximum million shares control company restrictions voting details shares purchased cancelled held rights major shareholders voting rights per share treasury shares disclosed note financial statements shareholders share capital share premium account known arrangements financial rights exact amount timing future purchases extent held person holder shares known repurchased shares held treasury shares rather agreements restrictions share transfers voting rights cancelled determined company dependent market conditions factors shares acquired share schemes plans rank equally shares issue special rights trustees market capitalisation employee share ownership plan trusts waived market capitalisation based shares issue excluding rights dividends shares held trusts treasury shares gsk december billion exchange controls limitations date gsk fifth largest company market capitalisation ftse index affecting security holders certain economic sanctions may force share price time time currently applicable laws decrees regulations restricting import export capital affecting remittance dividends payments holders companys january shares nonresidents uk similarly certain december economic sanctions may force time time increasedecrease limitations relating nonresidents uk english law companys articles association right holder high year vote respect companys shares low year table sets middle market closing prices interests voting rights companys share price increased compares stated far aware increase ftse index year persons significant direct indirect holdings company share price february information provided company pursuant financial conduct authoritys fca disclosure transparency rules uk us dtrs published regulatory information service companys website february company received notifications accordance fcas dtrs following notifiable interests voting rights companys issued share capital percentage issued shares capital blackrock inc invesco asset management legal general group plc p ercentage ordinary shares issue excluding treasury shares acquired disposed interests shares period review connection uk share price uk us ads price us share buyback programme gsk annual report analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary companys adss listed nyse ordinary shares representing companys adr programme managed depositary registered name bny nominees limited february bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date february number holders shares usa holdings shares number registered holders ads holdings ads certain shares ads held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse pence per share us dollars per ads ordinary shares high low ads high low february february january january december december november november october october september september quarter ended december quarter ended december quarter ended september quarter ended september quarter ended june quarter ended june quarter ended march quarter ended march quarter ended december quarter ended december quarter ended september quarter ended september quarter ended june quarter ended june quarter ended march quarter ended march year ended december year ended december year ended december year ended december year ended december year ended december february gsk annual report investor information shareholder information dividends uk shareholders summary applies uk resident shareholder holds company pays dividends quarterly continues return cash shares capital assets shareholders dividend policy ongoing longterm share buyback programme dividends remain essential component taxation dividends total shareholder return company committed increasing uk resident shareholders generally subject uk income tax dividend long term details dividends declared full amount dividends paid grossed amount amounts payment dates given note financial tax credit tax credit may set individuals income statements dividends tax liability respect gross dividend repayable shareholders tax liability less associated tax credit dividends per share tax year subsequent tax years additional rate table sets dividend per share per ads income tax dividends imposed taxpayers whose income last five years dividend per ads translated us dollars uk resident shareholders corporation applicable exchange rates taxpayers note dividends generally entitled exemption corporation tax year dividend pence us taxation capital gains uk shareholders may liable uk tax gains disposal shares adr disposals individuals subject supplemental availability exemption relief annual exempt amount taxable capital gain accruing disposal shares adr taxed allowable deductions shareholders taxable income tax year exceeds basic rate supplemental dividend related disposal certain income tax limit cases taxable capital gain accruing noncore otc brands north america paid fourth disposal shares adr may taxed quarter ordinary dividend combination rates corporation taxpayers may entitled dividend calendar indexation allowance applies reduce capital gains extent gains arise due inflation indexation allowance quarter exdividend date record date payment date may reduce chargeable gain create allowable loss q february february april inheritance tax q may may july individual shareholders may liable inheritance tax transfer q august august october shares adr tax may charged amount q november november january value shareholders estate reduced result transfer way gift disposal less full market value tax information shareholders gift disposal subject uk inheritance tax us estate gift tax estate gift tax convention would generally summary certain uk tax us federal income tax provide tax paid usa credited tax payable consequences holders shares adr citizens uk uk usa set complete analysis possible tax consequences purchase ownership stamp duty sale securities intended general guide uk stamp duty stamp duty reserve tax sdrt subject holders advised consult advisers respect tax certain exemptions payable transfer shares rate consequences purchase ownership sale shares consideration transfer adr consequences state local tax laws usa implications current ukus tax conventions us holders adr generally treated owners underlying shares purposes current usauk double taxation conventions relating income gains income tax convention estate gift taxes estate gift tax convention purposes internal revenue code amended code gsk annual report us shareholders stamp duty summary applies shareholder citizen uk stamp duty sdrt subject certain exemptions resident usa domestic corporation person payable transfer shares adr custodian depository otherwise subject us federal income tax net income basis rate amount consideration provided respect shares adr holds shares adr capital transferred sale value transferred consideration assets resident uk uk tax purposes sdrt would payable transfer agreement hold shares purposes trade profession vocation transfer adr uk stamp duty payable carried uk branch agency transfer adr provided instrument transfer summary also address tax treatment holders executed remains times outside uk stamp duty subject special tax rules banks taxexempt entities transfer adr would payable rate insurance companies dealers securities currencies persons consideration transfer sale underlying shares hold shares adr part integrated investment would subject certain exceptions result liability uk stamp including straddle comprised share adr one duty case may sdrt rate positions persons directly indirectly voting stock company annual general meeting taxation dividends pm uk wednesday may queen elizabeth ii conference centre broad sanctuary gross amount dividends received treated foreign source westminster london swp ee dividend income us tax purposes eligible dividend received deduction allowed us corporations dividends adr agm companys principal forum communication payable us dollars dividends shares payable pounds private shareholders addition formal business sterling dividends paid pounds sterling included income presentation ceo performance group us dollar amount calculated reference exchange rate future development opportunity questions day dividends received holder subject asked board chairmen boards committees take certain exceptions shortterm hedged positions individual questions relating committees eligible us holder subject us taxation maximum rate respect qualified dividends investors holding shares nominee service arrange nominee service appointed proxy respect taxation capital gains shareholding order attend vote meeting generally us holders subject uk capital gains tax adr holders wishing attend meeting must obtain proxy subject us tax capital gains realised sale bny mellon enable attend vote business disposal shares adr gains longterm capital gains transacted adr holders may instruct bny mellon subject reduced rates taxation individual holders way shares represented adr voted shares adr held one year completing returning voting card provided bank information reporting backup withholding documents display dividends payments proceeds sale shares articles association company documents adr paid within usa certain usrelated financial referred annual report available inspection intermediaries subject information reporting may companys registered office website made subject backup withholding unless us holder corporation available inspection agm exempt recipient provides taxpayer identification number certifies loss exemption occurred nonus holders generally subject information reporting backup withholding may required provide certification nonus status connection payments received amounts withheld allowed refund credit holders us federal income tax liability provided required information furnished internal revenue service estate gift taxes estate gift tax convention us shareholder generally subject uk inheritance tax gsk annual report investor information shareholder information financial reporting calendar definitions political donations political expenditure political organisations used legislation wide publication date particular definition eu political organisations may extend bodies concerned policy review law reform results announcements representation business community special interest groups quarter april concerned environment company quarter july subsidiaries might wish support result definitions quarter october may cover legitimate business activities ordinary sense preliminaryquarter february considered political donations political expenditure annual reportsummary februarymarch activities designed support political party results announcements independent election candidate authority board sought annually precautionary measure ensure company results announcements issued london stock exchange subsidiaries inadvertently breach legislation available news service also sent us securities exchange commission nyse issued directors media made available website directors powers determined uk legislation financial reports articles association available website articles may amended special resolution members company publishes annual report shareholder directors may exercise companys powers provided needing full detail annual report summary articles applicable legislation stipulate documents available website date powers must exercised members publication summary sent shareholders shareholders rules appointment replacement directors may elect receive annual report contacting registrar contained articles provide directors may alternatively shareholders may elect receive notification appointed ordinary resolution members resolution email publication financial reports registering directors provided latter instance director appointed wwwshareviewcouk way retires first agm following appointment copies previous financial reports available website articles also provide directors normally subject printed copies obtained registrar uk reelection agm intervals three years annually gsk response center usa see pages held office continuous period nine years contact details however board agreed directors wish donations political organisations continue members board seek reelection annually accordance uk corporate governance code members may political expenditure remove director passing ordinary resolution special notice given passing special resolution effect january ensure consistent approach political contributions across group introduced global director may automatically cease director policy stop voluntarily corporate political contributions becomes bankrupt compounds period january december group creditors generally make political donations eu noneu organisations ceases director virtue companies notwithstanding introduction policy accordance act articles federal election campaign act usa continue support suffering mental physical ill health employeeoperated political action committee pac facilitates board resolves shall cease director voluntary political donations eligible gsk employees missed directors meetings continuous pac controlled gsk decisions amounts period six months without permission board recipients contributions made participating employees resolves shall cease director exercising legal right pool resources make political contributions subject strict limitations total prohibited director law us us donated political resigns organisations gsk employee pac offers resign board accepts offer agm may shareholders first authorised company directors least three number require make donations eu political organisations incur eu resign political expenditure provisions political parties elections referendums act year authority since renewed annually companies act requires companies continue obtain shareholder approval make donations eu political organisations incur eu political expenditure however make intend make donations political parties independent election candidates make donations eu political organisations incur eu political expenditure gsk annual report directors conflicts interest us law regulation directors duty companies act avoid number provisions us law regulation apply situation could direct indirect conflict company shares quoted new york stock interest possible conflict company duty applies exchange nyse form ads particular exploitation property information opportunity whether company could take advantage articles nyse rules provide general power board authorise conflicts general nyse rules permit company follow uk nominations committee authorised board corporate governance practices instead applied usa grant periodically event annually review provided explain significant variations explanation potential actual conflict authorisations directors counted contained form f filing accessed quorum authorisation actual potential securities exchange commissions sec edgar database conflicts authorisations granted recorded company via website nyse rules came effect require us secretary register noted board next meeting file annual interim written affirmations concerning audit ongoing basis directors responsible informing risk committee statement significant differences company secretary new actual potential conflicts may corporate governance arise changes circumstances may affect sarbanesoxley act authorisation previously given even provided authorisation director absolved statutory duty following number corporate accounting scandals promote success company actual conflict arises usa congress passed sarbanesoxley act sarbanes postauthorisation board may choose exclude director oxley wideranging piece legislation concerned largely receipt relevant information participation financial reporting corporate governance debate suspend director board last resort recommended sec company established require director resign disclosure committee committee reports ceo cfo nominations committee reviewed register potential audit risk committee chaired company conflict authorisations october reported board secretary members consist senior managers finance conflicts appropriately authorised legal corporate communications investor relations process authorisation continues operate effectively except external legal counsel external auditors internal experts described note financial statements related party invited attend meetings periodically responsibility transactions end financial year director considering materiality information timely basis connected person material interest contract determining disclosure information responsibility significance group company timely filing reports sec formal review annual report form f committee met times independent advice sarbanesoxley requires annual report contains board recognises may occasions one statement whether member audit risk committee directors feel necessary take independent legal arc audit committee financial expert defined sarbanes andor financial advice companys expense agreed oxley statement relevant members arc procedure set website enable stacey cartwright judy lewent tom de swaan included indemnification directors audit risk committee report additional disclosure requirements arise section section sarbanes qualifying third party indemnity provisions defined oxley respect disclosure controls procedures internal companies act force benefit directors control financial reporting former directors held office signing annual report change control essential contracts contracts arrangements individually fundamental ability business operate effectively company party material agreements would take effect altered terminate upon change control following takeover bid agreements director would provide compensation loss office employment resulting takeover except provisions companys share plans may cause options awards granted plans vest takeover details termination provisions companys framework contracts executive directors given pages gsk annual report investor information shareholder information section corporate responsibility financial reports section managements annual report internal control sarbanesoxley also introduced requirement ceo financial reporting cfo complete formal certifications confirming accordance requirements section sarbanes oxley following report provided management respect reviewed annual report form f companys internal control financial reporting defined based knowledge annual report form f rules af df us securities exchange contains material misstatements omissions act based knowledge financial statements management responsible establishing maintaining financial information fairly present material respects adequate internal control financial reporting group financial condition results operations cash flows internal control financial reporting designed provide dates periods presented annual report reasonable assurance regarding reliability financial reporting form f preparation financial statements external purposes responsible establishing maintaining disclosure accordance ifrs controls procedures ensure material information management conducted evaluation effectiveness internal made known evaluated effectiveness control financial reporting based framework internal controls procedures yearend results control integrated framework issued committee evaluation contained annual report sponsoring organisations treadway commission form f changes groups internal control responsible establishing maintaining internal financial reporting materially affected control financial reporting provides reasonable assurance reasonably likely affect materially groups internal control regarding reliability financial reporting preparation financial reporting financial statements external purposes accordance management assessed effectiveness internal control generally accepted accounting principles financial reporting december disclosed annual report form f conclusion filed part groups form f changes internal controls financial reporting pricewaterhousecoopers llp audited consolidated period covered annual report form f financial statements group year ended december materially affected reasonably likely affect materially also assessed effectiveness groups internal companys internal control financial reporting control financial reporting auditing standard disclosed based recent evaluation internal control public company accounting oversight board united states financial reporting external auditors arc audit report filed groups form f significant deficiencies material weaknesses design operation internal controls financial reporting section r us securities exchange act reasonably likely affect adversely companys ability record section r us securities exchange act amended process summarise report financial information fraud requires issuers make specific disclosure annual reports regardless materiality involving persons significant certain types dealings iran including transactions dealings role companys internal control financial reporting governmentowned entities well dealings entities group carried evaluation supervision sanctioned activities related terrorism proliferation weapons participation management including ceo mass destruction even activities prohibited cfo effectiveness design operation us law involve us persons group groups disclosure controls procedures legal entity based iran export certain pharmaceutical december vaccine products pharmaceuticals vaccines businesses iran via sales nonus entities two privately held iranian inherent limitations effectiveness system distributors distributor uae group also disclosure controls procedures including possibility business via nonus entities jurisdictions targeted human error circumvention overriding controls sanctions laws including cuba syria sudan believe procedures accordingly even effective disclosure controls groups direct dealings iran require specific procedures provide reasonable assurance achieving disclosure requirements groups policies limit control objectives sales iran products high medicalpublic health need ceo cfo expect complete certifications determined part using criteria set world health organization report conclusions effectiveness disclosure controls group direct knowledge identity distributors procedures february following certificates downstream customers possible customers include filed sec part groups form f entities governmentowned hospitals pharmacies owned controlled directly indirectly iranian government persons entities sanctioned connection terrorism proliferation activities group direct knowledge distributors customers establish proportion gross revenue sales potentially attributable entities affiliated iranian government parties sanctioned disclosable activities result group reporting entire gross revenues million net profits million groups sales iran gsk annual report shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da tel uk wwwshareviewcouk tel outside uk equiniti provides range services shareholders service offers participate shareview service enables create free online portfolio view register share balance movements update address wwwshareviewcouk dividend payment instructions register votes agm corporate sponsored nominee account convenient way manage shares without application form downloaded requiring share certificate service provides facility hold shares nominee company sponsored wwwshareviewcouk company continue receive dividend payments requested telephoning equiniti annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join dividend payment direct bank currently receive dividends cheque dividend bank mandate form account post instead paid directly bank downloaded building society account quicker secure wwwshareviewcouk avoids risk cheque going astray requested telephoning equiniti dividend payment direct instead waiting sterling cheque arrive post details service bank account overseas shareholders equiniti convert dividend local currency costs involved please contact equiniti send direct local bank account service available countries worldwide dividend reinvestment plan alternative receiving cash dividends may choose drip election form drip reinvest dividends buy gsk shares downloaded wwwshareviewcouk requested telephoning equiniti duplicate publications mailings receive duplicate copies report mailings please contact equiniti please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificate form internet transactions please log please note market trading hours held corporate sponsored nominee internet wwwshareviewcoukdealing pm telephone postal dealing service provided equiniti uk monday friday excluding uk financial services limited telephone transactions please call public holidays uk outside uk postal transactions please call request dealing form individual savings accounts isas company arranged equiniti financial services details available limited provide gsk corporate isa hold gsk wwwshareviewcouk ordinary shares requested telephoning equiniti u k lines open pm monday friday except uk public holidays calls number charged p per minute plus network extras provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report investor information shareholder information adr depositary share scam alert receive unsolicited telephone call offering sell buy adr programme administered shares please take extra care caller may part highly bny mellon shareowner services organised financial scam po box uk shareholder please contact financial conduct college station tx authority information similar activities overnight correspondence sent consumer helpline bny mellon shareowner services tel uk quality circle suite lines open pm uk time college station tx monday friday except uk public holidays wwwbnymelloncomshareowner corporate responsibility report tel us toll free tel outside usa publishing corporate responsibility report online email shrrelationsbnymelloncom outline gsks approach performance key corporate responsibility areas health behaviour depositary also provides global buydirect direct ads people planet purchasesale dividend reinvestment plan adr holders details enrol please visit wwwmbnymdrcom call internet helpline number obtain enrolment pack information company including share price available website wwwgskcom information made available glaxo wellcome smithkline beecham website constitute part annual report corporate peps share centre limited contacts oxford house oxford road aylesbury bucks hp sz gsk response center tel tel us toll free donating shares save children investor relations gsk embarked ambitious global partnership investor relations may contacted follows save children share expertise resources aim helping save lives one million children uk gsk save children partnership focus particular great west road brentford developing childfriendly medicines reduce child mortality middlesex newborn deaths tw gs widening vaccination coverage reduce number child tel deaths hardest reach communities usa researching new affordable nutritional products help alleviate five crescent drive malnutrition children philadelphia pa increasing investment training reach scope health tel us toll free workers poorest communities help reduce child mortality tel outside usa shareholders small number shares value makes uneconomical sell may wish consider donating save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc corporate integrity agreement cia company entered settlement us federal government related past sales marketing practices part settlement company entered corporate integrity agreement us department health human services improvements built existing compliance programmes currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity glaxosmithkline exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report investor information index index accounting principles policies investor relations acquisitions disposals key accounting judgements estimates adjustments reconciling profit tax operating key performance indicators cash flows latestage pipeline summary annual general meeting legal proceedings assets held sale longterm incentive plans associates joint ventures major restructuring costs board movements equity cash cash equivalents net debt chairmans statement new accounting requirements chief executives review nonexecutive directors fees commitments notes financial statements committee reports operating profit competition intangible assets consolidated balance sheet investments consolidated cash flow statement noncurrent assets consolidated income statement noncurrent liabilities consolidated statement changes equity operating income consolidated statement comprehensive income provisions consumer healthcare products competition outlook contingent liabilities pensions postemployment benefits corporate executive team pharmaceutical products competition corporate governance intellectual property critical accounting policies pipeline directors senior management presentation financial statements directors interests shares principal group companies directors statement responsibilities property plant equipment dividends quarterly trend donations political organisations reconciliation net cash flow movement net debt political expenditure registrar earnings per share related party transactions employee costs relations shareholders employee share schemes remuneration policy report employees remuneration report exchange rates research development executive director remuneration responsible business finance expense risk factors finance income segment information financial instruments related disclosures segment reviews financial position resources share capital control financial review share capital share premium account financial statements glaxosmithkline plc prepared share price uk gaap shareholder information five year record strategy glossary terms taxation goodwill taxation information shareholders independent auditors report remuneration committee intellectual property trademarks trade payables inventories trade receivables investments associates joint ventures us law regulation gsk annual report gsk glaxosmithkline plc incorporated notice regarding limitations director liability english law english public limited company december uk companies act safe harbour limits liability directors respect statements omissions formed merger directors report see strategic report pages remuneration report glaxo wellcome plc smithkline beecham pages english law directors would liable company third party one plc gsk acquired two english companies reports contained errors result recklessness knowing misstatement dishonest concealment material december part merger fact would otherwise liable arrangements website glaxosmithklines website wwwgskcom gives additional information group notwithstanding references make annual report glaxosmithklines website shares listed london stock none information made available website constitutes part annual report shall deemed exchange new york stock exchange incorporated reference herein cautionary statement regarding forwardlooking statements read wwwgskcom groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report number adjusted measures used report performance business measures defined brand names brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies exception nicoderm trademark johnson johnson novartis sanofi glaxosmithkline potiga trademark valeant prolia xgeva trademarks amgen axentri trademark emcure pharmaceuticals volibris trademark gilead xyzal trademark ucb glaxosmithkline zyrtec trademark ucb glaxosmithkline used certain countries licence group printing printed pureprint group iso fsc certified carbonneutral paper annual report printed amadeus silk recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free manufacturing mill holds iso eu ecolabel certificates environmental managementwwwgskcom find downloadable pdfs annual report annual summary form f corporate responsibility report head office registered office glaxosmithkline plc great west road brentford middlesex tw gs also search us united kingdom tel registered number